285 results on '"Taramasso, L."'
Search Results
2. Low level viremia at the beginning and in course of long-acting treatment with injectable cabotegravir and rilpivirine
- Author
-
Taramasso, L, Ricci, E, De Vito, A, Squillace, N, Ferrara, S, Pontali, E, Cenderello, G, Pellicanò, G, Sarchi, E, Lagi, F, Salomoni, E, Carleo, M, Bargiacchi, O, Madeddu, G, Cascio, A, Menzaghi, B, De Socio, G, Falasca, K, Bonfanti, P, Di Biagio, A, Null, N, Pellicanò, GF, Carleo, MA, De Socio, GV, null, null, Taramasso, L, Ricci, E, De Vito, A, Squillace, N, Ferrara, S, Pontali, E, Cenderello, G, Pellicanò, G, Sarchi, E, Lagi, F, Salomoni, E, Carleo, M, Bargiacchi, O, Madeddu, G, Cascio, A, Menzaghi, B, De Socio, G, Falasca, K, Bonfanti, P, Di Biagio, A, Null, N, Pellicanò, GF, Carleo, MA, De Socio, GV, and null, null more...
- Published
- 2024
Catalog
3. Central nervous system and neuropsychiatric adverse events in Women living with HIV treated with INSTI-based regimens
- Author
-
De Vito, A, Bonfanti, P, Ricci, E, Menzaghi, B, Orofino, G, Squillace, N, Maggi, P, Molteni, C, Sarchi, E, De Socio, G, Celesia, B, Pellicanò, F, Lagi, F, Gulminetti, R, Taramasso, L, Albini, L, Di Biagio, A, Madeddu, G, De Socio, GV, Celesia, BM, Pellicanò, FG, De Vito, A, Bonfanti, P, Ricci, E, Menzaghi, B, Orofino, G, Squillace, N, Maggi, P, Molteni, C, Sarchi, E, De Socio, G, Celesia, B, Pellicanò, F, Lagi, F, Gulminetti, R, Taramasso, L, Albini, L, Di Biagio, A, Madeddu, G, De Socio, GV, Celesia, BM, and Pellicanò, FG more...
- Published
- 2024
4. Lipids, weight gain and body mass index in ARV experienced PLWH treated with doravirine-based treatments: a comparison between dual or triple regimens vs bictegravir based triple regimen
- Author
-
Masiello, A, Iodice, V, Menzaghi, B, Taramasso, L, Bellagamba, R, Molteni, C, Pellicanò, G, Squillace, N, Sarchi, E, Lagi, F, Cascio, A, Carleo, M, Celesia, B, Salomoni, E, Ferrara, S, Pontali, E, De Socio, G, Madeddu, G, Franzetti, M, Martini, S, Falasca, K, Orofino, G, Bargiacchi, O, Fiordelisi, D, Angioni, G, Cenderello, G, Calza, L, Di Biagio, A, Bonfanti, P, Maggi, P, Null, N, Pellicanò, GF, Carleo, MA, Celesia, BM, De Socio, GV, null, null, Masiello, A, Iodice, V, Menzaghi, B, Taramasso, L, Bellagamba, R, Molteni, C, Pellicanò, G, Squillace, N, Sarchi, E, Lagi, F, Cascio, A, Carleo, M, Celesia, B, Salomoni, E, Ferrara, S, Pontali, E, De Socio, G, Madeddu, G, Franzetti, M, Martini, S, Falasca, K, Orofino, G, Bargiacchi, O, Fiordelisi, D, Angioni, G, Cenderello, G, Calza, L, Di Biagio, A, Bonfanti, P, Maggi, P, Null, N, Pellicanò, GF, Carleo, MA, Celesia, BM, De Socio, GV, and null, null more...
- Published
- 2024
5. Changes in body mass index and lipid profile in PWH switching to a regimen without TAF vs PWH continuing TAF. Data from a real-life setting
- Author
-
Squillace, N, Taramasso, L, Ricci, E, Menzaghi, B, De Socio, G, Orofino, G, Celesia, B, Sarchi, E, Piconi, S, Pellicano', G, Attala, L, Di Biagio, A, Bonfanti, P, Celesia, BM, Squillace, N, Taramasso, L, Ricci, E, Menzaghi, B, De Socio, G, Orofino, G, Celesia, B, Sarchi, E, Piconi, S, Pellicano', G, Attala, L, Di Biagio, A, Bonfanti, P, and Celesia, BM more...
- Published
- 2024
6. Influence of efavirenz and 8-hydroxy-efavirenz plasma levels on cognition and central nervous system side effects
- Author
-
Ranzani, A, Castelli, F, Di Biagio, A, d'Arminio Monforte, A, D'Avolio, A, Soria, A, Bai, F, Focà, E, Taramasso, L, Calcagno, A, Bresciani, E, Torsello, A, Bonfanti, P, Lapadula, G, Ranzani, Alice, Castelli, Francesco, Di Biagio, Antonio, d'Arminio Monforte, Antonella, D'Avolio, Antonio, Soria, Alessandro, Bai, Francesca, Focà, Emanuele, Taramasso, Lucia, Calcagno, Andrea, Bresciani, Elena, Torsello, Antonio, Bonfanti, Paolo, Lapadula, Giuseppe, Ranzani, A, Castelli, F, Di Biagio, A, d'Arminio Monforte, A, D'Avolio, A, Soria, A, Bai, F, Focà, E, Taramasso, L, Calcagno, A, Bresciani, E, Torsello, A, Bonfanti, P, Lapadula, G, Ranzani, Alice, Castelli, Francesco, Di Biagio, Antonio, d'Arminio Monforte, Antonella, D'Avolio, Antonio, Soria, Alessandro, Bai, Francesca, Focà, Emanuele, Taramasso, Lucia, Calcagno, Andrea, Bresciani, Elena, Torsello, Antonio, Bonfanti, Paolo, and Lapadula, Giuseppe more...
- Abstract
Objectives: To investigate whether efavirenz (EFV) or 8-hydroxy-EFV (8-OH-EFV) plasma levels are associated with neurocognitive impairment and central nervous system (CNS) side effects. Methods: We conducted a cross-sectional analysis to explore the potential links between EFV/8-OH-EFV levels and cognitive performance or CNS-related side effects in patients screened within a randomized trial involving a switch from EFV to rilpivirine. The Mann–Whitney test was employed to compare drug levels in patients with or without cognitive impairment, depression, anxiety, sleep disorder or CNS symptoms. Additionally, Spearman's test was used to assess correlations between drug levels and test scores. Results: Among 104 patients, neither EFV nor 8-OH-EFV levels were linked to cognitive impairment, although trends towards higher EFV levels were observed in those with impaired executive function (p = 0.055) and language performances (p = 0.021). On the other hand, elevated 8-OH-EFV levels, but not EFV levels, were associated with more CNS side effects (222 vs. 151 ng/mL, p = 0.027), depressive symptoms (247 vs. 164 ng/mL, p = 0.067) and sleep impairment (247 vs. 164 ng/mL, p = 0.078). Consistently, a trend towards a correlation between EFV levels and lower z-scores in executive function and motor function was observed, while 8-OH-EFV levels, but not EFV levels, were directly correlated with symptom scores. Conclusions: Higher levels of 8-OH-EFV were associated with CNS side effects, while EFV levels were only marginally associated with cognitive performance, thus suggesting that EFV and its metabolite may act differently in determining detrimental neurological effects. more...
- Published
- 2024
7. Long-term outcomes of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohort
- Author
-
d’Arminio Monforte, A, Tavelli, A, Di Biagio, A, Sarmati, L, Marchetti, G, Bai, F, Cingolani, A, Quiros Roldan, E, Mussini, C, Lichtner, M, Vergori, A, Piconi, S, Orofino, G, Fusco, F, Bandera, A, Nozza, S, Castagna, A, Antinori, A, Antinori, S, Cauda, R, Di Perri, G, Girardi, E, Iardino, R, Lazzarin, A, Quiros-Roldan, E, Suligoi, B, von Schloesser, F, Viale, P, Ceccherini-Silberstein, F, Cozzi-Lepri, A, Gori, A, Lo Caputo, S, Maggiolo, F, Puoti, M, Perno, C, Torti, C, Bonora, S, Calcagno, A, Canetti, D, Cervo, A, Cinque, P, Gagliardini, R, Giacomelli, A, Gianotti, N, Guaraldi, G, Lanini, S, Lapadula, G, Lai, A, Madeddu, G, Malagnino, V, Mondi, A, Mazzotta, V, Pinnetti, C, Rossotti, R, Rusconi, S, Santoro, M, Saracino, A, Spagnuolo, V, Squillace, N, Svicher, V, Taramasso, L, De Benedittis, S, Fanti, I, Giotta, M, Rodano’, A, Bove, A, Cernuschi, M, Cosmaro, L, Errico, M, Perziano, A, Calvino, V, Augello, M, Carrara, S, Graziano, S, Prota, G, Truffa, S, Vincenti, D, Rovito, R, Giacometti, A, Costantini, A, Barocci, V, Santoro, C, Milano, E, Comi, L, Suardi, C, Badia, L, Cretella, S, Erne, E, Pieri, A, Focà, E, Minardi, C, Menzaghi, B, Abeli, C, Chessa, L, Pes, F, Maggi, P, Alessio, L, Cacopardo, B, Celesia, B, Vecchiet, J, Falasca, K, Pan, A, Dal Zoppo, S, Segala, D, Di Pietro, M, Costa, C, Ferrara, S, Bassetti, M, Pontali, E, Blanchi, S, Bobbio, N, Mazzarello, G, Fondaco, L, Molteni, C, Canavesi, G, Nunnari, G, Pellicanò, G, Rizzardini, G, Bono, V, Cossu, M, Lolatto, R, Moioli, M, Pezzati, L, Diotallevi, S, Tincati, C, Puzzolante, C, Bonfanti, P, Sangiovanni, V, Gentile, I, Esposito, V, Coppola, N, Di Filippo, G, Rizzo, V, Sangiovanni, N, Martini, S, Cattelan, A, Leoni, D, Cascio, A, Colomba, C, Francisci, D, Schiaroli, E, Parruti, G, Sozio, F, Blanc, P, Bonelli, S, Lazzaretti, C, Corsini, R, Mastroianni, C, Latini, A, Lamonica, S, Capozzi, M, Rivano Capparuccia, M, Iaiani, G, Stingone, C, Gianserra, L, Paulicelli, J, Plazzi, M, D’Ettore, G, Fusto, M, Coledan, I, De Vito, A, Fabbiani, M, Montagnani, F, Franco, A, Fontana Del Vecchio, R, Pasticci, B, Di Giuli, C, Calleri, G, Accardo, G, Tascini, C, Londero, A, Manfrin, V, Battagin, G, Starnini, G, Farinacci, D, Null, N, d’Arminio Monforte, Antonella, Tavelli, Alessandro, Di Biagio, Antonio, Sarmati, Loredana, Marchetti, Giulia C, Bai, Francesca, Cingolani, Antonella, Quiros Roldan, Eugenio, Mussini, Cristina, Lichtner, Miriam, Vergori, Alessandra, Piconi, Stefania, Orofino, Giancarlo, Fusco, Francesco Maria, Bandera, Alessandra, Nozza, Silvia, Castagna, Antonella, Antinori, Andrea, Marchetti, G C, Perno, C F, Santoro, M M, Erne, E M, Di Pietro, M A, Cossu, M V, Moioli, M C, Fusco, F M, Cattelan, A M, Bonelli, S I, Plazzi, M M, d’Ettore, G, Pasticci, B M, Orofino, G C, null, null, d’Arminio Monforte, A, Tavelli, A, Di Biagio, A, Sarmati, L, Marchetti, G, Bai, F, Cingolani, A, Quiros Roldan, E, Mussini, C, Lichtner, M, Vergori, A, Piconi, S, Orofino, G, Fusco, F, Bandera, A, Nozza, S, Castagna, A, Antinori, A, Antinori, S, Cauda, R, Di Perri, G, Girardi, E, Iardino, R, Lazzarin, A, Quiros-Roldan, E, Suligoi, B, von Schloesser, F, Viale, P, Ceccherini-Silberstein, F, Cozzi-Lepri, A, Gori, A, Lo Caputo, S, Maggiolo, F, Puoti, M, Perno, C, Torti, C, Bonora, S, Calcagno, A, Canetti, D, Cervo, A, Cinque, P, Gagliardini, R, Giacomelli, A, Gianotti, N, Guaraldi, G, Lanini, S, Lapadula, G, Lai, A, Madeddu, G, Malagnino, V, Mondi, A, Mazzotta, V, Pinnetti, C, Rossotti, R, Rusconi, S, Santoro, M, Saracino, A, Spagnuolo, V, Squillace, N, Svicher, V, Taramasso, L, De Benedittis, S, Fanti, I, Giotta, M, Rodano’, A, Bove, A, Cernuschi, M, Cosmaro, L, Errico, M, Perziano, A, Calvino, V, Augello, M, Carrara, S, Graziano, S, Prota, G, Truffa, S, Vincenti, D, Rovito, R, Giacometti, A, Costantini, A, Barocci, V, Santoro, C, Milano, E, Comi, L, Suardi, C, Badia, L, Cretella, S, Erne, E, Pieri, A, Focà, E, Minardi, C, Menzaghi, B, Abeli, C, Chessa, L, Pes, F, Maggi, P, Alessio, L, Cacopardo, B, Celesia, B, Vecchiet, J, Falasca, K, Pan, A, Dal Zoppo, S, Segala, D, Di Pietro, M, Costa, C, Ferrara, S, Bassetti, M, Pontali, E, Blanchi, S, Bobbio, N, Mazzarello, G, Fondaco, L, Molteni, C, Canavesi, G, Nunnari, G, Pellicanò, G, Rizzardini, G, Bono, V, Cossu, M, Lolatto, R, Moioli, M, Pezzati, L, Diotallevi, S, Tincati, C, Puzzolante, C, Bonfanti, P, Sangiovanni, V, Gentile, I, Esposito, V, Coppola, N, Di Filippo, G, Rizzo, V, Sangiovanni, N, Martini, S, Cattelan, A, Leoni, D, Cascio, A, Colomba, C, Francisci, D, Schiaroli, E, Parruti, G, Sozio, F, Blanc, P, Bonelli, S, Lazzaretti, C, Corsini, R, Mastroianni, C, Latini, A, Lamonica, S, Capozzi, M, Rivano Capparuccia, M, Iaiani, G, Stingone, C, Gianserra, L, Paulicelli, J, Plazzi, M, D’Ettore, G, Fusto, M, Coledan, I, De Vito, A, Fabbiani, M, Montagnani, F, Franco, A, Fontana Del Vecchio, R, Pasticci, B, Di Giuli, C, Calleri, G, Accardo, G, Tascini, C, Londero, A, Manfrin, V, Battagin, G, Starnini, G, Farinacci, D, Null, N, d’Arminio Monforte, Antonella, Tavelli, Alessandro, Di Biagio, Antonio, Sarmati, Loredana, Marchetti, Giulia C, Bai, Francesca, Cingolani, Antonella, Quiros Roldan, Eugenio, Mussini, Cristina, Lichtner, Miriam, Vergori, Alessandra, Piconi, Stefania, Orofino, Giancarlo, Fusco, Francesco Maria, Bandera, Alessandra, Nozza, Silvia, Castagna, Antonella, Antinori, Andrea, Marchetti, G C, Perno, C F, Santoro, M M, Erne, E M, Di Pietro, M A, Cossu, M V, Moioli, M C, Fusco, F M, Cattelan, A M, Bonelli, S I, Plazzi, M M, d’Ettore, G, Pasticci, B M, Orofino, G C, and null, null more...
- Abstract
Objectives: To assess the effectiveness of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) among people poorly represented in clinical trials and potentially at higher risk of suboptimal response to ART. Methods: Observational cohort study on persons with HIV (PWH) enrolled in ICONA who started BIC/FTC/TAF as initial therapy or as switching regimen while virologically suppressed. Primary endpoint was time to treatment failure (TF): new AIDS/death or virological failure (VF) or discontinuation for toxicity/failure. Secondary endpoints were time to treatment discontinuation for toxicity (TDT) and to VF. Groups of interest were those aged >50 years, female sex, and advanced HIV disease at first ART start. Probability of the events overall and according to groups and adjusted HR for every endpoint were calculated by Kaplan–Meier curves and Cox regression models. Results: Nine hundred and thirty-three ART-naive and 1655 ART-experienced PWH initiated BIC/FTC/TAF. Over a median follow-up of 69.8 weeks, 89 (9.6%) PWH at their first regimen experienced TF. PWH aged >50 years had 1.83-fold (95% CI: 1.19–2.83) higher risk of TF; PWH with advanced HIV disease had 2.21-fold (95% CI: 1.53–3.82) higher risk; there were no differences in TF according to sex. Over a median follow-up of 146.3 weeks, 109 (6.6%) out of 1655 switching PWH experienced TF; no differences were found in the risk of TF, TDT and VF according to groups of interest. Conclusions: Overall, BIC/FTC/TAF is well tolerated and virologically effective in the real-world scenario for ART-naive and -experienced PWH. Older ART-naive PWH and those with advanced HIV disease may respond less well as the burden of diseases might compromise treatment efficacy. more...
- Published
- 2024
8. Risk of Cardiovascular Events in People with HIV (PWH) Treated with Integrase Strand-Transfer Inhibitors: The Debate Is Not Over; Results of the SCOLTA Study
- Author
-
Corti, N, Menzaghi, B, Orofino, G, Guastavigna, M, Lagi, F, Di Biagio, A, Taramasso, L, De Socio, G, Molteni, C, Madeddu, G, Salomoni, E, Pellicanò, G, Pontali, E, Bellagamba, R, Celesia, B, Cascio, A, Sarchi, E, Gulminetti, R, Calza, L, Maggi, P, Cenderello, G, Bandera, A, Carleo, M, Falasca, K, Ferrara, S, Martini, S, Guadagnino, G, Angioni, G, Bargiacchi, O, Ricci, E, Squillace, N, Bonfanti, P, Corti, Nicolò, Menzaghi, Barbara, Orofino, Giancarlo, Guastavigna, Marta, Lagi, Filippo, Di Biagio, Antonio, Taramasso, Lucia, De Socio, Giuseppe Vittorio, Molteni, Chiara, Madeddu, Giordano, Salomoni, Elena, Pellicanò, Giovanni Francesco, Pontali, Emanuele, Bellagamba, Rita, Celesia, Benedetto Maurizio, Cascio, Antonio, Sarchi, Eleonora, Gulminetti, Roberto, Calza, Leonardo, Maggi, Paolo, Cenderello, Giovanni, Bandera, Alessandra, Carleo, Maria Aurora, Falasca, Katia, Ferrara, Sergio, Martini, Salvatore, Guadagnino, Giuliana, Angioni, Goffredo, Bargiacchi, Olivia, Ricci, Elena Delfina, Squillace, Nicola, Bonfanti, Paolo, Corti, N, Menzaghi, B, Orofino, G, Guastavigna, M, Lagi, F, Di Biagio, A, Taramasso, L, De Socio, G, Molteni, C, Madeddu, G, Salomoni, E, Pellicanò, G, Pontali, E, Bellagamba, R, Celesia, B, Cascio, A, Sarchi, E, Gulminetti, R, Calza, L, Maggi, P, Cenderello, G, Bandera, A, Carleo, M, Falasca, K, Ferrara, S, Martini, S, Guadagnino, G, Angioni, G, Bargiacchi, O, Ricci, E, Squillace, N, Bonfanti, P, Corti, Nicolò, Menzaghi, Barbara, Orofino, Giancarlo, Guastavigna, Marta, Lagi, Filippo, Di Biagio, Antonio, Taramasso, Lucia, De Socio, Giuseppe Vittorio, Molteni, Chiara, Madeddu, Giordano, Salomoni, Elena, Pellicanò, Giovanni Francesco, Pontali, Emanuele, Bellagamba, Rita, Celesia, Benedetto Maurizio, Cascio, Antonio, Sarchi, Eleonora, Gulminetti, Roberto, Calza, Leonardo, Maggi, Paolo, Cenderello, Giovanni, Bandera, Alessandra, Carleo, Maria Aurora, Falasca, Katia, Ferrara, Sergio, Martini, Salvatore, Guadagnino, Giuliana, Angioni, Goffredo, Bargiacchi, Olivia, Ricci, Elena Delfina, Squillace, Nicola, and Bonfanti, Paolo more...
- Abstract
Cardiovascular disease (CVD) is common in people with HIV (PWH), and has great impact in terms of morbidity and mortality. Several intertwined mechanisms are believed to play a role in determining the increased risk of CVD, including the effect of certain antiretrovirals; among these, the role of integrase strand-transfer inhibitors (INSTIs) is yet to be fully elucidated. We conducted a multicenter, observational study comprising 4984 PWH evaluating the antiretroviral therapy (ART)-related nature of CVD in real life settings, both in naïve vs. treatment-experienced people. A comparison was conducted between INSTIs vs. either protease inhibitors (PIs) or non-nucleoside reverse transcriptase inhibitors (NNRTIs) considering demographic, baseline clinical characteristics, incidence of CVD in both 2-year and complete follow-up periods. Among 2357 PWH exposed to INSTIs, 24 people experienced CVD; the corresponding figure was 12 cases out of 2599 PWH exposed to other ART classes. At univariate and multivariate analysis, a tendency towards an increased risk of CVD was observed in the 2-year follow-up period in PWH exposed to INSTIs in the absence, however, of statistical significance. These findings leave open the hypothesis that INSTIs may play a role, albeit minimal, in determining an increased risk of CVD in PWH. more...
- Published
- 2024
9. Long-term outcome of dolutegravir-containing regimens according to sex: data from the ICONA study
- Author
-
D'arminio Monforte, A, Tavelli, A, Sala, M, Mondi, A, Rusconi, S, Antinori, S, Puoti, M, Celesia, B, Taramasso, L, Saracino, A, Antinori, A, Cozzi-Lepri, A, D'arminio Monforte A., Tavelli A., Sala M., Mondi A., Rusconi S., Antinori S., Puoti M., Celesia B. M., Taramasso L., Saracino A., Antinori A., Cozzi-Lepri A., D'arminio Monforte, A, Tavelli, A, Sala, M, Mondi, A, Rusconi, S, Antinori, S, Puoti, M, Celesia, B, Taramasso, L, Saracino, A, Antinori, A, Cozzi-Lepri, A, D'arminio Monforte A., Tavelli A., Sala M., Mondi A., Rusconi S., Antinori S., Puoti M., Celesia B. M., Taramasso L., Saracino A., Antinori A., and Cozzi-Lepri A. more...
- Abstract
Objectives: To compare the long-term risk of treatment failure of dolutegravir-based ART in men and women in a real-life setting. Patients and methods: Persons living with HIV (PLWH) from the ICONA cohort were included if they had started dolutegravir in a two- or three-drug regimen as ART-naive or as virologically controlled ART-experienced. The primary endpoint was time to treatment failure (virological/clinical failure or dolutegravir discontinuation). Secondary endpoints were: time to dolutegravir discontinuation due to toxicity and to neuropsychiatric adverse events; and time to virological failure. Cox regression analyses focused on differences in outcomes by sex. Results: A total of 2304 PLWH (15% women) initiated dolutegravir-based therapy from ART-naive, and 1916 (19.8% women) while experienced. After a median follow-up of 2.2 (IQR: 0.9-3.9) years in ART-naive and 2.4 (IQR: 1.1-4.3) years in experienced, the 4-year cumulative probability of treatment failure was 33% (95% CI 30.5-35.1) and 20% (95% CI 17.8-22.3), respectively. In the multivariable analyses, in ART-naive the risk of treatment failure was higher for women, but not different after excluding women discontinuing dolutegravir for pregnancy concerns. We also observed a higher risk of discontinuation for toxicity in women (ART-naives: Adjusted Hazard Ratio (AHR): 1.56%; 95% CI: 1.03-2.37; ART-experienced: AHR: 1.53%; 95% CI: 1.01-2.32), although the absolute 4-year probability was low: 7.7% (95% CI 6.5-9.2) in ART-naive and 8.3% (95% CI 6.9-9.9) in experienced. Conclusions: In our cohort of PLWH treated with dolutegravir-based regimens and followed up for up to 4 years, we observed a low risk of treatment failure and no evidence for a difference by sex, after excluding discontinuation due to pregnancy concerns. However, we observed a higher risk of dolutegravir discontinuation for toxicity in women. more...
- Published
- 2023
10. Lipid profile improvement in virologically suppressed HIV-1-infected patients switched to dolutegravir/abacavir/lamivudine: data from the SCOLTA project
- Author
-
Bagella P, Squillace N, Ricci E, Gulminetti R, De Socio GV, Taramasso L, Pellicanò G, Menzaghi B, Celesia BM, Dentone C, Orofino G, Bonfanti P, and Madeddu G
- Subjects
HIV-1 infection ,dolutegravir/abacavir/lamivudine ,lipid profile ,Infectious and parasitic diseases ,RC109-216 - Abstract
Paola Bagella,1 Nicola Squillace,2 Elena Ricci,3 Roberto Gulminetti,4 Giuseppe Vittorio De Socio,5 Lucia Taramasso,6 Giovanni Pellicanò,7 Barbara Menzaghi,8 Benedetto Maurizio Celesia,9 Chiara Dentone,10 Giancarlo Orofino,11 Paolo Bonfanti,12 Giordano Madeddu13On behalf of the C.I.S.A.I. Study Group, Italy1Unit of Post-acute Long Term Care, ATS Sardegna, Sassari, Italy; 2Infectious Diseases Unit, San Gerardo Hospital, University of Milano-Bicocca, Monza, Italy; 3Department of Infectious Diseases, ASST Fatebenefratelli Sacco, Milan, Italy; 4Unit of Infectious Diseases, IRCCS San Matteo Hospital, Pavia, Italy; 5Infectious Diseases Unit Department of Medicine, Azienda Ospedaliero-Universitaria di Perugia, Santa Maria Hospital, Perugia, Italy; 6Infectious Diseases Unit, Department of Internal Medicine, Fondazione IRCCS Ca‘ Granda Ospedale Maggiore Policlinico, Milan, Italy; 7Department of Human Pathology of the Adult and the Developmental Age ‘G. Barresi‘, Unit of Infectious Diseases, University of Messina, Messina, Italy; 8Unit of Infectious Diseases, ASST della Valle Olona, Busto Arsizio, Italy; 9Unit of Infectious Diseases, Garibaldi Hospital, Catania, Italy; 10Unit of Infectious Diseases, Sanremo Hospital, Sanremo, Italy; 11Unit of Infectious Diseases, Amedeo di Savoia Hospital, Turin, Italy; 12Unit of Infectious Diseases, A. Manzoni Hospital, Lecco, Italy; 13Unit of Infectious Diseases, Department of Clinical, Surgical and Experimental Medicine, University of Sassari, Sassari, ItalyIntroduction: Metabolic disorders are common amongst HIV-infected patients. Data from real-life setting on the impact of DTG/ABC/3TC in virologically suppressed HIV-infected patients are scarce.Methods: We investigated the modification of metabolic profile including fasting glucose, lipid profile and markers of insulin resistance (IR) in experienced patients switching from a boosted protease inhibitors (bPI) or a non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimen to DTG/ABC/3TC in a prospective, observational, multicenter study.Results: We enrolled 131 HIV-infected patients, of whom 91 (69.5%) males, mean age was 50.5±10.6 years. CDC stage was A in 66 (50.4%) patients, of whom 91 (69.5%) had acquired HIV through sexual contacts. The previous regimen was bPI-based in 79 patients (60.3%) and NNRTI-based in 52 (39.7%). Patients switching from NNRTI showed a significant reduction at week 24 in total cholesterol (TC) and low-density lipoprotein cholesterol (LDL). Triglycerides/high-density lipoprotein cholesterol (TG/HDL) ratio, HDL, median TG and TG/HDL ratio did not show significant modification during follow-up times. Among patients switching from a bPI, we observed a significant reduction in TC and LDL at both follow-up times and a slight increase in HDL. Triglycerides/HDL ratio, median TG and TG/HDL ratio showed a decrease over time that became significant at weeks 24 and 48. Blood glucose levels did not significantly vary during the observation period in patients switching from both bPI and NNRTI-based regimens.Conclusion: Our data suggest an improvement in lipid profile and TG/HDL ratio in pretreated HIV-1-infected patients who switched to DTG/ABC/3TC over 48 weeks, especially in those previously receiving a bPI-based regimen.Keywords: HIV-1 infection, dolutegravir/abacavir/lamivudine, lipid profile more...
- Published
- 2019
11. Pregnancy and neonatal outcomes among a cohort of HIV-infected women in a large Italian teaching hospital : a 30-year retrospective study
- Author
-
FOR GENOVA HIV NEONATAL AND PREGNANCY WORKING GROUP, GRIGNOLO, S., AGNELLO, R., GERBALDO, D., GOTTA, C., ALICINO, C., DEL PUENTE, F., TARAMASSO, L., BRUZZONE, B., GUSTAVINO, C., TRASINO, S., DE MARIA, A., ICARDI, G., VISCOLI, C., and DI BIAGIO, A. more...
- Published
- 2017
12. Metabolic syndrome and body weight in people living with HIV infection: analysis of differences observed in three different cohort studies over a decade
- Author
-
Taramasso L., Bonfanti P., Ricci E., Maggi P., Orofino G., Squillace N., Menzaghi B., Madeddu G., Molteni C., Vichi F., Riguccini E., Saracino A., Santoro C., Guastavigna M., Francisci D., Di Biagio A., De Socio G. V., Sarchi E., Chichino G., Bolla C., Bellacosa C., Angarano G., Calza L., Farinazzo M., Angioni G., Gussio M., Celesia B. M., Falasca K., Mastroianni A., Guadagnino G., Salomoni E., Martinelli C., Dentone C., Bassetti M., Cenderello G., Pellicano G. F., Nunnari G., Valsecchi L., Cordier L., Parisini S., Rizzardini G., Rusconi S., Conti F., Bandera A., Gori A., Motta D., Puoti M., Migliorino G. M., Martini S., Cascio A., Trizzino M., Gulminetti R., Nofri M., Cibelli D., Parruti G., Mameli M. S., Taramasso L., Bonfanti P., Ricci E., Maggi P., Orofino G., Squillace N., Menzaghi B., Madeddu G., Molteni C., Vichi F., Riguccini E., Saracino A., Santoro C., Guastavigna M., Francisci D., Di Biagio A., De Socio G.V., Sarchi E., Chichino G., Bolla C., Bellacosa C., Angarano G., Calza L., Farinazzo M., Angioni G., Gussio M., Celesia B.M., Falasca K., Mastroianni A., Guadagnino G., Salomoni E., Martinelli C., Dentone C., Bassetti M., Cenderello G., Pellicano G.F., Nunnari G., Valsecchi L., Cordier L., Parisini S., Rizzardini G., Rusconi S., Conti F., Bandera A., Gori A., Motta D., Puoti M., Migliorino G.M., Martini S., Cascio A., Trizzino M., Gulminetti R., Nofri M., Cibelli D., Parruti G., Mameli M.S., Taramasso, L, Bonfanti, P, Ricci, E, Maggi, P, Orofino, G, Squillace, N, Menzaghi, B, Madeddu, G, Molteni, C, Vichi, F, Riguccini, E, Saracino, A, Santoro, C, Guastavigna, M, Francisci, D, Di Biagio, A, De Socio, G, Taramasso, Lucia, Bonfanti, Paolo, Ricci, Elena, Maggi, Paolo, Orofino, Giancarlo, Squillace, Nicola, Menzaghi, Barbara, Madeddu, Giordano, Molteni, Chiara, Vichi, Francesca, Riguccini, Erika, Saracino, Annalisa, Santoro, Carmen, Guastavigna, Marta, Francisci, Daniela, Di Biagio, Antonio, and De Socio, Giuseppe Vittorio more...
- Subjects
Adult ,Male ,dyslipidaemia ,antiretroviral therapy ,HIV Infections ,Overweight ,Logistic regression ,Body Mass Index ,Cohort Studies ,Prevalence ,medicine ,overweight ,Humans ,Pharmacology (medical) ,Metabolic Syndrome ,business.industry ,Health Policy ,Incidence (epidemiology) ,Body Weight ,HIV ,weight gain ,Odds ratio ,Middle Aged ,medicine.disease ,Confidence interval ,metabolic syndrome ,Cross-Sectional Studies ,Infectious Diseases ,Metabolic syndrome ,medicine.symptom ,business ,Weight gain ,Demography ,Cohort study - Abstract
Objectives: The aim of this study was to assess the incidence of being overweight and metabolic syndrome (MS) among people living with HIV (PHIV) in three different cross-sectional studies conducted over three different periods: 2005, 2011 and 2015. Methods: This was a multi-centre, nationwide study. Data were collected in three studies from the CISAI group - SIMOne, HIV-HY and STOPSHIV - and included a total of 3014 PHIV. Logistic regression [odds ratio (OR), 95% confidence interval (CI)] was used to account for age and gender difference among three groups when comparing MS prevalence and being overweight; potential confounders were accounted for by including them in the regression equation. Results: Overall, the mean age was 46.9±10.2years, and men comprised 73.3% of participants. Comparing 2005, 2011 and 2015, MS was present in 34.5%, 33.0% and 29.3% of PHIV, respectively. Adjusted OR for MS was 0.64 (95% CI: 0.52-0.78) in 2011 and 0.56 (95% CI: 0.46-0.69) in 2015 compared with 2005, while BMI (kg/m2 ) increased from 23.6 in 2005, 24.5 in 2011 and 24.5 in 2015, with a concomitant increase of being overweight from 29.4% to 39.5% to 39.6% (p  more...
- Published
- 2021
- Full Text
- View/download PDF
13. Bloodstream infections in patients living with HIV in the modern cART era
- Author
-
Taramasso, L., Liggieri, F., Cenderello, G., Bovis, F., Giannini, B., Mesini, A., Giacomini, M., Cassola, G., Viscoli, C., and Di Biagio, A.
- Published
- 2019
- Full Text
- View/download PDF
14. Pillars of long-term antiretroviral therapy success
- Author
-
Taramasso, L, Andreoni, M, Antinori, A, Bandera, A, Bonfanti, P, Bonora, S, Borderi, M, Castagna, A, Cattelan, A, Celesia, B, Cicalini, S, Cingolani, A, Cossarizza, A, Arminio Monforte, A, Ettorre, G, Di Biagio, A, Di Giambenedetto, S, Perri, G, Esposito, V, Focà, E, Gervasoni, C, Gori, A, Gianotti, N, Guaraldi, G, Gulminetti, R, Caputo, S, Madeddu, G, Maggi, P, Marandola, G, Marchetti, G, Mastroianni, C, Mussini, C, Perno, C, Rizzardini, G, Rusconi, S, Santoro, M, Sarmati, L, Zazzi, M, Maggiolo, F, Taramasso, Lucia, Andreoni, Massimo, Antinori, Andrea, Bandera, Alessandra, Bonfanti, Paolo, Bonora, Stefano, Borderi, Marco, Castagna, Antonella, Cattelan, Anna Maria, Celesia, Benedetto Maurizio, Cicalini, Stefania, Cingolani, Antonella, Cossarizza, Andrea, Arminio Monforte, Antonella d', Ettorre, Gabriella d', Di Biagio, Antonio, Di Giambenedetto, Simona, Perri, Giovanni Di, Esposito, Vincenzo, Focà, Emanuele, Gervasoni, Cristina, Gori, Andrea, Gianotti, Nicola, Guaraldi, Giovanni, Gulminetti, Roberto, Caputo, Sergio Lo, Madeddu, Giordano, Maggi, Paolo, Marandola, Giorgio, Marchetti, Giulia Carla, Mastroianni, Claudio Maria, Mussini, Cristina, Perno, Carlo Federico, Rizzardini, Giuliano, Rusconi, Stefano, Santoro, Maria, Sarmati, Loredana, Zazzi, Maurizio, Maggiolo, Franco, Taramasso, L, Andreoni, M, Antinori, A, Bandera, A, Bonfanti, P, Bonora, S, Borderi, M, Castagna, A, Cattelan, A, Celesia, B, Cicalini, S, Cingolani, A, Cossarizza, A, Arminio Monforte, A, Ettorre, G, Di Biagio, A, Di Giambenedetto, S, Perri, G, Esposito, V, Focà, E, Gervasoni, C, Gori, A, Gianotti, N, Guaraldi, G, Gulminetti, R, Caputo, S, Madeddu, G, Maggi, P, Marandola, G, Marchetti, G, Mastroianni, C, Mussini, C, Perno, C, Rizzardini, G, Rusconi, S, Santoro, M, Sarmati, L, Zazzi, M, Maggiolo, F, Taramasso, Lucia, Andreoni, Massimo, Antinori, Andrea, Bandera, Alessandra, Bonfanti, Paolo, Bonora, Stefano, Borderi, Marco, Castagna, Antonella, Cattelan, Anna Maria, Celesia, Benedetto Maurizio, Cicalini, Stefania, Cingolani, Antonella, Cossarizza, Andrea, Arminio Monforte, Antonella d', Ettorre, Gabriella d', Di Biagio, Antonio, Di Giambenedetto, Simona, Perri, Giovanni Di, Esposito, Vincenzo, Focà, Emanuele, Gervasoni, Cristina, Gori, Andrea, Gianotti, Nicola, Guaraldi, Giovanni, Gulminetti, Roberto, Caputo, Sergio Lo, Madeddu, Giordano, Maggi, Paolo, Marandola, Giorgio, Marchetti, Giulia Carla, Mastroianni, Claudio Maria, Mussini, Cristina, Perno, Carlo Federico, Rizzardini, Giuliano, Rusconi, Stefano, Santoro, Maria, Sarmati, Loredana, Zazzi, Maurizio, and Maggiolo, Franco more...
- Abstract
Background: Meeting the challenge of antiretroviral therapy (ART) whose efficacy can last a lifetime requires continuous updating of the virological, pharmacological, and quality of life outcomes to be pursued and a continuous review of literature data on the efficacy and tolerability of new drugs and therapeutic strategies. Methods: With the aim of identifying open questions and answers about the current controversies in modern ART, we adapted the Design Thinking methodology to the needs of the design phase of a scientific article, involving a team of experts in HIV care. Results: Five main pillars of treatment success were discussed: sustained virologic suppression over time; immunological recovery; pharmacological attributes; long-term tolerability and safety of ART; and people's satisfaction and quality of life. The definition of the outcomes to be achieved in each thematic area and the tools to achieve them were reviewed and discussed. Conclusions: Long-term treatment success should be intended as a combination of HIV-RNA suppression, immune recovery, and high quality of life. To achieve this, the regimen should be well-tolerated, with high potency, genetic barrier, and forgiveness, and should be tailored by a person-centered perspective, based on individual needs, preferences, and therapeutic history. more...
- Published
- 2023
15. Lipids and Transaminase in Antiretroviral-Treatment-Experienced People Living with HIV, Switching to a Doravirine-Based vs. a Rilpivirine-Based Regimen: Data from a Real-Life Setting
- Author
-
Maggi, P, Ricci, E, Martinelli, C, De Socio, G, Squillace, N, Molteni, C, Masiello, A, Orofino, G, Menzaghi, B, Bellagamba, R, Vichi, F, Celesia, B, Madeddu, G, Pellicanò, G, Carleo, M, Cascio, A, Parisini, A, Taramasso, L, Valsecchi, L, Calza, L, Rusconi, S, Sarchi, E, Martini, S, Bargiacchi, O, Falasca, K, Cenderello, G, Ferrara, S, Di Biagio, A, Bonfanti, P, Maggi, Paolo, Ricci, Elena Delfina, Martinelli, Canio Vito, De Socio, Giuseppe Vittorio, Squillace, Nicola, Molteni, Chiara, Masiello, Addolorata, Orofino, Giancarlo, Menzaghi, Barbara, Bellagamba, Rita, Vichi, Francesca, Celesia, Benedetto Maurizio, Madeddu, Giordano, Pellicanò, Giovanni Francesco, Carleo, Maria Aurora, Cascio, Antonio, Parisini, Andrea, Taramasso, Lucia, Valsecchi, Laura, Calza, Leonardo, Rusconi, Stefano, Sarchi, Eleonora, Martini, Salvatore, Bargiacchi, Olivia, Falasca, Katia, Cenderello, Giovanni, Ferrara, Sergio, Di Biagio, Antonio, Bonfanti, Paolo, Maggi, P, Ricci, E, Martinelli, C, De Socio, G, Squillace, N, Molteni, C, Masiello, A, Orofino, G, Menzaghi, B, Bellagamba, R, Vichi, F, Celesia, B, Madeddu, G, Pellicanò, G, Carleo, M, Cascio, A, Parisini, A, Taramasso, L, Valsecchi, L, Calza, L, Rusconi, S, Sarchi, E, Martini, S, Bargiacchi, O, Falasca, K, Cenderello, G, Ferrara, S, Di Biagio, A, Bonfanti, P, Maggi, Paolo, Ricci, Elena Delfina, Martinelli, Canio Vito, De Socio, Giuseppe Vittorio, Squillace, Nicola, Molteni, Chiara, Masiello, Addolorata, Orofino, Giancarlo, Menzaghi, Barbara, Bellagamba, Rita, Vichi, Francesca, Celesia, Benedetto Maurizio, Madeddu, Giordano, Pellicanò, Giovanni Francesco, Carleo, Maria Aurora, Cascio, Antonio, Parisini, Andrea, Taramasso, Lucia, Valsecchi, Laura, Calza, Leonardo, Rusconi, Stefano, Sarchi, Eleonora, Martini, Salvatore, Bargiacchi, Olivia, Falasca, Katia, Cenderello, Giovanni, Ferrara, Sergio, Di Biagio, Antonio, and Bonfanti, Paolo more...
- Abstract
Doravirine (DOR) is a newly approved non-nucleoside reverse transcriptase inhibitor (NNRTI). We aimed to investigate, in a real-life setting, how switching to a DOR-based regimen rather than a rilpivirine (RPV)-based regimen impacted metabolic and hepatic safety. The analysis included 551 antiretroviral treatment (ART)-experienced people living with HIV (PLWH), starting RPV-based or DOR-based regimens with viral load < 200 copies/mL, baseline (T0), and at least one control visit (6-month visit, T1). We enrolled 295 PLWH in the RPV and 256 in the DOR cohort. At T1, total cholesterol (TC), low-density lipoprotein-C (LDL-C), and triglycerides significantly decreased in both DOR and RPV cohorts, while high-density lipoprotein-C (HDL-C) only decreased in RPV-treated people. Consistently, the TC/HDL-C ratio declined more markedly in the DOR (−0.36, p < 0.0001) than in the RPV cohort (−0.08, p = 0.25) (comparison p = 0.39). Similar trends were observed when excluding the PLWH on lipid-lowering treatment from the analysis. People with normal alanine aminotransferase (ALT) levels showed a slight ALT increase in both cohorts, and those with baseline ALT > 40 IU/L experienced a significant decline (−14 IU/L, p = 0.008) only in the DOR cohort. Lipid profile improved in both cohorts, and there was a significant reduction in ALT in PLWH with higher-than-normal baseline levels on DOR-based ART. more...
- Published
- 2023
16. Real-life safety of Emtricitabine/Tenofovir Alafenamide/Bictegravir
- Author
-
Squillace, N, Ricci, E, Maggi, P, Taramasso, L, Menzaghi, B, De Socio, G, Piconi, S, Maurizio Celesia, B, Orofino, G, Sarchi, E, Pellicanò, G, Simeone, F, Valsecchi, L, Bandera, A, Cenderello, G, Attala, L, Angioni, G, Falasca, K, Cascio, A, Bargiacchi, O, Di Biagio, A, Bonfanti, P, Squillace, Nicola, Ricci, Elena, Maggi, Paolo, Taramasso, Lucia, Menzaghi, Barbara, De Socio, Giuseppe Vittorio, Piconi, Stefania, Maurizio Celesia, Benedetto, Orofino, Giancarlo, Sarchi, Eleonora, Pellicanò, Giovanni Francesco, Simeone, Filomena, Valsecchi, Laura, Bandera, Alessandra, Cenderello, Giovanni, Attala, Letizia, Angioni, Goffredo, Falasca, Katia, Cascio, Antonio, Bargiacchi, Olivia, Di Biagio, Antonio, Bonfanti, Paolo, Squillace, N, Ricci, E, Maggi, P, Taramasso, L, Menzaghi, B, De Socio, G, Piconi, S, Maurizio Celesia, B, Orofino, G, Sarchi, E, Pellicanò, G, Simeone, F, Valsecchi, L, Bandera, A, Cenderello, G, Attala, L, Angioni, G, Falasca, K, Cascio, A, Bargiacchi, O, Di Biagio, A, Bonfanti, P, Squillace, Nicola, Ricci, Elena, Maggi, Paolo, Taramasso, Lucia, Menzaghi, Barbara, De Socio, Giuseppe Vittorio, Piconi, Stefania, Maurizio Celesia, Benedetto, Orofino, Giancarlo, Sarchi, Eleonora, Pellicanò, Giovanni Francesco, Simeone, Filomena, Valsecchi, Laura, Bandera, Alessandra, Cenderello, Giovanni, Attala, Letizia, Angioni, Goffredo, Falasca, Katia, Cascio, Antonio, Bargiacchi, Olivia, Di Biagio, Antonio, and Bonfanti, Paolo more...
- Abstract
Introduction Integrase strand transfer inhibitors (INSTI) are one of the most prescribed drug classes for the treatment of HIV infection worldwide. Emtricitabine/Tenofovir Alafenamide/ Bictegravir (FTC/TAF/BIC) has been evaluated in randomized clinical trials; few studies have verified tolerability and safety in clinical practice. Our aim was to investigate the metabolic and hepatic safety in a real-life setting of FTC/TAF/BIC. Materials and methods Consecutive people living with HIV infection (PLWH) enrolled in the SCOLTA project, switching to or initiating their first antiretroviral treatment with FTC/TAF/BIC were included. PLWH with HBV co-infection were excluded. Metabolic and hepatic variables were collected at T0 and T1, were defined as baseline and 6-month follow-up respectively, and their modifications were analysed using the paired t-test and the analysis of variance. Results Five hundred and thirty-nine PLWH with at least one follow-up visit were included in the analysis. Mean age was 48 years (±12.1), 74% were male, 16.1% were naïve to antiretrovirals (ART). At T1, ART-experienced PLWH showed a significant reduction of total cholesterol (TC) and triglycerides, and a slight increase in blood glucose (BG) and ALT. On the contrary, in ART-naïve PLWH blood lipids significantly increased, although with an unaffected TC/high density lipoprotein (HDL)-c ratio, while alanine aminotransferase (ALT) decreased significantly, mainly in those with altered baseline level. The treatment interruptions were 45 (8.4%) over the whole observation period, 13 (2.4%) due to AEs. The most frequent AEs were related to the central nervous system (6 events of depression, insomnia, headache, agitation) and 3 PLWH discontinued the regimen because of grade 1-2 weight gain. Conclusions In ART-experienced PLWH switching to FTC/TAF/BIC a significant improvement of lipid profile occurred but with significant BG and ALT variation without clinical relevance. In ARTnaïve PLWH, blood lipid more...
- Published
- 2023
17. Incident diabetes in course of antiretroviral therapy
- Author
-
Taramasso, L, Squillace, N, Ricci, E, Menzaghi, B, Orofino, G, Socio, G, Molteni, C, Martinelli, C, Madeddu, G, Vichi, F, Valsecchi, L, Celesia, B, Maggi, P, Rusconi, S, Pellicanò, G, Cascio, A, Sarchi, E, Gulminetti, R, Falasca, K, Di Biagio, A, Bonfanti, P, Taramasso, Lucia, Squillace, Nicola, Ricci, Elena, Menzaghi, Barbara, Orofino, Giancarlo, Socio, Giuseppe Vittorio De, Molteni, Chiara, Martinelli, Canio Vito, Madeddu, Giordano, Vichi, Francesca, Valsecchi, Laura, Celesia, Benedetto Maurizio, Maggi, Paolo, Rusconi, Stefano, Pellicanò, Giovanni Francesco, Cascio, Antonio, Sarchi, Eleonora, Gulminetti, Roberto, Falasca, Katia, Di Biagio, Antonio, Bonfanti, Paolo, Taramasso, L, Squillace, N, Ricci, E, Menzaghi, B, Orofino, G, Socio, G, Molteni, C, Martinelli, C, Madeddu, G, Vichi, F, Valsecchi, L, Celesia, B, Maggi, P, Rusconi, S, Pellicanò, G, Cascio, A, Sarchi, E, Gulminetti, R, Falasca, K, Di Biagio, A, Bonfanti, P, Taramasso, Lucia, Squillace, Nicola, Ricci, Elena, Menzaghi, Barbara, Orofino, Giancarlo, Socio, Giuseppe Vittorio De, Molteni, Chiara, Martinelli, Canio Vito, Madeddu, Giordano, Vichi, Francesca, Valsecchi, Laura, Celesia, Benedetto Maurizio, Maggi, Paolo, Rusconi, Stefano, Pellicanò, Giovanni Francesco, Cascio, Antonio, Sarchi, Eleonora, Gulminetti, Roberto, Falasca, Katia, Di Biagio, Antonio, and Bonfanti, Paolo more...
- Abstract
Objective:Recent reports of excessive weight gain in people with HIV (PWH) have raised increasing concerns on the possible increase of diabetes mellitus (DM) risk in course of integrase inhibitors (INSTIs) treatment. In this study, we aimed at describing DM incidence in course of antiretroviral therapy (ART) and identifying the factors associated with new DM onset.Design:Observational prospective SCOLTA (Surveillance Cohort Long-Term Toxicity Antiretrovirals) cohort.Methods:All people enrolled in SCOLTA between January 2003 and November 2021 were included. Multivariable Cox regression yielded adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs) for incident DM.Results:4366 PWH were included, 72.6% male, with mean age 45.6 years, and median CD4+ 460 [interquartile range (IQR) 256-710] cells/mm3cells/mm3. During the follow up, 120 incident cases of DM occurred (1.26 cases/100 person year-follow up, 95% CI 1.05-1.50).Baseline weight, but not the amount of weight gain, resulted significantly correlated to diabetes incidence (aHR by 1 kg 1.03; 95% CI 1.01-1.04), as well as older age (aHR 1.03 by 1 year; 95% CI 1.01-1.06), being ART-experienced with detectable HIV RNA at study entry (aHR 2.27, 95% CI 1.48-3.49), having untreated high blood pressure (aHR 2.90; 95% CI 1.30-6.45) and baseline blood glucose >100 mg/dl (aHR 5.47; 95% CI 3.82-7.85). Neither the INSTI class nor individual antiretrovirals were associated with an increased risk of DM.Conclusions:Baseline weight, but not weight gain or the ART class, was associated with incident DM in this observational cohort. more...
- Published
- 2023
18. Evidence gaps on weight gain in people living with HIV: a scoping review to define a research agenda
- Author
-
Guaraldi, G, Bonfanti, P, Di Biagio, A, Gori, A, Milić, J, Saltini, P, Segala, F, Squillace, N, Taramasso, L, Cingolani, A, Guaraldi, Giovanni, Bonfanti, Paolo, Di Biagio, Antonio, Gori, Andrea, Milić, Jovana, Saltini, Paola, Segala, Francesco V, Squillace, Nicola, Taramasso, Lucia, Cingolani, Antonella, Guaraldi, G, Bonfanti, P, Di Biagio, A, Gori, A, Milić, J, Saltini, P, Segala, F, Squillace, N, Taramasso, L, Cingolani, A, Guaraldi, Giovanni, Bonfanti, Paolo, Di Biagio, Antonio, Gori, Andrea, Milić, Jovana, Saltini, Paola, Segala, Francesco V, Squillace, Nicola, Taramasso, Lucia, and Cingolani, Antonella more...
- Abstract
Background: Combined antiretroviral therapy (cART) dramatically improved survival in people living with HIV (PLWH) but is associated with weight gain (WG), raising concern for a possible obesity epidemic in PLWH. This scoping review aims to identify the gaps in the existing evidence on WG in PLWH and generate a future research agenda. Methods: This review was conducted according to the methodology for scoping studies and reported according to the PRISMA Extension for Scoping Review checklist. Articles published in English in the last 10 years indexed in Pubmed, WHO Global Index Medicus, or Embase were searched using specific queries focused on WG in PLWH. Results: Following the selection process, 175 included articles were reviewed to search for the available evidence on four specific topics: (I) definition of WG in PLWH, (II) pathogenesis of WG in PLWH, (III) impact of ART on WG, (IV) correlation of WG with clinical outcomes. A summary of the data enabled us to identify gaps and clearly define the following research agenda: (I) develop a data-driven definition of WG in PLWH and define noninvasive assessment methods for body weight and fat composition; (II) further investigate the interaction between HIV/cART and immunity, metabolism, and adipose tissue; (III) establish the specific role of individual drugs on WG; (IV) clarify the independent role of WG, cART, HIV, and metabolic factors on clinical events. Conclusions: The proposed research agenda may help define future research and fill the knowledge gaps that have emerged from this review. more...
- Published
- 2023
19. Lipids and transaminase elevations in ARV-experienced PLWH switching to a doravirine-based regimen from rilpivirine or other regimens
- Author
-
Maggi, P, Ricci, E, Cicalini, S, Pellicanò, G, Celesia, B, Vichi, F, Cascio, A, Sarchi, E, Orofino, G, Squillace, N, Madeddu, G, De Socio, G, Bargiacchi, O, Molteni, C, Masiello, A, Saracino, A, Menzaghi, B, Falasca, K, Taramasso, L, Di Biagio, A, Bonfanti, P, Maggi, Paolo, Ricci, Elena Delfina, Cicalini, Stefania, Pellicanò, Giovanni Francesco, Celesia, Benedetto Maurizio, Vichi, Francesca, Cascio, Antonio, Sarchi, Eleonora, Orofino, Giancarlo, Squillace, Nicola, Madeddu, Giordano, De Socio, Giuseppe Vittorio, Bargiacchi, Olivia, Molteni, Chiara, Masiello, Addolorata, Saracino, Annalisa, Menzaghi, Barbara, Falasca, Katia, Taramasso, Lucia, Di Biagio, Antonio, Bonfanti, Paolo, Maggi, P, Ricci, E, Cicalini, S, Pellicanò, G, Celesia, B, Vichi, F, Cascio, A, Sarchi, E, Orofino, G, Squillace, N, Madeddu, G, De Socio, G, Bargiacchi, O, Molteni, C, Masiello, A, Saracino, A, Menzaghi, B, Falasca, K, Taramasso, L, Di Biagio, A, Bonfanti, P, Maggi, Paolo, Ricci, Elena Delfina, Cicalini, Stefania, Pellicanò, Giovanni Francesco, Celesia, Benedetto Maurizio, Vichi, Francesca, Cascio, Antonio, Sarchi, Eleonora, Orofino, Giancarlo, Squillace, Nicola, Madeddu, Giordano, De Socio, Giuseppe Vittorio, Bargiacchi, Olivia, Molteni, Chiara, Masiello, Addolorata, Saracino, Annalisa, Menzaghi, Barbara, Falasca, Katia, Taramasso, Lucia, Di Biagio, Antonio, and Bonfanti, Paolo more...
- Abstract
Background: Doravirine (DOR) is a newly approved antiretroviral belonging to the class of non-nucleoside reverse transcriptase inhibitors (NNRTI), well tolerated and leading to an improved lipid profile in antiretroviral experienced people living with HIV (PLWH). We aimed at evaluating if the lipid-lowering effect is linked to the drug class, using real-life data from the SCOLTA cohort. Methods: We compared the lipid profile modifications in experienced PLWH switching to a DOR-based regimen from rilpivirine or another NNRTI-based regimen or from an integrase strand transferase (INSTI)-based regimen. T0 and T1 were defined as the baseline and 6-month follow-up respectively. Data were collected at baseline and prospectively every six months and changes from baseline were compared using a multivariable linear model. Results: In 107 PLWH, enrolled in the SCOLTA DOR cohort, with undetectable HIV-RNA at baseline, 32.7% switched from RPV-based regimens (DOR1), 29.9% from other NNRTI-including regimens (DOR2) and 37.4% switched from INSTI-including regimens (DOR3). At T1, TC significantly decreased in DOR2 (-15 mg/dL) and DOR3 (-23 mg/dL), and significantly more in DOR3 than in DOR1 (-6 mg/dL) (p = 0.016). HDL-C declined in DOR2 (-2 mg/dL) whereas it increased in DOR1 (+ 3 mg/dL) (p = 0.042) and remained stable in DOR3. LDL-C significantly decreased from baseline in DOR2 (-12 mg/dL) and DOR3 (-22 mg/dL) and was different between DOR1 (-8 mg/dL) and DOR3 (p = 0.022). TC/HDL ratio showed a significant decline in the DOR3 group (-0.45), although similar to DOR1 (-0.23, p = 0.315) and DOR2 (-0.19, p = 0.254). Triglycerides did not noticeably change. ALT significantly decreased in PLWH with a baseline level > 40 UI/mL. Conclusions: PLWH on doravirine treatment showed different trends in blood lipids according to their previous regimen. In PLWH switching from RPV, minimal modifications were seen, whereas in those switching from other NNRTIs and from INSTI-including regimens, w more...
- Published
- 2023
20. Causes of HIV Treatment Interruption during the Last 20 Years: A Multi-Cohort Real-Life Study
- Author
-
De Vito, A, Ricci, E, Menzaghi, B, Orofino, G, Martinelli, C, Squillace, N, Taramasso, L, De Socio, G, Molteni, C, Valsecchi, L, Costa, C, Celesia, B, Parruti, G, Pellicanò, G, Sarchi, E, Cascio, A, Cenderello, G, Falasca, K, Di Biagio, A, Bonfanti, P, Madeddu, G, De Vito, Andrea, Ricci, Elena, Menzaghi, Barbara, Orofino, Giancarlo, Martinelli, Canio Vito, Squillace, Nicola, Taramasso, Lucia, De Socio, Giuseppe Vittorio, Molteni, Chiara, Valsecchi, Laura, Costa, Cecilia, Celesia, Benedetto Maurizio, Parruti, Giustino, Pellicanò, Giovanni Francesco, Sarchi, Eleonora, Cascio, Antonio, Cenderello, Giovanni, Falasca, Katia, Di Biagio, Antonio, Bonfanti, Paolo, Madeddu, Giordano, De Vito, A, Ricci, E, Menzaghi, B, Orofino, G, Martinelli, C, Squillace, N, Taramasso, L, De Socio, G, Molteni, C, Valsecchi, L, Costa, C, Celesia, B, Parruti, G, Pellicanò, G, Sarchi, E, Cascio, A, Cenderello, G, Falasca, K, Di Biagio, A, Bonfanti, P, Madeddu, G, De Vito, Andrea, Ricci, Elena, Menzaghi, Barbara, Orofino, Giancarlo, Martinelli, Canio Vito, Squillace, Nicola, Taramasso, Lucia, De Socio, Giuseppe Vittorio, Molteni, Chiara, Valsecchi, Laura, Costa, Cecilia, Celesia, Benedetto Maurizio, Parruti, Giustino, Pellicanò, Giovanni Francesco, Sarchi, Eleonora, Cascio, Antonio, Cenderello, Giovanni, Falasca, Katia, Di Biagio, Antonio, Bonfanti, Paolo, and Madeddu, Giordano more...
- Abstract
In the last years, many antiretroviral drugs (ART) have been developed with increased efficacy. Nowadays, the main reasons for treatment switches are adverse events, proactive strategy or simplification. We conducted a retrospective cohort study to investigate the reason for treatment interruption in the last 20 years. We merged data of eight cohorts of the SCOLTA project: lopinavir/r (LPV), atazanavir/r (ATV), darunavir/r or /c (DRV), rilpivirine (RPV), raltegravir (RAL), elvitegravir/c (EVG), dolutegravir (DTG) and bictegravir (BIC). We included 4405 people with HIV (PWH). Overall, 664 (15.1%), 489 (11.1%), and 271 (6.2%) PWH interrupted the treatment in the first, second, and third years after starting a new ART. Looking at the interruption in the first year, the most frequent causes were adverse events (3.8%), loss to follow-up (3.7%), patients’ decisions (2.6%), treatment failure (1.7%), and simplification (1.3%). In the multivariate analysis regarding experienced patients, treatment with LPV, ATV, RPV or EVG/c, having less than 250 CD4 cells/mL, history of intravenous drug use, and HCV positivity were associated with an increased risk of interruption. In naive people, only LPV/r was associated with an increased risk of interruption, while RPV was associated with a lower risk. In conclusion, our data on more than 4400 PWH show that adverse events have represented the most frequent cause of treatment interruptions in the first year of ART (3.84%). Treatment discontinuations were more frequent during the first year of follow-up and decreased thereafter. First-generation PI in both naïve and experienced PWH, and EVG/c, in experienced PWH, were associated with a higher risk of treatment interruptions. more...
- Published
- 2023
21. Raltegravir-based therapy in a cohort of HIV/HCV co-infected individuals
- Author
-
Taramasso, L., Madeddu, G., Ricci, E., De Socio, G.V., Menzaghi, B., Orofino, G., Passerini, S., Franzetti, M., Maggi, P., Dentone, C., Martinelli, C., Celesia, B.M., Penco, G., Libertone, R., Quirino, T., Bonfanti, P., and Di Biagio, A. more...
- Published
- 2015
- Full Text
- View/download PDF
22. Off-label use of combined antiretroviral therapy, analysis of data collected by the Italian Register for HIV-1 infection in paediatrics in a large cohort of children
- Author
-
Chiappini, E., Lisi, C., Giacomet, V., Erba, P., Bernardi, S., Zangari, P., Di Biagio, A., Taramasso, L., Giaquinto, C., Rampon, O., Gabiano, C., Garazzino, S., Tagliabue, C., Esposito, S., Bruzzese, E., Badolato, R., Zanaboni, D., Cellini, M., Dedoni, M., Mazza, A., Pession, A., Giannini, A. M., Salvini, F., Dodi, I., Carloni, I., Cazzato, S., Tovo, P. A., de Martino, M., Galli, L., Parigi, S., Orlandi, F., de Martino, A., Pinzani, R., Abbagnato, L., Ruggeri, M., Baldi, F., Faldella, G., Chiriaco, P., Dessi, C., Panto, M. G., Anastasio, E., Govoni, M. R., Bigi, M., Bondi, E., Borea, R., Cenderello, G., Tommasi, D., Nogare, E. R. D., Saitta, M., Felici, L., Consolini, R., Antonellini, A., Anzidei, G., Genovese, O., Catania, S., Natale, F., Olmeo, P., Cristiano, L., Portelli, V., Rabusin, M., Di Pietro, G. M., Fabrizio, L., Chiappini, Elena, Lisi, Catiuscia, Giacomet, Vania, Erba, Paola, Bernardi, Stefania, Zangari, Paola, Di Biagio, Antonio, Taramasso, Lucia, Giaquinto, Carlo, Rampon, Osvalda, Gabiano, Clara, Garazzino, Silvia, Tagliabue, Claudia, Esposito, Susanna, Bruzzese, Eugenia, Badolato, Raffaele, Zanaboni, Domenico, Cellini, Monica, Dedoni, Maurizio, Mazza, Antonio, Pession, Andrea, Giannini, Anna Maria, Salvini, Filippo, Dodi, Icilio, Carloni, Ine, Cazzato, Salvatore, Tovo, Pier Angelo, de Martino, Maurizio, and Galli, Luisa more...
- Subjects
Register (sociolinguistics) ,Pediatrics ,medicine.medical_specialty ,HAART ,Adolescent ,Anti-HIV Agents ,Off-label therapy ,Human immunodeficiency virus (HIV) ,HIV Infections ,Infectious and parasitic diseases ,RC109-216 ,HIV-1 infection ,medicine.disease_cause ,Off-label use ,Retrospective Studie ,Antiretroviral Therapy, Highly Active ,medicine ,Humans ,Highly Active ,HIV Infection ,Child ,Children ,Antiretroviral therapy ,CD4 Lymphocyte Count ,Off-Label Use ,Retrospective Studies ,Viral Load ,HIV-1 ,business.industry ,Research ,Anti-HIV Agent ,virus diseases ,Large cohort ,Infectious Diseases ,business ,Human - Abstract
Background Early start of highly active antiretroviral therapy (HAART) in perinatally HIV-1 infected children is the optimal strategy to prevent immunological and clinical deterioration. To date, according to EMA, only 35% of antiretroviral drugs are licenced in children Methods An observational retrospective study investigating the rate and the outcomes of off-label prescription of HAART was conducted on 225 perinatally HIV-1 infected children enrolled in the Italian Register for HIV Infection in Children and followed-up from 2001 to 2018. Results 22.2% (50/225) of included children were receiving an off-label HAART regimen at last check. Only 26% (13/50) of off-label children had an undetectable viral load (VL) before the commencing of the regimen and the 52.0% (26/50) had a CD4 + T lymphocyte percentage > 25%. At last check, during the off label regimen, the 80% (40/50) of patients had an undetectable VL, and 90% (45/50) of them displayed CD4 + T lymphocyte percentage > 25%. The most widely used off-label drugs were: dolutegravir/abacavir/lamivudine (16%; 8/50), emtricitbine/tenofovir disoproxil (22%; 11/50), lopinavir/ritonavir (20%; 10/50) and elvitegravir/cobicistat/emtricitabine/ tenofovir alafenamide (10%; 10/50). At logistic regression analysis, detectable VL before starting the current HAART regimen was a risk factor for receiving an off-label therapy (OR: 2.41; 95% CI 1.13–5.19; p = 0.024). Moreover, children Conclusion The prescription of an off-label HAART regimen in perinatally HIV-1 infected children was common, in particular in children with detectable VL despite previous HAART and in younger children, especially those receiving their first regimen. Our data suggest similar proportions of virological and immunological successes at last check among children receiving off-label or on-label HAART. Larger studies are needed to better clarify efficacy and safety of off-label HAART regimens in children, in order to allow the enlargement of on-label prescription in children. more...
- Published
- 2022
23. Weight Gain: A Possible Side Effect of All Antiretrovirals
- Author
-
Taramasso, Lucia, Ricci, Elena, Menzaghi, Barbara, Orofino, Giancarlo, Passerini, Simone, Madeddu, Giordano, Martinelli, Canio Vito, De Socio, Giuseppe Vittorio, Squillace, Nicola, Rusconi, Stefano, Bonfanti, Paolo, Di Biagio, Antonio, Quirino, T, Bonfanti, P, Ricci, E, Bellacosa, C, Maggi, P, Calza, L, Abeli, C, Menzaghi, B, Celesia, B M, Grosso, C, Stagno, A, Vichi, F, Mazzotta, F, Martinelli, C, Penco, G, Cassola, G, Di Biagio, A, Taramasso, L, Nicolini, L A, Dentone, C, Molteni, C, Palvarini, L, Scalzini, A, Carenzi, L, Rizzardini, G, Valsecchi, L, Cordier, L, Rusconi, S, Colombo, V, Galli, M, Franzetti, M, De Socio, G V, Mazzotta, E, Parruti, G, Madeddu, G, Bagella, P, S. Mura, M, Libertone, R, Antinori, A, Di Giambenedetto, S, Orofino, G, Guastavigna, M, and Caramell, P more...
- Published
- 2017
- Full Text
- View/download PDF
24. The impact of DAA-mediated HCV eradication on CD4+ and CD8+ T lymphocyte trajectories in HIV/HCV coinfected patients: Data from the ICONA Foundation Cohort
- Author
-
Bandera, A, Lorenzini, P, Taramasso, L, Cozzi-Lepri, A, Lapadula, G, Mussini, C, Saracino, A, Ceccherini-Silberstein, F, Puoti, M, Quiros-Roldan, E, Montagnani, F, Antinori, A, d'Arminio Monforte, A, Gori, A, Andreoni, M, Castagna, A, Castelli, F, Cauda, R, Di Perri, G, Galli, M, Iardino, R, Ippolito, G, Lazzarin, A, Marchetti, G, Rezza, G, von Shloesser, F, Viale, P, Girardi, E, Lo Caputo, S, Maggiolo, F, Perno, C, Bai, F, Bonora, S, Borderi, M, Calcagno, A, Capobianchi, M, Cicalini, S, Cingolani, A, Cinque, P, Di Biagio, A, Gagliardini, R, Gianotti, N, Guaraldi, G, Lichtner, M, Lai, A, Madeddu, G, Merlini, E, Nozza, S, Piconi, S, Pinnetti, C, Rossotti, R, Rusconi, S, Santoro, M, Sarmati, L, Spagnuolo, V, Svicher, V, Fanti, I, Galli, L, Rodano', A, Macchia, M, Tavelli, A, Bove, A, Camposeragna, A, Errico, M, Manfredini, M, Perziano, A, Calvino, V, Carletti, F, Carrara, S, Di Caro, A, Graziano, S, Petroni, F, Prota, G, Truffa, S, Giacometti, A, Costantini, A, Barocci, V, Angarano, G, Monno, L, Milano, E, Suardi, C, Donati, V, Verucchi, G, Castelnuovo, F, Minardi, C, Menzaghi, B, Abeli, C, Chessa, L, Pes, F, Cacopardo, B, Celesia, B, Vecchiet, J, Falasca, K, Pan, A, Lorenzotti, S, Sighinolfi, L, Segala, D, Blanc, P, Vichi, F, Cassola, G, Bassetti, M, Alessandrini, A, Bobbio, N, Mazzarello, G, Fondaco, L, Bonfanti, P, Molteni, C, Chiodera, A, Milini, P, Nunnari, G, Pellicano, G, Rizzardini, G, Cannizzo, E, Moioli, M, Piolini, R, Bernacchia, D, Poli, A, Tincati, C, Puzzolante, C, Migliorino, C, Sangiovanni, V, Borgia, G, Esposito, V, Di Flumeri, G, Gentile, I, Rizzo, V, Cattelan, A, Marinello, S, Cascio, A, Trizzino, M, Francisci, D, Schiaroli, E, Parruti, G, Sozio, F, Lazzaretti, C, Corsini, R, Qqwdreoni, Q, Cristaudo, A, Vullo, V, Acinapura, R, Lamonica, S, Capozzi, M, Mondi, A, Rivano Capparuccia, M, Iaiani, G, Latini, A, Onnelli, G, Plazzi, M, De Girolamo, G, Vergori, A, Cecchetto, M, Viviani, F, De Vito, A, Rossetti, B, Franco, A, Fontana Del Vecchio, R, Di Giuli, C, Caramello, P, Orofino, G, Sciandra, M, Londero, A, Manfrin, V, Battagin, G, Starnini, G, Ialungo, A, Bandera A., Lorenzini P., Taramasso L., Cozzi-Lepri A., Lapadula G., Mussini C., Saracino A., Ceccherini-Silberstein F., Puoti M., Quiros-Roldan E., Montagnani F., Antinori A., d'Arminio Monforte A., Gori A., Andreoni M., Castagna A., Castelli F., Cauda R., Di Perri G., Galli M., Iardino R., Ippolito G., Lazzarin A., Marchetti G. C., Rezza G., von Shloesser F., Viale P., Girardi E., Lo Caputo S., Maggiolo F., Perno C. F., Bai F., Bonora S., Borderi M., Calcagno A., Capobianchi M. R., Cicalini S., Cingolani A., Cinque P., Di Biagio A., Gagliardini R., Gianotti N., Guaraldi G., Lichtner M., Lai A., Madeddu G., Marchetti G., Merlini E., Nozza S., Piconi S., Pinnetti C., Rossotti R., Rusconi S., Santoro M. M., Sarmati L., Spagnuolo V., Svicher V., Fanti I., Galli L., Rodano' A., Macchia M., Tavelli A., Bove A., Camposeragna A., Errico M., Manfredini M., Perziano A., Calvino V., Carletti F., Carrara S., Di Caro A., Graziano S., Petroni F., Prota G., Truffa S., Giacometti A., Costantini A., Barocci V., Angarano G., Monno L., Milano E., Suardi C., Donati V., Verucchi G., Castelnuovo F., Minardi C., Menzaghi B., Abeli C., Chessa L., Pes F., Cacopardo B., Celesia B., Vecchiet J., Falasca K., Pan A., Lorenzotti S., Sighinolfi L., Segala D., Blanc P., Vichi F., Cassola G., Bassetti M., Alessandrini A., Bobbio N., Mazzarello G., Fondaco L., Bonfanti P., Molteni C., Chiodera A., Milini P., Nunnari G., Pellicano G., Rizzardini G., Cannizzo E. S., Moioli M. C., Piolini R., Bernacchia D., Poli A., Tincati C., Puzzolante C., Migliorino C., Sangiovanni V., Borgia G., Esposito V., Di Flumeri G., Gentile I., Rizzo V., Cattelan A. M., Marinello S., Cascio A., Trizzino M., Francisci D., Schiaroli E., Parruti G., Sozio F., Lazzaretti C., Corsini R., Qqwdreoni Q., Cristaudo A., Vullo V., Acinapura R., Lamonica S., Capozzi M., Mondi A., Rivano Capparuccia M., Iaiani G., Latini A., Onnelli G., Plazzi M. M., De Girolamo G., Vergori A., Cecchetto M., Viviani F., De Vito A., Rossetti B., Franco A., Fontana Del Vecchio R., Di Giuli C., Caramello P., Orofino G. C., Sciandra M., Londero A., Manfrin V., Battagin G., Starnini G., Ialungo A., Bandera, A, Lorenzini, P, Taramasso, L, Cozzi-Lepri, A, Lapadula, G, Mussini, C, Saracino, A, Ceccherini-Silberstein, F, Puoti, M, Quiros-Roldan, E, Montagnani, F, Antinori, A, d'Arminio Monforte, A, Gori, A, Andreoni, M, Castagna, A, Castelli, F, Cauda, R, Di Perri, G, Galli, M, Iardino, R, Ippolito, G, Lazzarin, A, Marchetti, G, Rezza, G, von Shloesser, F, Viale, P, Girardi, E, Lo Caputo, S, Maggiolo, F, Perno, C, Bai, F, Bonora, S, Borderi, M, Calcagno, A, Capobianchi, M, Cicalini, S, Cingolani, A, Cinque, P, Di Biagio, A, Gagliardini, R, Gianotti, N, Guaraldi, G, Lichtner, M, Lai, A, Madeddu, G, Merlini, E, Nozza, S, Piconi, S, Pinnetti, C, Rossotti, R, Rusconi, S, Santoro, M, Sarmati, L, Spagnuolo, V, Svicher, V, Fanti, I, Galli, L, Rodano', A, Macchia, M, Tavelli, A, Bove, A, Camposeragna, A, Errico, M, Manfredini, M, Perziano, A, Calvino, V, Carletti, F, Carrara, S, Di Caro, A, Graziano, S, Petroni, F, Prota, G, Truffa, S, Giacometti, A, Costantini, A, Barocci, V, Angarano, G, Monno, L, Milano, E, Suardi, C, Donati, V, Verucchi, G, Castelnuovo, F, Minardi, C, Menzaghi, B, Abeli, C, Chessa, L, Pes, F, Cacopardo, B, Celesia, B, Vecchiet, J, Falasca, K, Pan, A, Lorenzotti, S, Sighinolfi, L, Segala, D, Blanc, P, Vichi, F, Cassola, G, Bassetti, M, Alessandrini, A, Bobbio, N, Mazzarello, G, Fondaco, L, Bonfanti, P, Molteni, C, Chiodera, A, Milini, P, Nunnari, G, Pellicano, G, Rizzardini, G, Cannizzo, E, Moioli, M, Piolini, R, Bernacchia, D, Poli, A, Tincati, C, Puzzolante, C, Migliorino, C, Sangiovanni, V, Borgia, G, Esposito, V, Di Flumeri, G, Gentile, I, Rizzo, V, Cattelan, A, Marinello, S, Cascio, A, Trizzino, M, Francisci, D, Schiaroli, E, Parruti, G, Sozio, F, Lazzaretti, C, Corsini, R, Qqwdreoni, Q, Cristaudo, A, Vullo, V, Acinapura, R, Lamonica, S, Capozzi, M, Mondi, A, Rivano Capparuccia, M, Iaiani, G, Latini, A, Onnelli, G, Plazzi, M, De Girolamo, G, Vergori, A, Cecchetto, M, Viviani, F, De Vito, A, Rossetti, B, Franco, A, Fontana Del Vecchio, R, Di Giuli, C, Caramello, P, Orofino, G, Sciandra, M, Londero, A, Manfrin, V, Battagin, G, Starnini, G, Ialungo, A, Bandera A., Lorenzini P., Taramasso L., Cozzi-Lepri A., Lapadula G., Mussini C., Saracino A., Ceccherini-Silberstein F., Puoti M., Quiros-Roldan E., Montagnani F., Antinori A., d'Arminio Monforte A., Gori A., Andreoni M., Castagna A., Castelli F., Cauda R., Di Perri G., Galli M., Iardino R., Ippolito G., Lazzarin A., Marchetti G. C., Rezza G., von Shloesser F., Viale P., Girardi E., Lo Caputo S., Maggiolo F., Perno C. F., Bai F., Bonora S., Borderi M., Calcagno A., Capobianchi M. R., Cicalini S., Cingolani A., Cinque P., Di Biagio A., Gagliardini R., Gianotti N., Guaraldi G., Lichtner M., Lai A., Madeddu G., Marchetti G., Merlini E., Nozza S., Piconi S., Pinnetti C., Rossotti R., Rusconi S., Santoro M. M., Sarmati L., Spagnuolo V., Svicher V., Fanti I., Galli L., Rodano' A., Macchia M., Tavelli A., Bove A., Camposeragna A., Errico M., Manfredini M., Perziano A., Calvino V., Carletti F., Carrara S., Di Caro A., Graziano S., Petroni F., Prota G., Truffa S., Giacometti A., Costantini A., Barocci V., Angarano G., Monno L., Milano E., Suardi C., Donati V., Verucchi G., Castelnuovo F., Minardi C., Menzaghi B., Abeli C., Chessa L., Pes F., Cacopardo B., Celesia B., Vecchiet J., Falasca K., Pan A., Lorenzotti S., Sighinolfi L., Segala D., Blanc P., Vichi F., Cassola G., Bassetti M., Alessandrini A., Bobbio N., Mazzarello G., Fondaco L., Bonfanti P., Molteni C., Chiodera A., Milini P., Nunnari G., Pellicano G., Rizzardini G., Cannizzo E. S., Moioli M. C., Piolini R., Bernacchia D., Poli A., Tincati C., Puzzolante C., Migliorino C., Sangiovanni V., Borgia G., Esposito V., Di Flumeri G., Gentile I., Rizzo V., Cattelan A. M., Marinello S., Cascio A., Trizzino M., Francisci D., Schiaroli E., Parruti G., Sozio F., Lazzaretti C., Corsini R., Qqwdreoni Q., Cristaudo A., Vullo V., Acinapura R., Lamonica S., Capozzi M., Mondi A., Rivano Capparuccia M., Iaiani G., Latini A., Onnelli G., Plazzi M. M., De Girolamo G., Vergori A., Cecchetto M., Viviani F., De Vito A., Rossetti B., Franco A., Fontana Del Vecchio R., Di Giuli C., Caramello P., Orofino G. C., Sciandra M., Londero A., Manfrin V., Battagin G., Starnini G., and Ialungo A. more...
- Abstract
HCV infection has been hypothesized as a contributor of poor CD4+ recovery in patients living with HIV (PLWHIV). Aim of this study was to evaluate CD4+, CD8+ cells and CD4/CD8 ratio trends before and after HCV treatment with direct acting agents (DAA) in PLWHIV. HIV/HCV patients enrolled in ICONA and HepaICONA cohorts with HIV-RNA≤50 copies/ml who achieved a sustained viral response after DAA treatment were studied. A linear regression model was used to investigate CD4+, CD8+ and CD4/CD8 changes 12 months before and after DAA treatment. A total of 939 HIV/HCV patients were included, 225 (24.0%) female, median age: 53 years (IQR 50–56). At DAA initiation, CD4+ T cell count was <350 cells/mm3 in 164 patients (17.5%), and 246 patients (26.2%) had liver stiffness>12.5 kPa. Trends of CD4+ and CD4/CD8 ratio were similar before and after DAA in all study populations (CD4+ change +17.6 cells/mm3 (95%CI −33.5; 69.4, p = 0.494); CD4/CD8 change 0.013 (95%CI −0.061; 0.036, p = 0.611). However, patients treated with ribavirin (RBV)-free DAA showed a significant decrease in CD8+ cells (−204.3 cells/mm3, 95%CI −375.0;-33.4, p = 0.019), while patients treated with RBV experienced CD8+ cell increase (+141.2 cells/mm3, 95%CI 40.3; 242.1, p = 0.006). In conclusion, HCV eradication following DAA treatment does not seem to have an impact on CD4+ T cell recovery in PLWHIV. However, a fast decline of CD8+T cells has been observed in patients treated without RBV, suggesting a favourable effect of HCV clearance on the general state of immune activation. more...
- Published
- 2021
25. The impact of DAA-mediated HCV eradication on CD4+ and CD8+ T lymphocyte trajectories in HIV/HCV coinfected patients: Data from the ICONA Foundation Cohort
- Author
-
Bandera, A., Lorenzini, P., Taramasso, L., Cozzi-Lepri, A., Lapadula, G., Mussini, C., Saracino, A., Ceccherini-Silberstein, F., Puoti, M., Quiros-Roldan, E., Montagnani, F., Antinori, A., d'Arminio Monforte, A., Gori, A., Andreoni, M., Castagna, A., Castelli, F., Cauda, R., Di Perri, G., Galli, M., Iardino, R., Ippolito, G., Lazzarin, A., Marchetti, G. C., Rezza, G., von Shloesser, F., Viale, P., Girardi, E., Lo Caputo, S., Maggiolo, F., Perno, C. F., Bai, F., Bonora, S., Borderi, M., Calcagno, A., Capobianchi, M. R., Cicalini, S., Cingolani, A., Cinque, P., Di Biagio, A., Gagliardini, R., Gianotti, N., Guaraldi, G., Lichtner, M., Lai, A., Madeddu, G., Marchetti, G., Merlini, E., Nozza, S., Piconi, S., Pinnetti, C., Rossotti, R., Rusconi, S., Santoro, M. M., Sarmati, L., Spagnuolo, V., Svicher, V., Fanti, I., Galli, L., Rodano', A., Macchia, M., Tavelli, A., Bove, A., Camposeragna, A., Errico, M., Manfredini, M., Perziano, A., Calvino, V., Carletti, F., Carrara, S., Di Caro, A., Graziano, S., Petroni, F., Prota, G., Truffa, S., Giacometti, A., Costantini, A., Barocci, V., Angarano, G., Monno, L., Milano, E., Suardi, C., Donati, V., Verucchi, G., Castelnuovo, F., Minardi, C., Menzaghi, B., Abeli, C., Chessa, L., Pes, F., Cacopardo, B., Celesia, B., Vecchiet, J., Falasca, K., Pan, A., Lorenzotti, S., Sighinolfi, L., Segala, D., Blanc, P., Vichi, F., Cassola, G., Bassetti, M., Alessandrini, A., Bobbio, N., Mazzarello, G., Fondaco, L., Bonfanti, P., Molteni, C., Chiodera, A., Milini, P., Nunnari, G., Pellicano, G., Rizzardini, G., Cannizzo, E. S., Moioli, M. C., Piolini, R., Bernacchia, D., Poli, A., Tincati, C., Puzzolante, C., Migliorino, C., Sangiovanni, V., Borgia, G., Esposito, V., Di Flumeri, G., Gentile, I., Rizzo, V., Cattelan, A. M., Marinello, S., Cascio, A., Trizzino, M., Francisci, D., Schiaroli, E., Parruti, G., Sozio, F., Lazzaretti, C., Corsini, R., Cristaudo, A., Vullo, V., Acinapura, R., Lamonica, S., Capozzi, M., Mondi, A., Rivano Capparuccia, M., Iaiani, G., Latini, A., Onnelli, G., Plazzi, M. M., De Girolamo, G., Vergori, A., Cecchetto, M., Viviani, F., De Vito, A., Rossetti, B., Franco, A., Fontana Del Vecchio, R., Di Giuli, C., Caramello, P., Orofino, G. C., Sciandra, M., Londero, A., Manfrin, V., Battagin, G., Starnini, G., Ialungo, A., Bandera A., Lorenzini P., Taramasso L., Cozzi-Lepri A., Lapadula G., Mussini C., Saracino A., Ceccherini-Silberstein F., Puoti M., Quiros-Roldan E., Montagnani F., Antinori A., d'Arminio Monforte A., Gori A., Andreoni M., Castagna A., Castelli F., Cauda R., Di Perri G., Galli M., Iardino R., Ippolito G., Lazzarin A., Marchetti G.C., Rezza G., von Shloesser F., Viale P., Girardi E., Lo Caputo S., Maggiolo F., Perno C.F., Bai F., Bonora S., Borderi M., Calcagno A., Capobianchi M.R., Cicalini S., Cingolani A., Cinque P., Di Biagio A., Gagliardini R., Gianotti N., Guaraldi G., Lichtner M., Lai A., Madeddu G., Merlini E., Nozza S., Piconi S., Pinnetti C., Rossotti R., Rusconi S., Santoro M.M., Sarmati L., Spagnuolo V., Svicher V., Fanti I., Galli L., Rodano' A., Macchia M., Tavelli A., Bove A., Camposeragna A., Errico M., Manfredini M., Perziano A., Calvino V., Carletti F., Carrara S., Di Caro A., Graziano S., Petroni F., Prota G., Truffa S., Giacometti A., Costantini A., Barocci V., Angarano G., Monno L., Milano E., Suardi C., Donati V., Verucchi G., Castelnuovo F., Minardi C., Menzaghi B., Abeli C., Chessa L., Pes F., Cacopardo B., Celesia B., Vecchiet J., Falasca K., Pan A., Lorenzotti S., Sighinolfi L., Segala D., Blanc P., Vichi F., Cassola G., Bassetti M., Alessandrini A., Bobbio N., Mazzarello G., Fondaco L., Bonfanti P., Molteni C., Chiodera A., Milini P., Nunnari G., Pellicano G., Rizzardini G., Cannizzo E.S., Moioli M.C., Piolini R., Bernacchia D., Poli A., Tincati C., Puzzolante C., Migliorino C., Sangiovanni V., Borgia G., Esposito V., Di Flumeri G., Gentile I., Rizzo V., Cattelan A.M., Marinello S., Cascio A., Trizzino M., Francisci D., Schiaroli E., Parruti G., Sozio F., Lazzaretti C., Corsini R., Qqwdreoni Q., Cristaudo A., Vullo V., Acinapura R., Lamonica S., Capozzi M., Mondi A., Rivano Capparuccia M., Iaiani G., Latini A., Onnelli G., Plazzi M.M., De Girolamo G., Vergori A., Cecchetto M., Viviani F., De Vito A., Rossetti B., Franco A., Fontana Del Vecchio R., Di Giuli C., Caramello P., Orofino G.C., Sciandra M., Londero A., Manfrin V., Battagin G., Starnini G., Ialungo A., Bandera, A, Lorenzini, P, Taramasso, L, Cozzi-Lepri, A, Lapadula, G, Mussini, C, Saracino, A, Ceccherini-Silberstein, F, Puoti, M, Quiros-Roldan, E, Montagnani, F, Antinori, A, d'Arminio Monforte, A, Gori, A, Andreoni, M, Castagna, A, Castelli, F, Cauda, R, Di Perri, G, Galli, M, Iardino, R, Ippolito, G, Lazzarin, A, Marchetti, G, Rezza, G, von Shloesser, F, Viale, P, Girardi, E, Lo Caputo, S, Maggiolo, F, Perno, C, Bai, F, Bonora, S, Borderi, M, Calcagno, A, Capobianchi, M, Cicalini, S, Cingolani, A, Cinque, P, Di Biagio, A, Gagliardini, R, Gianotti, N, Guaraldi, G, Lichtner, M, Lai, A, Madeddu, G, Merlini, E, Nozza, S, Piconi, S, Pinnetti, C, Rossotti, R, Rusconi, S, Santoro, M, Sarmati, L, Spagnuolo, V, Svicher, V, Fanti, I, Galli, L, Rodano', A, Macchia, M, Tavelli, A, Bove, A, Camposeragna, A, Errico, M, Manfredini, M, Perziano, A, Calvino, V, Carletti, F, Carrara, S, Di Caro, A, Graziano, S, Petroni, F, Prota, G, Truffa, S, Giacometti, A, Costantini, A, Barocci, V, Angarano, G, Monno, L, Milano, E, Suardi, C, Donati, V, Verucchi, G, Castelnuovo, F, Minardi, C, Menzaghi, B, Abeli, C, Chessa, L, Pes, F, Cacopardo, B, Celesia, B, Vecchiet, J, Falasca, K, Pan, A, Lorenzotti, S, Sighinolfi, L, Segala, D, Blanc, P, Vichi, F, Cassola, G, Bassetti, M, Alessandrini, A, Bobbio, N, Mazzarello, G, Fondaco, L, Bonfanti, P, Molteni, C, Chiodera, A, Milini, P, Nunnari, G, Pellicano, G, Rizzardini, G, Cannizzo, E, Moioli, M, Piolini, R, Bernacchia, D, Poli, A, Tincati, C, Puzzolante, C, Migliorino, C, Sangiovanni, V, Borgia, G, Esposito, V, Di Flumeri, G, Gentile, I, Rizzo, V, Cattelan, A, Marinello, S, Cascio, A, Trizzino, M, Francisci, D, Schiaroli, E, Parruti, G, Sozio, F, Lazzaretti, C, Corsini, R, Qqwdreoni, Q, Cristaudo, A, Vullo, V, Acinapura, R, Lamonica, S, Capozzi, M, Mondi, A, Rivano Capparuccia, M, Iaiani, G, Latini, A, Onnelli, G, Plazzi, M, De Girolamo, G, Vergori, A, Cecchetto, M, Viviani, F, De Vito, A, Rossetti, B, Franco, A, Fontana Del Vecchio, R, Di Giuli, C, Caramello, P, Orofino, G, Sciandra, M, Londero, A, Manfrin, V, Battagin, G, Starnini, G, Ialungo, A, Bandera, A., Lorenzini, P., Taramasso, L., Cozzi-Lepri, A., Lapadula, G., Mussini, C., Saracino, A., Ceccherini-Silberstein, F., Puoti, M., Quiros-Roldan, E., Montagnani, F., Antinori, A., d'Arminio Monforte, A., Gori, A., Andreoni, M., Castagna, A., Castelli, F., Cauda, R., Di Perri, G., Galli, M., Iardino, R., Ippolito, G., Lazzarin, A., Marchetti, G. C., Rezza, G., von Shloesser, F., Viale, P., Girardi, E., Lo Caputo, S., Maggiolo, F., Perno, C. F., Bai, F., Bonora, S., Borderi, M., Calcagno, A., Capobianchi, M. R., Cicalini, S., Cingolani, A., Cinque, P., Di Biagio, A., Gagliardini, R., Gianotti, N., Guaraldi, G., Lichtner, M., Lai, A., Madeddu, G., Merlini, E., Nozza, S., Piconi, S., Pinnetti, C., Rossotti, R., Rusconi, S., Santoro, M. M., Sarmati, L., Spagnuolo, V., Svicher, V., Fanti, I., Galli, L., Rodano', A., Macchia, M., Tavelli, A., Bove, A., Camposeragna, A., Errico, M., Manfredini, M., Perziano, A., Calvino, V., Carletti, F., Carrara, S., Di Caro, A., Graziano, S., Petroni, F., Prota, G., Truffa, S., Giacometti, A., Costantini, A., Barocci, V., Angarano, G., Monno, L., Milano, E., Suardi, C., Donati, V., Verucchi, G., Castelnuovo, F., Minardi, C., Menzaghi, B., Abeli, C., Chessa, L., Pes, F., Cacopardo, B., Celesia, B., Vecchiet, J., Falasca, K., Pan, A., Lorenzotti, S., Sighinolfi, L., Segala, D., Blanc, P., Vichi, F., Cassola, G., Bassetti, M., Alessandrini, A., Bobbio, N., Mazzarello, G., Fondaco, L., Bonfanti, P., Molteni, C., Chiodera, A., Milini, P., Nunnari, G., Pellicano, G., Rizzardini, G., Cannizzo, E. S., Moioli, M. C., Piolini, R., Bernacchia, D., Poli, A., Tincati, C., Puzzolante, C., Migliorino, C., Sangiovanni, V., Borgia, G., Esposito, V., Di Flumeri, G., Gentile, I., Rizzo, V., Cattelan, A. M., Marinello, S., Cascio, A., Trizzino, M., Francisci, D., Schiaroli, E., Parruti, G., Sozio, F., Lazzaretti, C., Corsini, R., Qqwdreoni, Q., Cristaudo, A., Vullo, V., Acinapura, R., Lamonica, S., Capozzi, M., Mondi, A., Rivano Capparuccia, M., Iaiani, G., Latini, A., Onnelli, G., Plazzi, M. M., De Girolamo, G., Vergori, A., Cecchetto, M., Viviani, F., De Vito, A., Rossetti, B., Franco, A., Fontana Del Vecchio, R., Di Giuli, C., Caramello, P., Orofino, G. C., Sciandra, M., Londero, A., Manfrin, V., Battagin, G., Starnini, G., and Ialungo, A. more...
- Subjects
CD4-Positive T-Lymphocytes ,HIV Infections ,Hepacivirus ,CD8-Positive T-Lymphocytes ,Gastroenterology ,Settore MED/07 ,chemistry.chemical_compound ,0302 clinical medicine ,Cd8 t lymphocyte ,HIV Infection ,030212 general & internal medicine ,Coinfection ,CD4 ,CD8 ,DAA ,HCV/HIV ,immune activation ,Hcv clearance ,virus diseases ,Middle Aged ,Hepatitis C ,Infectious Diseases ,medicine.anatomical_structure ,CD4-Positive T-Lymphocyte ,Cohort ,030211 gastroenterology & hepatology ,Female ,CD4, CD8, DAA, HCV/HIV, immune activation ,Human ,Immune activation ,medicine.medical_specialty ,T cell ,Antiviral Agents ,NO ,03 medical and health sciences ,Virology ,Internal medicine ,medicine ,Humans ,In patient ,Antiviral Agent ,Hepaciviru ,Hepatology ,business.industry ,Ribavirin ,CD8-Positive T-Lymphocyte ,CD4 Lymphocyte Count ,chemistry ,business - Abstract
HCV infection has been hypothesized as a contributor of poor CD4+ recovery in patients living with HIV (PLWHIV). Aim of this study was to evaluate CD4+, CD8+ cells and CD4/CD8 ratio trends before and after HCV treatment with direct acting agents (DAA) in PLWHIV. HIV/HCV patients enrolled in ICONA and HepaICONA cohorts with HIV-RNA≤50copies/ml who achieved a sustained viral response after DAA treatment were studied. A linear regression model was used to investigate CD4+, CD8+ and CD4/CD8 changes 12months before and after DAA treatment. A total of 939 HIV/HCV patients were included, 225 (24.0%) female, median age: 53years (IQR 50–56). At DAA initiation, CD4+ T cell count was 12.5kPa. Trends of CD4+ and CD4/CD8 ratio were similar before and after DAA in all study populations (CD4+ change +17.6 cells/mm3 (95%CI −33.5; 69.4, p=0.494); CD4/CD8 change 0.013 (95%CI −0.061; 0.036, p=0.611). However, patients treated with ribavirin (RBV)-free DAA showed a significant decrease in CD8+ cells (−204.3 cells/mm3, 95%CI −375.0;-33.4, p=0.019), while patients treated with RBV experienced CD8+ cell increase (+141.2 cells/mm3, 95%CI 40.3; 242.1, p=0.006). In conclusion, HCV eradication following DAA treatment does not seem to have an impact on CD4+ T cell recovery in PLWHIV. However, a fast decline of CD8+T cells has been observed in patients treated without RBV, suggesting a favourable effect of HCV clearance on the general state of immune activation. more...
- Published
- 2021
26. Computed tomography assessment of PEEP-induced alveolar recruitment in patients with severe COVID-19 pneumonia
- Author
-
Ball, L., Robba, C., Maiello, L., Herrmann, J., Gerard, S. E., Xin, Y., Battaglini, D., Brunetti, I., Minetti, G., Seitun, S., Vena, A., Giacobbe, D. R., Bassetti, M., Rocco, P. R. M., Cereda, M., Castellan, L., Patroniti, N., Pelosi, P., Gratarola, A., Loconte, M., Molin, A., Orefice, G., Iannuzzi, F., Costantino, F., Battioni, D., Bovio, G., Buconte, G., Casaleggio, A., Cittadini, G., Dogliotti, L., Giasotto, V., Pigati, M., Santacroce, E., Zaottini, F., Dentone, C., Taramasso, L., Magnasco, L., Valbusa, A., and Bastianello, M. more...
- Subjects
Male ,CT scan ,medicine.medical_specialty ,ARDS ,medicine.medical_treatment ,Respiratory system mechanics ,Critical Care and Intensive Care Medicine ,Severity of Illness Index ,law.invention ,Cohort Studies ,Positive-Pressure Respiration ,03 medical and health sciences ,0302 clinical medicine ,Mechanical ventilation ,Interquartile range ,law ,Internal medicine ,Severity of illness ,medicine ,Humans ,COVID-19 ,Aged ,Female ,Italy ,Middle Aged ,Pneumonia, Viral ,Pulmonary Alveoli ,Tomography, X-Ray Computed ,Treatment Outcome ,Viral ,030212 general & internal medicine ,Respiratory system ,Tomography ,business.industry ,lcsh:Medical emergencies. Critical care. Intensive care. First aid ,030208 emergency & critical care medicine ,Pneumonia ,Oxygenation ,lcsh:RC86-88.9 ,respiratory system ,medicine.disease ,Intensive care unit ,X-Ray Computed ,respiratory tract diseases ,Cardiology ,business ,circulatory and respiratory physiology - Abstract
Background There is a paucity of data concerning the optimal ventilator management in patients with COVID-19 pneumonia; particularly, the optimal levels of positive-end expiratory pressure (PEEP) are unknown. We aimed to investigate the effects of two levels of PEEP on alveolar recruitment in critically ill patients with severe COVID-19 pneumonia. Methods A single-center cohort study was conducted in a 39-bed intensive care unit at a university-affiliated hospital in Genoa, Italy. Chest computed tomography (CT) was performed to quantify aeration at 8 and 16 cmH2O PEEP. The primary endpoint was the amount of alveolar recruitment, defined as the change in the non-aerated compartment at the two PEEP levels on CT scan. Results Forty-two patients were included in this analysis. Alveolar recruitment was median [interquartile range] 2.7 [0.7–4.5] % of lung weight and was not associated with excess lung weight, PaO2/FiO2 ratio, respiratory system compliance, inflammatory and thrombophilia markers. Patients in the upper quartile of recruitment (recruiters), compared to non-recruiters, had comparable clinical characteristics, lung weight and gas volume. Alveolar recruitment was not different in patients with lower versus higher respiratory system compliance. In a subgroup of 20 patients with available gas exchange data, increasing PEEP decreased respiratory system compliance (median difference, MD − 9 ml/cmH2O, 95% CI from − 12 to − 6 ml/cmH2O, p p = 0.003), increased PaO2 with FiO2 = 0.5 (MD 24 mmHg, 95% CI from 12 to 51 mmHg, p 2 with FiO2 = 1.0 (MD 7 mmHg, 95% CI from − 12 to 49 mmHg, p = 0.313). Moreover, alveolar recruitment was not correlated with improvement of oxygenation or venous admixture. Conclusions In patients with severe COVID-19 pneumonia, higher PEEP resulted in limited alveolar recruitment. These findings suggest limiting PEEP strictly to the values necessary to maintain oxygenation, thus avoiding the use of higher PEEP levels. more...
- Published
- 2021
27. Prevalence and Clinical Significance of Persistent Viral Shedding in Hospitalized Adult Patients with SARS-CoV-2 Infection: A Prospective Observational Study
- Author
-
Vena, A., Taramasso, L., Di Biagio, A., Mikulska, M., Dentone, C., De Maria, A., Magnasco, L., Nicolini, L. A., Bruzzone, B., Icardi, G., Orsi, A., Pelosi, P., Ball, L., Battaglini, D., Brunetti, I., Loconte, M., Patroniti, N. A., Robba, C., Bavastro, M., Cerchiaro, M., Giacobbe, D. R., Schiavetti, I., Berruti, M., Bassetti, M., Alessandrini, A., Camera, M., Delfino, E., Dodi, F., Ferrazin, A., Mazzarello, G., Nicolini, L., Toscanini, F., Balletto, E., Portunato, F., Schenone, E., Rosseti, N., Baldi, F., Briano, F., Dettori, S., Labate, L., Mirabella, M., Pincino, R., Russo, C., Sarteschi, G., Sepulcri, C., Tutino, S., Pontremoli, R., Beccati, V., Casciaro, S., Casu, M., Gavaudan, F., Ghinatti, M., Gualco, E., Leoncini, G., Pitto, P., and Salam, K. more...
- Subjects
0301 basic medicine ,Microbiology (medical) ,medicine.medical_specialty ,Multivariate analysis ,medicine.medical_treatment ,030106 microbiology ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,law ,Internal medicine ,Clinical endpoint ,medicine ,Clinical significance ,030212 general & internal medicine ,Viral shedding ,Original Research ,Outcome ,Mechanical ventilation ,Univariate analysis ,IL-6 ,COVID-19 ,SARS-CoV-2 ,business.industry ,Immunosuppression ,Intensive care unit ,Infectious Diseases ,business - Abstract
Background The goal of this study was to investigate the prevalence and factors associated with persistent viral shedding (PVS) in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Methods This was a prospective observational study including all consecutive adults hospitalized with SARS-CoV-2 infection. When the first nasopharyngeal swab was positive for SARS-CoV-2 RNA (day 0), additional samples were obtained on days + 3, + 5, + 7 and then once every 7 days until virus detection was negative. PVS was defined as the duration of shedding of at least 21 days after diagnosis. The primary endpoint of this study was the prevalence of PVS. Results Data were obtained regarding 121 consecutive hospitalized patients with SARS-CoV-2 infection (median age 66 years, male sex 65.3%). Overall, the prevalence of PVS was 38% (46/121 patients). According to univariate analysis, factors associated with PVS were immunosuppression (6.7% vs 21.7%, p = 0.02), increased interleukin-6 (IL-6) levels (≥ 35 ng/ml) at the time of diagnosis (43.4% vs 67.3%, p = 0.02), time from onset of symptoms to diagnosis (median days 7.0 vs 3.5, p = 0.001), intensive care unit admission (22.7% vs 43.5%, p = 0.02), and need for invasive mechanical ventilation (20.0% vs 41.3%, p = 0.01). The multivariate analysis indicated that immunosuppression, increased IL-6 levels at the time of diagnosis, time from onset of symptoms to diagnosis, and need for mechanical ventilation were independent factors associated with PVS. Conclusions PVS was detected in up to 38% of hospitalized patients with SARS-CoV-2 infection and was strongly associated with immunosuppression, increased IL-6 levels, and the need for mechanical ventilation. Supplementary Information The online version contains supplementary material available at 10.1007/s40121-020-00381-8. more...
- Published
- 2021
28. Prevalence and prognostic value of cardiac troponin in elderly patients hospitalized for COVID-19
- Author
-
de Marzo, V., Di Biagio, A., della Bona, R., Vena, A., Arboscello, E., Emirjona, H., Mora, S., Giacomini, M., da Rin, G., Pelosi, P., Bassetti, M., Ameri, P., Porto, I., Alessandrini, A., Camera, M., Delfino, E., de Maria, A., Dentone, C., Dodi, F., Ferrazin, A., Mazzarello, G., Mikulska, M., Nicolini, L., Toscanini, F., Giacobbe, D. R., Taramasso, L., Balletto, E., Portunato, F., Schenone, E., Rosseti, N., Baldi, F., Berruti, M., Briano, F., Dettori, S., Labate, L., Magnasco, L., Mirabella, M., Pincino, R., Russo, C., Sarteschi, G., Sepulcri, C., Tutino, S., Pontremoli, R., Beccati, V., Casciaro, S., Casu, M., Gavaudan, F., Ghinatti, M., Gualco, E., Leoncini, G., Pitto, P., Salam, K., Gratarola, A., Bixio, M., Amelia, A., Balestra, A., Ballarino, P., Bardi, N., Boccafogli, R., Caserza, F., Calzolari, E., Castelli, M., Cenni, E., Cortese, P., Cuttone, G., Feltrin, S., Giovinazzo, S., Giuntini, P., Nat-Ale, L., Orsi, D., Pastorino, M., Perazzo, T., Pescetelli, F., Schenone, F., Serra, M. G., Sottano, M., Brunetti, I., Loconte, M., Ball, L., Battaglini, D., Robba, C., Patroniti, N., Tallone, R., Amelotti, M., Majabo, M. J., Merlini, M., Perazzo, F., Ahamd, N., Barbera, P., Bovio, M., Cam-Podonico, P., Collida, A., Cutuli, O., Lomeo, A. -N., Fezza, F., Gentilucci, N., Hussein, N., Malvezzi, E., Mas-Sobrio, L., Motta, G., Pastorino, L., Pol-Licardo, N., Sartini, S., Vacca, P., Virga, V., Bezante, G. P., la Malfa, G., Valbusa, A., V. G., Ad, Bari-Sione, E., Bellotti, M., Teresita, A., Blanco, A., Grosso, M., Piroddi, M. G., Mosca-Telli, P., Caiti, M., Magnani, O., Sukkar, S., Cogorno, L., Gradaschi, R., Guiddo, E., Martino, E., Pisciotta, L., Cavagliere, B., Cristina, R., Francesca, F., Garibotto, G., Esposito, P., Passalacqua, G., Bagnasco, D., Braido, F., Riccio, A., Tagliabue, E., Gustavino, C., Ferraiolo, A., Giuffrida, S., Rosso, N., Morando, A., Papalia, R., Passerini, D., Tiberio, G., Orengo, G., Battaglini, A., Ruffoni, S., and Caglieris, S. more...
- Subjects
Reseach Article - Abstract
BACKGROUND Increases in cardiac troponin (cTn) in coronavirus disease 2019 (COVID-19) have been associated with worse prognosis. Nonetheless, data about the significance of cTn in elderly subjects with COVID-19 are lacking. METHODS From a registry of consecutive patients with COVID-19 admitted to a hub hospital in Italy from 25/02/2020 to 03/07/2020, we selected those ≥ 60 year-old and with cTnI measured within three days from the molecular diagnosis of SARS-CoV-2 infection. When available, a second cTnI value within 48 h was also extracted. The relationship between increased cTnI and all-cause in-hospital mortality was evaluated by a Cox regression model and restricted cubic spline functions with three knots. RESULTS Of 343 included patients (median age: 75.0 (68.0−83.0) years, 34.7% men), 88 (25.7%) had cTnI above the upper-reference limit (0.046 µg/L). Patients with increased cTnI had more comorbidities, greater impaired respiratory exchange and higher inflammatory markers on admission than those with normal cTnI. Furthermore, they died more (73.9%vs. 37.3%, P < 0.001) over 15 (6−25) days of hospitalization. The association of elevated cTnI with mortality was confirmed by the adjusted Cox regression model (HR = 1.61, 95%CI: 1.06−2.52, P = 0.039) and was linear until 0.3 µg/L, with a subsequent plateau. Of 191 (55.7%) patients with a second cTnI measurement, 49 (25.7%) had an increasing trend, which was not associated with mortality (univariate HR = 1.39, 95%CI: 0.87−2.22, P = 0.265). CONCLUSIONS In elderly COVID-19 patients, an initial increase in cTn is common and predicts a higher risk of death. Serial cTn testing may not confer additional prognostic information. more...
- Published
- 2021
29. Reversibility of Central Nervous System Adverse Events in Course of Art
- Author
-
Taramasso, L, Orofino, G, Ricci, E, Menzaghi, B, De Socio, G, Squillace, N, Madeddu, G, Vichi, F, Celesia, B, Molteni, C, Conti, F, Del Puente, F, Sarchi, E, Angioni, G, Cascio, A, Grosso, C, Parruti, G, Di Biagio, A, Bonfanti, P, Taramasso, Lucia, Orofino, Giancarlo, Ricci, Elena, Menzaghi, Barbara, De Socio, Giuseppe Vittorio, Squillace, Nicola, Madeddu, Giordano, Vichi, Francesca, Celesia, Benedetto Maurizio, Molteni, Chiara, Conti, Federico, Del Puente, Filippo, Sarchi, Eleonora, Angioni, Goffredo, Cascio, Antonio, Grosso, Carmela, Parruti, Giustino, Di Biagio, Antonio, Bonfanti, Paolo, Taramasso, L, Orofino, G, Ricci, E, Menzaghi, B, De Socio, G, Squillace, N, Madeddu, G, Vichi, F, Celesia, B, Molteni, C, Conti, F, Del Puente, F, Sarchi, E, Angioni, G, Cascio, A, Grosso, C, Parruti, G, Di Biagio, A, Bonfanti, P, Taramasso, Lucia, Orofino, Giancarlo, Ricci, Elena, Menzaghi, Barbara, De Socio, Giuseppe Vittorio, Squillace, Nicola, Madeddu, Giordano, Vichi, Francesca, Celesia, Benedetto Maurizio, Molteni, Chiara, Conti, Federico, Del Puente, Filippo, Sarchi, Eleonora, Angioni, Goffredo, Cascio, Antonio, Grosso, Carmela, Parruti, Giustino, Di Biagio, Antonio, and Bonfanti, Paolo more...
- Abstract
The purpose of this study is to evaluate the frequency of central nervous system adverse events (CNS-AE) on dolutegravir (DTG) and non-DTG containing ART, and their reversibility, in the observational prospective SCOLTA cohort. Factors associated with CNS-AE were estimated using a Cox proportional-hazards model. 4939 people living with HIV (PLWH) were enrolled in DTG (n = 1179) and non-DTG (n = 3760) cohorts. Sixty-six SNC-AE leading to ART discontinuation were reported, 39/1179 (3.3%) in DTG and 27/3760 (0.7%) in non-DTG cohort. PLWH naïve to ART, with higher CD4 + T count and with psychiatric disorders were more likely to develop a CNS-AE. The risk was lower in non-DTG than DTG-cohort (aHR 0.33, 95% CI 0.19–0.55, p < 0.0001). One-year follow-up was available for 63/66 PLWH with CNS-AE. AE resolution was reported in 35/39 and 23/24 cases in DTG and non-DTG cohorts, respectively. The probability of AE reversibility was not different based on ART class, sex, ethnicity, CDC stage, or baseline psychiatric disorder. At the same time, a lower rate of event resolution was found in PLWH older than 50 years (p = 0.017). In conclusion, CNS-AE leading to ART discontinuation was more frequent in DTG than non-DTG treated PLWH. Most CNS-AE resolved after ART switch, similarly in both DTG and non-DTG cohorts. more...
- Published
- 2022
30. Growing old with antiretroviral therapy or elderly people in antiretroviral therapy: two different profiles of comorbidity?
- Author
-
Maggi, P, De Socio, G, Menzaghi, B, Molteni, C, Squillace, N, Taramasso, L, Guastavigna, M, Gamboni, G, Madeddu, G, Vichi, F, Cascio, A, Sarchi, E, Pellicanò, G, Martinelli, C, Celesia, B, Valsecchi, L, Gulminetti, R, Cenderello, G, Parisini, A, Calza, L, Falasca, K, Orofino, G, Ricci, E, Di Biagio, A, Bonfanti, P, Maggi, Paolo, De Socio, Giuseppe Vittorio, Menzaghi, Barbara, Molteni, Chiara, Squillace, Nicola, Taramasso, Lucia, Guastavigna, Marta, Gamboni, Giulia, Madeddu, Giordano, Vichi, Francesca, Cascio, Antonio, Sarchi, Eleonora, Pellicanò, Giovanni, Martinelli, Canio Vito, Celesia, Benedetto Maurizio, Valsecchi, Laura, Gulminetti, Roberto, Cenderello, Giovanni, Parisini, Andrea, Calza, Leonardo, Falasca, Katia, Orofino, Giancarlo, Ricci, Elena, Di Biagio, Antonio, Bonfanti, Paolo, Maggi, P, De Socio, G, Menzaghi, B, Molteni, C, Squillace, N, Taramasso, L, Guastavigna, M, Gamboni, G, Madeddu, G, Vichi, F, Cascio, A, Sarchi, E, Pellicanò, G, Martinelli, C, Celesia, B, Valsecchi, L, Gulminetti, R, Cenderello, G, Parisini, A, Calza, L, Falasca, K, Orofino, G, Ricci, E, Di Biagio, A, Bonfanti, P, Maggi, Paolo, De Socio, Giuseppe Vittorio, Menzaghi, Barbara, Molteni, Chiara, Squillace, Nicola, Taramasso, Lucia, Guastavigna, Marta, Gamboni, Giulia, Madeddu, Giordano, Vichi, Francesca, Cascio, Antonio, Sarchi, Eleonora, Pellicanò, Giovanni, Martinelli, Canio Vito, Celesia, Benedetto Maurizio, Valsecchi, Laura, Gulminetti, Roberto, Cenderello, Giovanni, Parisini, Andrea, Calza, Leonardo, Falasca, Katia, Orofino, Giancarlo, Ricci, Elena, Di Biagio, Antonio, and Bonfanti, Paolo more...
- Abstract
Background In persons living with HIV (PLWH), the burden of non-communicable chronic diseases increased over time, because of aging associated with chronic inflammation, systemic immune activation, and long-term exposure to the combination antiretroviral therapy (ART).Methods To explore the association of chronological age, age at first ART, and exposure to ART with non-communicable chronic diseases, we performed a cross-sectional analysis to evaluate the prevalence of comorbidities in patients enrolled in the SCOLTA Project, stratified by groups of chronological age (50–59 and 60–69 years) and by years of antiretroviral treatment (ART, ≤ 3 or > 3 years).Results In 1394 subjects (23.8% women), mean age at enrollment was 57.4 (SD 6.5) years, and at first ART 45.3 (SD 10.7). Men were older than women both at enrollment (57.6 vs 56.8, p = 0.06) and at first ART (45.8 vs 43.6, p = 0.0009). ART duration was longer in women (13.1 vs 11.7 years, p = 0.01). The age- and sex-adjusted rate ratios (aRRs, and 95% confidence interval, CI) showed that longer ART exposure was associated with dyslipidemia (aRR 1.35, 95% CI 1.20–1.52), hypertension (aRR 1.52, 95% CI 1.22–1.89), liver disease (aRR 1.78, 95% CI 1.32–2.41), osteopenia/osteoporosis (aRR 2.88, 95% CI 1.65–5.03) and multimorbidity (aRR 1.36, 95% CI 1.21–1.54). These findings were confirmed in strata of age, adjusting for sex.Conclusions Our data suggest that longer ART exposure was associated with increased risk of dyslipidemia, hypertension, and osteopenia/osteoporosis, hence the presence of multimorbidity, possibly due to the exposition to more toxic antiretrovirals. We observed different comorbidities, according to ART exposure and age. more...
- Published
- 2022
31. Invecchiare con la terapia antiretrovirale o essere anziani in terapia antiretrovirale: due profili di comorbidità differenti?
- Author
-
Zollo, V, Menzaghi, B, Molteni, C, Squillace, N, Taramasso, L, De Luca, I, Gamboni, G, Altobelli, D, Guastavigna, M, Madeddu, G, Vichi9 Antonio Cascio, F, Sarchi, E, Pellicanò, G, Martinelli, C, Maurizio Celesia, B, Valsecchi, L, Gulminetti, R, Cenderello, G, Parisini, A, Calza, L, Falasca, K, Di Biagio, A, Bonfanti, P, Orofino, G, Maggi., P, Verdiana Zollo, Barbara Menzaghi, Chiara Molteni, Nicola Squillace, Lucia Taramasso, Ilaria De Luca, Giulia Gamboni, Debora Altobelli, Marta Guastavigna, Giordano Madeddu, Francesca Vichi9 Antonio Cascio, Eleonora Sarchi, Giovanni Pellicanò, Canio Martinelli, Benedetto Maurizio Celesia, Laura Valsecchi, Roberto Gulminetti, Giovanni Cenderello, Andrea Parisini, Leonardo Calza, Katia Falasca, Antonio Di Biagio, Paolo Bonfanti, Giancarlo Orofino, Paolo Maggi., Zollo, V, Menzaghi, B, Molteni, C, Squillace, N, Taramasso, L, De Luca, I, Gamboni, G, Altobelli, D, Guastavigna, M, Madeddu, G, Vichi9 Antonio Cascio, F, Sarchi, E, Pellicanò, G, Martinelli, C, Maurizio Celesia, B, Valsecchi, L, Gulminetti, R, Cenderello, G, Parisini, A, Calza, L, Falasca, K, Di Biagio, A, Bonfanti, P, Orofino, G, Maggi., P, Verdiana Zollo, Barbara Menzaghi, Chiara Molteni, Nicola Squillace, Lucia Taramasso, Ilaria De Luca, Giulia Gamboni, Debora Altobelli, Marta Guastavigna, Giordano Madeddu, Francesca Vichi9 Antonio Cascio, Eleonora Sarchi, Giovanni Pellicanò, Canio Martinelli, Benedetto Maurizio Celesia, Laura Valsecchi, Roberto Gulminetti, Giovanni Cenderello, Andrea Parisini, Leonardo Calza, Katia Falasca, Antonio Di Biagio, Paolo Bonfanti, Giancarlo Orofino, and Paolo Maggi. more...
- Abstract
In Persons Living With HIV (PLWH), the burden of non-communicable chronic diseases increased over time, because of aging linked to prolonged survival, chronic inflammation, systemic immune activation, and long-term exposure to the combination antiretroviral therapy (ART). Chronological age, age at HIV diagnosis, and exposure to ART may exert an effect on qualitative and quantitative differences. To explore this hypothesis, we evaluated the prevalence of some selected comorbidities in patients enrolled in the SCOLTA Project, by groups of chronological age (50- 59 and ≥60 years old) and ART duration. In 1336 subjects (23.9% women), ART duration was similar between age groups, both when considered in continuous (p=0.85) and in categories (p=0.88). As expected, comorbidities and multimorbidity were less frequent in the 50-59 than in the ≥60 years class. The age- and sex-adjusted odds ratios (ORs) showed that, in the 50-59 years group, a consistent and significant risk increase was observed through ART duration categories for CVD (ORs from 1.68 to 2.18), dyslipidemia (ORs from 3.61 to 9.08) and osteopenia/osteoporosis (ORs from 3.74 to 6.23). Consequently, the risk of multimorbidity also increased across ART duration categories (ORs from 2.04 to 4.40). In the ≥60 years group, the CVD risk was significantly increased only in those patients with ART duration ≥20 years (OR 2.61, 95% CI 1.22-5.58, reference category ≤6 months). Dyslipidemia and multimorbidity increase were consistently associated with longer ART duration. In conclusion, age, age at HIV infection diagnosis, and ART exposure were associated to multimorbidity in PLWH.  more...
- Published
- 2022
32. Trajectories of CD4+/CD8+ T-Cells Ratio 96 Weeks after Switching to Dolutegravir-Based Two-Drug Regimens: Results from a Multicenter Prospective Cohort Study
- Author
-
Taramasso, L, Falletta, A, Ricci, E, Orofino, G, Squillace, N, Menzaghi, B, De Socio, G, Molteni, C, Pellicanò, G, Gulminetti, R, Madeddu, G, Sarchi, E, Vichi, F, Celesia, B, Bonfanti, P, Di Biagio, A, Taramasso, Lucia, Falletta, Antonio, Ricci, Elena, Orofino, Giancarlo, Squillace, Nicola, Menzaghi, Barbara, De Socio, Giuseppe Vittorio, Molteni, Chiara, Pellicanò, Giovanni Francesco, Gulminetti, Roberto, Madeddu, Giordano, Sarchi, Eleonora, Vichi, Francesca, Celesia, Benedetto Maurizio, Bonfanti, Paolo, Di Biagio, Antonio, Taramasso, L, Falletta, A, Ricci, E, Orofino, G, Squillace, N, Menzaghi, B, De Socio, G, Molteni, C, Pellicanò, G, Gulminetti, R, Madeddu, G, Sarchi, E, Vichi, F, Celesia, B, Bonfanti, P, Di Biagio, A, Taramasso, Lucia, Falletta, Antonio, Ricci, Elena, Orofino, Giancarlo, Squillace, Nicola, Menzaghi, Barbara, De Socio, Giuseppe Vittorio, Molteni, Chiara, Pellicanò, Giovanni Francesco, Gulminetti, Roberto, Madeddu, Giordano, Sarchi, Eleonora, Vichi, Francesca, Celesia, Benedetto Maurizio, Bonfanti, Paolo, and Di Biagio, Antonio more...
- Abstract
The aim of the present study was to evaluate CD4/CD8 dynamics in patients on dolutegravir (DTG)-based two-drug regimens (2DRs) and compare them with DTG-containing triple-drug regimens (3DRs). A prospective observational study was performed in the context of the SCOLTA cohort. Experienced PWH with HIV-RNA < 50 copies/mL were included if they were on the DTG-2DR, the DTG + tenofovir/emtricitabine (TDF/FTC) regimen, the DTG + tenofovir alafenamide (TAF)/FTC regimen, or the DTG + abacavir/lamivudine (ABC/3TC) regimen; they were followed-up for at least one year. A total of 533 PWH were enrolled, 120 in the DTG + 3TC group, 38 in the DTG + protease inhibitors (PI) group, 67 in the DTG + rilpivirine (RPV) group, 49 in the DTG + TDF/FTC group, 27 in the DTG + TAF/FTC group, and 232 in the DTG + ABC/3TC group. After one year, the CD4/CD8 ratio significantly increased in the PWH treated with DTG + 3TC (+0.08 ± 0.26), DTG + TDF/FTC (+0.1 ± 0.19), and DTG + ABC/3TC (+0.08 ± 0.25). At two years, the CD4/CD8 increase was confirmed for PWH on DTG + TDF/FTC (+0.16 ± 0.28) and DTG + ABC/3TC (+0.1 ± 0.3). In the SCOLTA cohort, PWH on 2DRs experienced a CD4/CD8 increase only in the DTG + 3TC group. Controlled studies with longer follow-up will clarify the long-term immunological and clinical impacts of DTG-2DR. more...
- Published
- 2022
33. Metabolic syndrome and body weight in people living with HIV infection: analysis of differences observed in three different cohort studies over a decade
- Author
-
Taramasso, L, Bonfanti, P, Ricci, E, Maggi, P, Orofino, G, Squillace, N, Menzaghi, B, Madeddu, G, Molteni, C, Vichi, F, Riguccini, E, Saracino, A, Santoro, C, Guastavigna, M, Francisci, D, Di Biagio, A, De Socio, G, Taramasso, Lucia, Bonfanti, Paolo, Ricci, Elena, Maggi, Paolo, Orofino, Giancarlo, Squillace, Nicola, Menzaghi, Barbara, Madeddu, Giordano, Molteni, Chiara, Vichi, Francesca, Riguccini, Erika, Saracino, Annalisa, Santoro, Carmen, Guastavigna, Marta, Francisci, Daniela, Di Biagio, Antonio, De Socio, Giuseppe Vittorio, Taramasso, L, Bonfanti, P, Ricci, E, Maggi, P, Orofino, G, Squillace, N, Menzaghi, B, Madeddu, G, Molteni, C, Vichi, F, Riguccini, E, Saracino, A, Santoro, C, Guastavigna, M, Francisci, D, Di Biagio, A, De Socio, G, Taramasso, Lucia, Bonfanti, Paolo, Ricci, Elena, Maggi, Paolo, Orofino, Giancarlo, Squillace, Nicola, Menzaghi, Barbara, Madeddu, Giordano, Molteni, Chiara, Vichi, Francesca, Riguccini, Erika, Saracino, Annalisa, Santoro, Carmen, Guastavigna, Marta, Francisci, Daniela, Di Biagio, Antonio, and De Socio, Giuseppe Vittorio more...
- Abstract
Objectives: The aim of this study was to assess the incidence of being overweight and metabolic syndrome (MS) among people living with HIV (PHIV) in three different cross-sectional studies conducted over three different periods: 2005, 2011 and 2015. Methods: This was a multi-centre, nationwide study. Data were collected in three studies from the CISAI group – SIMOne, HIV-HY and STOPSHIV – and included a total of 3014 PHIV. Logistic regression [odds ratio (OR), 95% confidence interval (CI)] was used to account for age and gender difference among three groups when comparing MS prevalence and being overweight; potential confounders were accounted for by including them in the regression equation. Results: Overall, the mean age was 46.9 ± 10.2 years, and men comprised 73.3% of participants. Comparing 2005, 2011 and 2015, MS was present in 34.5%, 33.0% and 29.3% of PHIV, respectively. Adjusted OR for MS was 0.64 (95% CI: 0.52–0.78) in 2011 and 0.56 (95% CI: 0.46–0.69) in 2015 compared with 2005, while BMI (kg/m2) increased from 23.6 in 2005, 24.5 in 2011 and 24.5 in 2015, with a concomitant increase of being overweight from 29.4% to 39.5% to 39.6% (p < 0.0001). Conclusions: In recent years, PHIV have had a significantly improved metabolic profile compared with previously, despite increasing weight and BMI. more...
- Published
- 2022
34. The effects of switching from dolutegravir/abacavir/ lamivudine to bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed people living with HIV on neuropsychiatric symptoms: preliminary findings from a randomised study
- Author
-
Rossetti, Barbara, Ferrara, M, Taramasso, L, Bai, F, Lombardi, F, Ciccarelli, Nicoletta, Durante, M, Alladio, F, Rancan, I, Montagnani, F, A Di Biagio, A d’Arminio Monforte, Zazzi, M, and Fabbiani, M
- Subjects
Settore M-PSI/02 - PSICOBIOLOGIA E PSICOLOGIA FISIOLOGICA ,neuropsychiatric symptoms - Published
- 2022
35. Pineal Germinoma in a Child with Interferon-γ Receptor 1 Deficiency. Case Report and Literature Review
- Author
-
Taramasso, L., Boisson-Dupuis, S., Garrè, M. L., Bondi, E., Cama, A., Nozza, P., Morana, G., Casanova, J. L., and Marazzi, M. G.
- Published
- 2014
- Full Text
- View/download PDF
36. Evaluation of HIV transmission clusters among natives and foreigners living in Italy
- Author
-
Fabeni, L, Santoro, M, Lorenzini, P, Rusconi, S, Gianotti, N, Costantini, A, Sarmati, L, Antinori, A, Ceccherini-Silberstein, F, d'Arminio Monforte, A, Saracino, A, Girardi, E, Castagna, A, Castelli, F, Cauda, R, Di Perri, G, Galli, M, Iardino, R, Ippolito, G, Lazzarin, A, Marchetti, G, Rezza, G, von Schloesser, F, Viale, P, Cozzi-Lepri, A, Gori, A, Lo Caputo, S, Maggiolo, F, Mussini, C, Puoti, M, Perno, C, Bai, F, Bandera, A, Bonora, S, Borderi, M, Calcagno, A, Capobianchi, M, Cicalini, S, Cingolani, A, Cinque, P, Di Biagio, A, Gagliardini, R, Guaraldi, G, Lapadula, G, Lichtner, M, Lai, A, Madeddu, G, Merlini, E, Nozza, S, Piconi, S, Pinnetti, C, Quiros Roldan, E, Rossotti, R, Spagnuolo, V, Svicher, V, Taramasso, L, Fanti, I, Galli, L, Rodano, A, Macchia, M, Tavelli, A, Bove, A, Camposeragna, A, Errico, M, Manfredini, M, Perziano, A, Calvino, V, Carrara, S, Di Caro, A, Graziano, S, Petroni, F, Prota, G, Truffa, S, Giacometti, A, Barocci, V, Angarano, G, Monno, L, Milano, E, Suardi, C, Donati, V, Verucchi, G, Castelnuovo, F, Minardi, C, Menzaghi, B, Abeli, C, Chessa, L, Pes, F, Cacopardo, B, Celesia, B, Vecchiet, J, Falasca, K, Pan, A, Lorenzotti, S, Sighinolfi, L, Segala, D, Blanc, P, Vichi, F, Cassola, G, Bassetti, M, Alessandrini, A, Bobbio, N, Mazzarello, G, Fondaco, L, Bonfanti, P, Molteni, C, Chiodera, A, Milini, P, Nunnari, G, Pellicano, G, Rizzardini, G, Cannizzo, E, Moioli, M, Piolini, R, Bernacchia, D, Poli, A, Tincati, C, Puzzolante, C, Migliorino, C, Sangiovanni, V, Borgia, G, Esposito, V, Di Flumeri, G, Gentile, I, Rizzo, V, Cattelan, A, Marinello, S, Cascio, A, Trizzino, M, Francisci, D, Schiaroli, E, Parruti, G, Sozio, F, Lazzaretti, C, Corsini, R, Cristaudo, A, Vullo, V, Acinapura, R, Lamonica, S, Capozzi, M, Mondi, A, Rivano Capparuccia, M, Iaiani, G, Latini, A, Onnelli, G, Plazzi, M, de Girolamo, G, Vergori, A, Cecchetto, M, Viviani, F, de Vito, A, Rossetti, B, Montagnani, F, Franco, A, Fontana Del Vecchio, R, Di Giuli, C, Caramello, P, Orofino, G, Sciandra, M, Londero, A, Manfrin, V, Battagin, G, Starnini, G, Ialungo, A, Fabeni L., Santoro M. M., Lorenzini P., Rusconi S., Gianotti N., Costantini A., Sarmati L., Antinori A., Ceccherini-Silberstein F., d'Arminio Monforte A., Saracino A., Girardi E., Castagna A., Castelli F., Cauda R., Di Perri G., Galli M., Iardino R., Ippolito G., Lazzarin A., Marchetti G. C., Rezza G., von Schloesser F., Viale P., Cozzi-Lepri A., Gori A., Lo Caputo S., Maggiolo F., Mussini C., Puoti M., Perno C. F., Bai F., Bandera A., Bonora S., Borderi M., Calcagno A., Capobianchi M. R., Cicalini S., Cingolani A., Cinque P., Di Biagio A., Gagliardini R., Guaraldi G., Lapadula G., Lichtner M., Lai A., Madeddu G., Merlini E., Nozza S., Piconi S., Pinnetti C., Quiros Roldan E., Rossotti R., Spagnuolo V., Svicher V., Taramasso L., Fanti I., Galli L., Rodano A., Macchia M., Tavelli A., Bove A., Camposeragna A., Errico M., Manfredini M., Perziano A., Calvino V., Carrara S., Di Caro A., Graziano S., Petroni F., Prota G., Truffa S., Giacometti A., Barocci V., Angarano G., Monno L., Milano E., Suardi C., Donati V., Verucchi G., Castelnuovo F., Minardi C., Menzaghi B., Abeli C., Chessa L., Pes F., Cacopardo B., Celesia B., Vecchiet J., Falasca K., Pan A., Lorenzotti S., Sighinolfi L., Segala D., Blanc P., Vichi F., Cassola G., Bassetti M., Alessandrini A., Bobbio N., Mazzarello G., Fondaco L., Bonfanti P., Molteni C., Chiodera A., Milini P., Nunnari G., Pellicano G., Rizzardini G., Cannizzo E. S., Moioli M. C., Piolini R., Bernacchia D., Poli A., Tincati C., Puzzolante C., Migliorino C., Sangiovanni V., Borgia G., Esposito V., Di Flumeri G., Gentile I., Rizzo V., Cattelan A. M., Marinello S., Cascio A., Trizzino M., Francisci D., Schiaroli E., Parruti G., Sozio F., Lazzaretti C., Corsini R., Cristaudo A., Vullo V., Acinapura R., Lamonica S., Capozzi M., Mondi A., Rivano Capparuccia M., Iaiani G., Latini A., Onnelli G., Plazzi M. M., de Girolamo G., Vergori A., Cecchetto M., Viviani F., de Vito A., Rossetti B., Montagnani F., Franco A., Fontana Del Vecchio R., Di Giuli C., Caramello P., Orofino G. C., Sciandra M., Londero A., Manfrin V., Battagin G., Starnini G., Ialungo A., Fabeni, L, Santoro, M, Lorenzini, P, Rusconi, S, Gianotti, N, Costantini, A, Sarmati, L, Antinori, A, Ceccherini-Silberstein, F, d'Arminio Monforte, A, Saracino, A, Girardi, E, Castagna, A, Castelli, F, Cauda, R, Di Perri, G, Galli, M, Iardino, R, Ippolito, G, Lazzarin, A, Marchetti, G, Rezza, G, von Schloesser, F, Viale, P, Cozzi-Lepri, A, Gori, A, Lo Caputo, S, Maggiolo, F, Mussini, C, Puoti, M, Perno, C, Bai, F, Bandera, A, Bonora, S, Borderi, M, Calcagno, A, Capobianchi, M, Cicalini, S, Cingolani, A, Cinque, P, Di Biagio, A, Gagliardini, R, Guaraldi, G, Lapadula, G, Lichtner, M, Lai, A, Madeddu, G, Merlini, E, Nozza, S, Piconi, S, Pinnetti, C, Quiros Roldan, E, Rossotti, R, Spagnuolo, V, Svicher, V, Taramasso, L, Fanti, I, Galli, L, Rodano, A, Macchia, M, Tavelli, A, Bove, A, Camposeragna, A, Errico, M, Manfredini, M, Perziano, A, Calvino, V, Carrara, S, Di Caro, A, Graziano, S, Petroni, F, Prota, G, Truffa, S, Giacometti, A, Barocci, V, Angarano, G, Monno, L, Milano, E, Suardi, C, Donati, V, Verucchi, G, Castelnuovo, F, Minardi, C, Menzaghi, B, Abeli, C, Chessa, L, Pes, F, Cacopardo, B, Celesia, B, Vecchiet, J, Falasca, K, Pan, A, Lorenzotti, S, Sighinolfi, L, Segala, D, Blanc, P, Vichi, F, Cassola, G, Bassetti, M, Alessandrini, A, Bobbio, N, Mazzarello, G, Fondaco, L, Bonfanti, P, Molteni, C, Chiodera, A, Milini, P, Nunnari, G, Pellicano, G, Rizzardini, G, Cannizzo, E, Moioli, M, Piolini, R, Bernacchia, D, Poli, A, Tincati, C, Puzzolante, C, Migliorino, C, Sangiovanni, V, Borgia, G, Esposito, V, Di Flumeri, G, Gentile, I, Rizzo, V, Cattelan, A, Marinello, S, Cascio, A, Trizzino, M, Francisci, D, Schiaroli, E, Parruti, G, Sozio, F, Lazzaretti, C, Corsini, R, Cristaudo, A, Vullo, V, Acinapura, R, Lamonica, S, Capozzi, M, Mondi, A, Rivano Capparuccia, M, Iaiani, G, Latini, A, Onnelli, G, Plazzi, M, de Girolamo, G, Vergori, A, Cecchetto, M, Viviani, F, de Vito, A, Rossetti, B, Montagnani, F, Franco, A, Fontana Del Vecchio, R, Di Giuli, C, Caramello, P, Orofino, G, Sciandra, M, Londero, A, Manfrin, V, Battagin, G, Starnini, G, Ialungo, A, Fabeni L., Santoro M. M., Lorenzini P., Rusconi S., Gianotti N., Costantini A., Sarmati L., Antinori A., Ceccherini-Silberstein F., d'Arminio Monforte A., Saracino A., Girardi E., Castagna A., Castelli F., Cauda R., Di Perri G., Galli M., Iardino R., Ippolito G., Lazzarin A., Marchetti G. C., Rezza G., von Schloesser F., Viale P., Cozzi-Lepri A., Gori A., Lo Caputo S., Maggiolo F., Mussini C., Puoti M., Perno C. F., Bai F., Bandera A., Bonora S., Borderi M., Calcagno A., Capobianchi M. R., Cicalini S., Cingolani A., Cinque P., Di Biagio A., Gagliardini R., Guaraldi G., Lapadula G., Lichtner M., Lai A., Madeddu G., Merlini E., Nozza S., Piconi S., Pinnetti C., Quiros Roldan E., Rossotti R., Spagnuolo V., Svicher V., Taramasso L., Fanti I., Galli L., Rodano A., Macchia M., Tavelli A., Bove A., Camposeragna A., Errico M., Manfredini M., Perziano A., Calvino V., Carrara S., Di Caro A., Graziano S., Petroni F., Prota G., Truffa S., Giacometti A., Barocci V., Angarano G., Monno L., Milano E., Suardi C., Donati V., Verucchi G., Castelnuovo F., Minardi C., Menzaghi B., Abeli C., Chessa L., Pes F., Cacopardo B., Celesia B., Vecchiet J., Falasca K., Pan A., Lorenzotti S., Sighinolfi L., Segala D., Blanc P., Vichi F., Cassola G., Bassetti M., Alessandrini A., Bobbio N., Mazzarello G., Fondaco L., Bonfanti P., Molteni C., Chiodera A., Milini P., Nunnari G., Pellicano G., Rizzardini G., Cannizzo E. S., Moioli M. C., Piolini R., Bernacchia D., Poli A., Tincati C., Puzzolante C., Migliorino C., Sangiovanni V., Borgia G., Esposito V., Di Flumeri G., Gentile I., Rizzo V., Cattelan A. M., Marinello S., Cascio A., Trizzino M., Francisci D., Schiaroli E., Parruti G., Sozio F., Lazzaretti C., Corsini R., Cristaudo A., Vullo V., Acinapura R., Lamonica S., Capozzi M., Mondi A., Rivano Capparuccia M., Iaiani G., Latini A., Onnelli G., Plazzi M. M., de Girolamo G., Vergori A., Cecchetto M., Viviani F., de Vito A., Rossetti B., Montagnani F., Franco A., Fontana Del Vecchio R., Di Giuli C., Caramello P., Orofino G. C., Sciandra M., Londero A., Manfrin V., Battagin G., Starnini G., and Ialungo A. more...
- Abstract
We aimed at evaluating the characteristics of HIV-1 molecular transmission clusters (MTCs) among natives and migrants living in Italy, diagnosed between 1998 and 2018. Phylogenetic analyses were performed on HIV-1 polymerase (pol) sequences to characterise subtypes and identify MTCs, divided into small (SMTCs, 2-3 sequences), medium (MMTCs, 4-9 sequences) and large (LMTCs, ≥10 sequences). Among 3499 drug-naïve individuals enrolled in the Italian Cohort Naive Antiretroviral (ICONA) cohort (2804 natives; 695 migrants), 726 (20.8%; 644 natives, 82 migrants) were involved in 228 MTCs (6 LMTCs, 36 MMTCs, 186 SMTCs). Migrants contributed 14.4% to SMTCs, 7.6% to MMTCs and 7.1% to LMTCs, respectively. HIV-1 non-B subtypes were found in 51 MTCs; noteworthy was that non-B infections involved in MTCs were more commonly found in natives (n = 47) than in migrants (n = 4). Factors such as Italian origin, being men who have sex with men (MSM), younger age, more recent diagnosis and a higher CD4 count were significantly associated with MTCs. Our findings show that HIV-1 clustering transmission among newly diagnosed individuals living in Italy is prevalently driven by natives, mainly MSM, with a more recent diagnosis and frequently infected with HIV-1 non-B subtypes. These results can contribute to monitoring of the HIV epidemic and guiding the public health response to prevent new HIV infections. more...
- Published
- 2020
37. Evaluation of HIV transmission clusters among natives and foreigners living in Italy
- Author
-
Fabeni L., Santoro M. M., Lorenzini P., Rusconi S., Gianotti N., Costantini A., Sarmati L., Antinori A., Ceccherini-Silberstein F., d'Arminio Monforte A., Saracino A., Girardi E., Castagna A., Castelli F., Cauda R., Di Perri G., Galli M., Iardino R., Ippolito G., Lazzarin A., Marchetti G. C., Rezza G., von Schloesser F., Viale P., Cozzi-Lepri A., Gori A., Lo Caputo S., Maggiolo F., Mussini C., Puoti M., Perno C. F., Bai F., Bandera A., Bonora S., Borderi M., Calcagno A., Capobianchi M. R., Cicalini S., Cingolani A., Cinque P., Di Biagio A., Gagliardini R., Guaraldi G., Lapadula G., Lichtner M., Lai A., Madeddu G., Merlini E., Nozza S., Piconi S., Pinnetti C., Quiros Roldan E., Rossotti R., Spagnuolo V., Svicher V., Taramasso L., Fanti I., Galli L., Rodano A., Macchia M., Tavelli A., Bove A., Camposeragna A., Errico M., Manfredini M., Perziano A., Calvino V., Carrara S., Di Caro A., Graziano S., Petroni F., Prota G., Truffa S., Giacometti A., Barocci V., Angarano G., Monno L., Milano E., Suardi C., Donati V., Verucchi G., Castelnuovo F., Minardi C., Menzaghi B., Abeli C., Chessa L., Pes F., Cacopardo B., Celesia B., Vecchiet J., Falasca K., Pan A., Lorenzotti S., Sighinolfi L., Segala D., Blanc P., Vichi F., Cassola G., Bassetti M., Alessandrini A., Bobbio N., Mazzarello G., Fondaco L., Bonfanti P., Molteni C., Chiodera A., Milini P., Nunnari G., Pellicano G., Rizzardini G., Cannizzo E. S., Moioli M. C., Piolini R., Bernacchia D., Poli A., Tincati C., Puzzolante C., Migliorino C., Sangiovanni V., Borgia G., Esposito V., Di Flumeri G., Gentile I., Rizzo V., Cattelan A. M., Marinello S., Cascio A., Trizzino M., Francisci D., Schiaroli E., Parruti G., Sozio F., Lazzaretti C., Corsini R., Cristaudo A., Vullo V., Acinapura R., Lamonica S., Capozzi M., Mondi A., Rivano Capparuccia M., Iaiani G., Latini A., Onnelli G., Plazzi M. M., de Girolamo G., Vergori A., Cecchetto M., Viviani F., de Vito A., Rossetti B., Montagnani F., Franco A., Fontana Del Vecchio R., Di Giuli C., Caramello P., Orofino G. C., Sciandra M., Londero A., Manfrin V., Battagin G., Starnini G., Ialungo A., Fabeni L., Santoro M.M., Lorenzini P., Rusconi S., Gianotti N., Costantini A., Sarmati L., Antinori A., Ceccherini-Silberstein F., d'Arminio Monforte A., Saracino A., Girardi E., Castagna A., Castelli F., Cauda R., Di Perri G., Galli M., Iardino R., Ippolito G., Lazzarin A., Marchetti G.C., Rezza G., von Schloesser F., Viale P., Cozzi-Lepri A., Gori A., Lo Caputo S., Maggiolo F., Mussini C., Puoti M., Perno C.F., Bai F., Bandera A., Bonora S., Borderi M., Calcagno A., Capobianchi M.R., Cicalini S., Cingolani A., Cinque P., Di Biagio A., Gagliardini R., Guaraldi G., Lapadula G., Lichtner M., Lai A., Madeddu G., Merlini E., Nozza S., Piconi S., Pinnetti C., Quiros Roldan E., Rossotti R., Spagnuolo V., Svicher V., Taramasso L., Fanti I., Galli L., Rodano A., Macchia M., Tavelli A., Bove A., Camposeragna A., Errico M., Manfredini M., Perziano A., Calvino V., Carrara S., Di Caro A., Graziano S., Petroni F., Prota G., Truffa S., Giacometti A., Barocci V., Angarano G., Monno L., Milano E., Suardi C., Donati V., Verucchi G., Castelnuovo F., Minardi C., Menzaghi B., Abeli C., Chessa L., Pes F., Cacopardo B., Celesia B., Vecchiet J., Falasca K., Pan A., Lorenzotti S., Sighinolfi L., Segala D., Blanc P., Vichi F., Cassola G., Bassetti M., Alessandrini A., Bobbio N., Mazzarello G., Fondaco L., Bonfanti P., Molteni C., Chiodera A., Milini P., Nunnari G., Pellicano G., Rizzardini G., Cannizzo E.S., Moioli M.C., Piolini R., Bernacchia D., Poli A., Tincati C., Puzzolante C., Migliorino C., Sangiovanni V., Borgia G., Esposito V., Di Flumeri G., Gentile I., Rizzo V., Cattelan A.M., Marinello S., Cascio A., Trizzino M., Francisci D., Schiaroli E., Parruti G., Sozio F., Lazzaretti C., Corsini R., Cristaudo A., Vullo V., Acinapura R., Lamonica S., Capozzi M., Mondi A., Rivano Capparuccia M., Iaiani G., Latini A., Onnelli G., Plazzi M.M., de Girolamo G., Vergori A., Cecchetto M., Viviani F., de Vito A., Rossetti B., Montagnani F., Franco A., Fontana Del Vecchio R., Di Giuli C., Caramello P., Orofino G.C., Sciandra M., Londero A., Manfrin V., Battagin G., Starnini G., Ialungo A., Fabeni, L., Santoro, M. M., Lorenzini, P., Rusconi, S., Gianotti, N., Costantini, A., Sarmati, L., Antinori, A., Ceccherini-Silberstein, F., d'Arminio Monforte, A., Saracino, A., Girardi, E., Castagna, A., Castelli, F., Cauda, R., Di Perri, G., Galli, M., Iardino, R., Ippolito, G., Lazzarin, A., Marchetti, G. C., Rezza, G., von Schloesser, F., Viale, P., Cozzi-Lepri, A., Gori, A., Lo Caputo, S., Maggiolo, F., Mussini, C., Puoti, M., Perno, C. F., Bai, F., Bandera, A., Bonora, S., Borderi, M., Calcagno, A., Capobianchi, M. R., Cicalini, S., Cingolani, A., Cinque, P., Di Biagio, A., Gagliardini, R., Guaraldi, G., Lapadula, G., Lichtner, M., Lai, A., Madeddu, G., Merlini, E., Nozza, S., Piconi, S., Pinnetti, C., Quiros Roldan, E., Rossotti, R., Spagnuolo, V., Svicher, V., Taramasso, L., Fanti, I., Galli, L., Rodano, A., Macchia, M., Tavelli, A., Bove, A., Camposeragna, A., Errico, M., Manfredini, M., Perziano, A., Calvino, V., Carrara, S., Di Caro, A., Graziano, S., Petroni, F., Prota, G., Truffa, S., Giacometti, A., Barocci, V., Angarano, G., Monno, L., Milano, E., Suardi, C., Donati, V., Verucchi, G., Castelnuovo, F., Minardi, C., Menzaghi, B., Abeli, C., Chessa, L., Pes, F., Cacopardo, B., Celesia, B., Vecchiet, J., Falasca, K., Pan, A., Lorenzotti, S., Sighinolfi, L., Segala, D., Blanc, P., Vichi, F., Cassola, G., Bassetti, M., Alessandrini, A., Bobbio, N., Mazzarello, G., Fondaco, L., Bonfanti, P., Molteni, C., Chiodera, A., Milini, P., Nunnari, G., Pellicano, G., Rizzardini, G., Cannizzo, E. S., Moioli, M. C., Piolini, R., Bernacchia, D., Poli, A., Tincati, C., Puzzolante, C., Migliorino, C., Sangiovanni, V., Borgia, G., Esposito, V., Di Flumeri, G., Gentile, I., Rizzo, V., Cattelan, A. M., Marinello, S., Cascio, A., Trizzino, M., Francisci, D., Schiaroli, E., Parruti, G., Sozio, F., Lazzaretti, C., Corsini, R., Cristaudo, A., Vullo, V., Acinapura, R., Lamonica, S., Capozzi, M., Mondi, A., Rivano Capparuccia, M., Iaiani, G., Latini, A., Onnelli, G., Plazzi, M. M., de Girolamo, G., Vergori, A., Cecchetto, M., Viviani, F., de Vito, A., Rossetti, B., Montagnani, F., Franco, A., Fontana Del Vecchio, R., Di Giuli, C., Caramello, P., Orofino, G. C., Sciandra, M., Londero, A., Manfrin, V., Battagin, G., Starnini, G., and Ialungo, A. more...
- Subjects
0301 basic medicine ,Male ,lcsh:QR1-502 ,Subtype ,HIV Infections ,migrants ,Bioinformatics ,Cluster detection ,Drug resistance testing ,Human immunodeficiency virus (HIV) ,Migrants ,Molecular epidemiology ,Phylogenetic analysis ,Risk factors ,Subtypes ,Transmission networks and clusters ,Adult ,Cohort Studies ,Female ,Genotype ,HIV-1 ,Humans ,Italy ,Middle Aged ,Sexual and Gender Minorities ,pol Gene Products, Human Immunodeficiency Virus ,Emigrants and Immigrants ,Phylogeny ,lcsh:Microbiology ,Men who have sex with men ,0302 clinical medicine ,human immunodeficiency virus (HIV) ,molecular epidemiology ,phylogenetic analysis ,cluster detection ,transmission networks and clusters ,subtypes ,drug resistance testing ,risk factors ,bioinformatics ,Medicine ,030212 general & internal medicine ,pol Gene Products ,Hiv transmission ,Transmission (medicine) ,virus diseases ,Infectious Diseases ,Cohort ,Human Immunodeficiency Virus ,Cohort study ,medicine.medical_specialty ,Article ,NO ,03 medical and health sciences ,Phylogenetic analysi ,Virology ,Bioinformatic ,business.industry ,Public health ,Migrant ,Settore MED/17 ,030104 developmental biology ,Risk factor ,business ,Demography - Abstract
We aimed at evaluating the characteristics of HIV-1 molecular transmission clusters (MTCs) among natives and migrants living in Italy, diagnosed between 1998 and 2018. Phylogenetic analyses were performed on HIV-1 polymerase (pol) sequences to characterise subtypes and identify MTCs, divided into small (SMTCs, 2&ndash, 3 sequences), medium (MMTCs, 4&ndash, 9 sequences) and large (LMTCs, &ge, 10 sequences). Among 3499 drug-naï, ve individuals enrolled in the Italian Cohort Naive Antiretroviral (ICONA) cohort (2804 natives, 695 migrants), 726 (20.8%, 644 natives, 82 migrants) were involved in 228 MTCs (6 LMTCs, 36 MMTCs, 186 SMTCs). Migrants contributed 14.4% to SMTCs, 7.6% to MMTCs and 7.1% to LMTCs, respectively. HIV-1 non-B subtypes were found in 51 MTCs, noteworthy was that non-B infections involved in MTCs were more commonly found in natives (n = 47) than in migrants (n = 4). Factors such as Italian origin, being men who have sex with men (MSM), younger age, more recent diagnosis and a higher CD4 count were significantly associated with MTCs. Our findings show that HIV-1 clustering transmission among newly diagnosed individuals living in Italy is prevalently driven by natives, mainly MSM, with a more recent diagnosis and frequently infected with HIV-1 non-B subtypes. These results can contribute to monitoring of the HIV epidemic and guiding the public health response to prevent new HIV infections. more...
- Published
- 2020
38. Smoking habits in HIV-infected people compared with the general population in Italy: a cross-sectional study
- Author
-
De Socio, G. V., Pasqualini, M., Ricci, E., Maggi, P., Orofino, G., Squillace, N., Menzaghi, B., Madeddu, G., Taramasso, L., Francisci, D., Bonfanti, P., Vichi, F., Dell'Omo, M., Pieroni, L., Santoro, C., Quirino, T., Farinazzo, M., Magne, F., Molteni, C., Malincarne, L., Riguccini, E., Nofri, M., Bagella, P., Mameli, M. S., Tiri, B., Guastavigna, M., De Socio, G, Pasqualini, M, Ricci, E, Maggi, P, Orofino, G, Squillace, N, Menzaghi, B, Madeddu, G, Taramasso, L, Francisci, D, Bonfanti, P, Vichi, F, Dell’Omo, M, and Pieroni, L more...
- Subjects
Adult ,Male ,medicine.medical_specialty ,Cross-sectional study ,medicine.medical_treatment ,Population ,HIV Infections ,030312 virology ,03 medical and health sciences ,0302 clinical medicine ,Acquired immunodeficiency syndrome (AIDS) ,Surveys and Questionnaires ,Epidemiology ,Tobacco ,medicine ,Odds Ratio ,Prevalence ,Tobacco Smoking ,Humans ,030212 general & internal medicine ,education ,0303 health sciences ,education.field_of_study ,Smokers ,business.industry ,Public health ,lcsh:Public aspects of medicine ,Smoking ,Public Health, Environmental and Occupational Health ,HIV ,lcsh:RA1-1270 ,Middle Aged ,medicine.disease ,Lifestyle ,Cardiovascular disease ,Stratified sampling ,AIDS ,Smoking, Tobacco, Italy, Lifestyle, HIV, AIDS, Cardiovascular disease ,Cross-Sectional Studies ,Italy ,Smoking cessation ,Female ,Smoking Cessation ,Biostatistics ,business ,Demography ,Research Article - Abstract
Background Tobacco use is a leading cause of preventable diseases and death for all individuals, even more so for people living with HIV (PLWH), due to their status of chronic inflammation. To date, in Italy no study was performed to compare smoking habits in PLWH and the general population. We aimed to investigate smoking habits in PLWH, as compared to the general population. Methods Multi-center cross-sectional study. Smoking habits were compared between PLWH and the general population. PLWH were enrolled in the STOPSHIV Study. The comparison group from the general population was derived from a survey performed by the National Statistics Institute (ISTAT), with a stratified random sampling procedure matching 2:1 general population subjects with PLWH by age class, sex, and macro-area of residence. Results The total sample consisted of 1087 PLWH (age 47.9 ± 10.8 years, male 73.5%) and 2218 comparable subjects from the general population. Prevalence of current smokers was 51.6% vs 25.9% (p p p p p 20 cigarettes per day) (aOR = 4.84; 95% CI = 3.74–6.27; p p Conclusion HIV-infected patients showed a higher rate of current smokers, a larger number of cigarettes smoked and a lower quitting rate than the general population. Our findings emphasize the need for smoking cessation strategies targeting HIV persons. more...
- Published
- 2020
39. Prevalence and Clinical Outcomes of Poor Immune Response Despite Virologically Suppressive Antiretroviral Therapy Among Children and Adolescents With Human Immunodeficiency Virus in Europe and Thailand: Cohort Study
- Author
-
Chappell, E., Riordan, A., Jourdain, G., Soriano-Arandes, A., Ene, L., Scherpbier, H., Warszawski, J., Collins, I., Smit, C., Marques, L., Klein, N., Guillén, S., Judd, A., Thorne, C., Goodall, R., Königs, C., Spoulou, V., Prata, F., Goetghebuer, T., Chiappini, E., Galli, L., Naver, L., Giaquinto, C., Gibb, D., Marczynska, M., Okhonskaia, L., Klimkait, T., Lallemant, M., Ngo-Giang-Huong, N., Kiseleva, G., Malyuta, R., Volokha, A., Hainaut, M., Delforge, M., Le Chenadec, J., Ramos, E., Dialla, O., Wack, T., Laurent, C., Ait Si Selmi, L., Leymarie, I., Ait Benali, F., Brossard, M., Boufassa, L., Floch-Tudal, C., Firtion, G., Hau, I., Chace, A., Bolot, P., Blanche, S., Levine, M., Bicëtre, L., Fourcade, C., Heller-Roussin, B., Runel-Belliard, C., Tricoire, J., Chirouze, C., Reliquet, V., Brouard, J., Kebaili, K., Fialaire, P., Lalande, M., Schultze-Strasser, S., Baumann, U., Niehues, T., Neubert, J., Kobbe, R., Berlin, C., Feiterna-Sperling, C., Buchholz, B., Notheis, G., de Martino, M., Angelo Tovo, P., Patrizia, O., Larovere, D., Ruggeri, M., Faldella, G., Baldi, F., Badolato, R., Montagnani, C., Venturini, E., Lisi, C., Di Biagio, A., Taramasso, L., Giacomet, V., Erba, P., Esposito, S., Lipreri, R., Salvini, F., Tagliabue, C., Cellini, M., Bruzzese, E., Lo Vecchio, A., Rampon, O., Donà, D., Romano, A., Dodi, I., Maccabruni, A., Consolini, R., Bernardi, S., Tchidjou Kuekou, H., Genovese, O., Olmeo, P., Cristiano, L., Mazza, A., Gabiano, C., Garazzino, S., Pellegatta, A., Pajkrt, D., Weijsenfeld, A., de Boer CG, Jurriaans, S., Back, N., Zaaijer, H., Berkhout, B., Cornelissen, M., Schinkel, C., Wolthers, K., Fraaij, P., van Rossum AMC, van der Knaap LC, Visser, E., Koopmans, M., van Kampen JJA, Pas, S., Henriet, S., van de Flier, M., van Aerde, K., Strik-Albers, R., Rahamat-Langendoen, J., Stelma, F., Schölvinck, E., de Groot-de Jonge, H., Niesters, H., van Leer-Buter CC, Knoester, M., Bont, L., Geelen, S., Wolfs, T., Nauta, N., Ang, C., van Houdt, R., Pettersson, A., Vandenbroucke-Grauls, C., Reiss, P., Bezemer, D., van Sighem AI, Wit, F., Boender, T., Zaheri, S., Hillebregt, M., de Jong, A., Bergsma, D., Grivell, S., Jansen, A., Raethke, M., Meijering, R., de Groot, L., van den Akker, M., Bakker, Y., Claessen, E., El Berkaoui, A., Koops, J., Kruijne, E., Lodewijk, C., Munjishvili, L., Peeck, B., Ree, C., Regtop, R., Ruijs, Y., Rutkens, T., Schoorl, M., Timmerman, A., Tuijn, E., Veenenberg, L., van der Vliet, S., Wisse, A., Woudstra, T., Tuk, B., Popielska, J., Pokorska-Śpiewak, M., Ołdakowska, A., Zawadka, K., Coupland, U., DorobaLaura Marques, M., Teixeira, C., Fernandes, A., Voronin, E., Miloenko, M., Labutina, S., Tomás Ramos, J., Prieto, L., Luisa Navarro, M., Saavedra, J., Santos, M., Angeles Muñoz, M., Ruiz, B., Mc Phee CF, de Ory SJ, Alvarez, S., Ángel Roa, M., Beceiro, J., Martínez, J., Badillo, K., Apilanez, M., Pocheville, I., Garrote, E., Colino, E., Gómez Sirvent, J., Garzón, M., Román, V., Montesdeoca, A., Mateo, M., José Muñoz, M., Angulo, R., Neth, O., Falcón, L., Terol, P., Luis Santos, J., Moreno, D., Lendínez, F., Grande, A., José Romero, F., Lillo, M., Losada, B., Herranz, M., Bustillo, M., Guerrero, C., Collado, P., Antonio Couceiro, J., Pérez, A., Isabel Piqueras, A., Bretón, R., Segarra, I., Gavilán, C., Jareño, E., Montesinos, E., Dapena, M., Álvarez, C., Gloria Andrés, A., Marugán, V., Ochoa, C., Alfayate, S., Isabel Menasalvas, A., de Miguel, E., Aebi-Popp, K., Asner, S., Aubert, V., Battegay, M., Baumann, M., Bernasconi, E., Böni, J., Brazzola, P., Bucher, H., Calmy, A., Cavassini, M., Ciuffi, A., Duppenthaler, A., Dollenmaier, G., Egger, M., Elzi, L., Fehr, J., Fellay, J., Francini, K., Furrer, H., Fux, C., Grawe, C., Günthard, H., Haerry, D., Hasse, B., Hirsch, H., Hoffmann, M., Hösli, I., Kahlert, C., Kaiser, L., Keiser, O., Kovari, H., Kouyos, R., Ledergerber, B., Martinetti, G., de Tejada BM, Metzner, K., Müller, N., Nicca, D., Paioni, P., Pantaleo, G., Polli, C., Posfay-Barbe, K., Rauch, A., Rudin, C., Schmid, P., Scherrer, A., Speck, R., Tarr, P., Thanh Lecompte, M., Trkola, A., Vernazza, P., Wagner, N., Wandeler, G., Weber, R., Wyler, C., Yerly, S., Techakunakorn, P., Hansudewechakul, R., Kham, C., Wanchaitanawong, V., Theansavettrakul, S., Sai, M., Nanta, S., Ngampiyaskul, C., Phanomcheong, S., Hongsiriwon, S., Karnchanamayul, W., Kwanchaipanich, R., Kanjanavanit, S., Kamonpakorn, N., Nantarukchaikul, M., Layangool, P., Mekmullica, J., Lucksanapisitkul, P., Watanayothin, S., Lertpienthum, N., Warachit, B., Hanpinitsak, S., Potchalongsin, S., Thanasiri, P., Krikajornkitti, S., Attavinijtrakarn, P., Srirojana, S., Bunjongpak, S., Puangsombat, A., Na-Rajsima, S., Ananpatharachai, P., Akarathum, N., Phuket, V., Lawtongkum, W., Kheunjan, P., Suriyaboon, T., Saipanya, A., Than-In-At, K., Jaisieng, N., Suaysod, R., Chailoet, S., Naratee, N., Kawilapat, S., Kaleeva, T., Baryshnikova, Y., Soloha, S., Bashkatova, N., Raus, I., Glutshenko, O., Ruban, Z., Prymak, N., Bailey, H., Bamford, A., Butler, K., Doerholt, K., Doherty, C., Foster, C., Francis, K., Harrison, I., Kenny, J., Letting, G., Mcmaster, P., Murau, F., Nsangi, E., Peters, H., Prime, K., Shackley, F., Shingadia, D., Storey, S., Tudor-Williams, G., Turkova, A., Welch, S., Jeannie Collins, I., Cook, C., Crichton, S., Dobson, D., Fairbrother, K., M Gibb D, Harper, L., Le Prevost, M., Van Looy, N., Walsh, A., Thrasyvoulou, L., Bernatoniene, J., Manyika, F., Sharpe, G., Subramaniam, B., Sloper, K., Fidler, K., Hague, R., Price, V., Clapson, M., Flynn, J., Cardoso, A., Abou-Rayyah, M., Gurtin, D., Yeadon, S., Segal, S., Ball, C., Hawkins, S., Dowie, M., Bandi, S., Percival, E., Eisenhut, M., Duncan, K., Clough, S., Anguvaa, L., Conway, S., Flood, T., Pickering, A., Murphy, C., Daniels, J., Lees, Y., Thompson, F., Williams, B., Pope, S., Cliffe, L., Smyth, A., Southall, S., Freeman, A., Freeman, H., Christie, S., Gordon, A., Rogahn, D., Clarke, L., Jones, L., Offerman, B., Greenberg, M., Benson, C., Ibberson, L., Faust, S., Hancock, J., Sharland, M., Lyall, H., Monrose, C., Seery, P., Menson, E., Callaghan, A., Bridgwood, A., Evans, J., Blake, E., Yannoulias, A., Critchton, S., Duff, C., Gomezpena, D., Lundin, R., Mangiarini, L., Nardone, A., Posfay Barbe, Klara, Universidad de Alcalá - University of Alcalá (UAH), Department of Sciences for Woman and Child's Health, Università degli Studi di Firenze = University of Florence (UniFI), Épidémiologie clinique, santé mère-enfant et VIH en Asie du Sud-Est (IRD_PHPT), Harvard University-Chiang Mai University (CMU), Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier de Saint-Denis [Ile-de-France], CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Laboratoire Chrono-environnement (UMR 6249) (LCE), Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), service de maladies infectieuses CHU J Minjoz Besancon, Service des maladies infectieuses et tropicales [CHU Nantes], Centre hospitalier universitaire de Nantes (CHU Nantes), Service de Pédiatrie Médicale [Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Service d'hématologie : Immuno-Hématologie pédiatrique et transplantation de moelle osseuse, Hôpital Debrousse, Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Universitätsklinikum Frankfurt, Infectious Diseases, San Martino Hospital, Università degli studi di Genova = University of Genoa (UniGe), Department of Maternal and Pediatric Sciences, University of Milan, Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Maternal-Infantile Department, Unit of Paediatrics and Oncohematology, University Hospital of Parma, Department of Infectious Diseases, IRCCS S. Matteo, Department of Paediatrics, Università cattolica del Sacro Cuore = Catholic University of the Sacred Heart [Roma] (Unicatt), Dipartimento di Ingegneria [Benevento], Università degli Studi del Sannio, University of Twente, Institut de génétique humaine (IGH), Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Laboratory for Infectious Diseases and Perinatal Screening, Center for Infectious Disease Control, National Institute for Public Health and the Environment [Bilthoven] (RIVM), Architecture et réactivité de l'ARN (ARN), Université Louis Pasteur - Strasbourg I-Centre National de la Recherche Scientifique (CNRS), Synthèse, Structure et Propriétés de Matériaux Fonctionnels (STEP), SYstèmes Moléculaires et nanoMatériaux pour l’Energie et la Santé (SYMMES), Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut de Recherche Interdisciplinaire de Grenoble (IRIG), Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut de Recherche Interdisciplinaire de Grenoble (IRIG), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Département Interfaces pour l'énergie, la Santé et l'Environnement (DIESE), Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Stichting HIV Monitoring, Universidade Federal do Ceará = Federal University of Ceará (UFC), Departamento de Química Orgánica, Universidade de Vigo, Polytechnical University of Valencia, Fac Biol, Dept Genet, Universidad Complutense de Madrid = Complutense University of Madrid [Madrid] (UCM), University of the Basque Country/Euskal Herriko Unibertsitatea (UPV/EHU), Service des maladies infectieuses, Hôpitaux Universitaires de Genève (HUG), University of Basel (Unibas), Dysfonctions métaboliques et diabètes: Mécanismes et approches thérapeutiques, Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-IFR50-Institut National de la Santé et de la Recherche Médicale (INSERM), University Heart Centre Freiburg - Bad Krozingen, Prapokklao Hospital [Chanthaburi, Thailand], Nakornping Hospital [Chiang Mai, Thailand], Samutsakhon Hospital [Samutsakhon, Thailand], Kalasin Hospital [Kalasin, Thailand], Sanpatong Hospital [Chiang Mai, Thailand], Chiang Mai University (CMU), Microbiology Department, St. Jame's Hospital, University of Edinburgh, Infectious Diseases and Microbiology Unit, Great Ormond Street Hospital for Children [London] (GOSH)-Institute of Child Health, European Synchrotron Radiation Facility (ESRF), Centre for Ecology and Hydrology [Bangor] (CEH), Natural Environment Research Council (NERC), Jet Propulsion Laboratory (JPL), NASA-California Institute of Technology (CALTECH), University of London [London], London South Bank University (LSBU), Dipartimento di Pediatria, Azienda Ospedaliera di Padova, Université Grenoble Alpes - UFR Pharmacie (UGA UFRP), Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), The European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) Study Group in EuroCoord, Florence University, Harvard University [Cambridge]-Chiang Mai University (CMU), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Laboratoire Chrono-environnement - CNRS - UBFC (UMR 6249) (LCE), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), University of Genoa (UNIGE), Catholic University of Rome, University of Twente [Netherlands], Institut de Chimie du CNRS (INC)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut de Recherche Interdisciplinaire de Grenoble (IRIG), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS)-Institut de Chimie du CNRS (INC)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut de Recherche Interdisciplinaire de Grenoble (IRIG), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), University of the Basque Country [Bizkaia] (UPV/EHU), Université Nice Sophia Antipolis (... - 2019) (UNS), Pediatrics, Virology, Chappell, Elizabeth, Riordan, Andrew, Jourdain, Gonzague, Soriano-Arandes, Antoni, Ene, Luminita, J Scherpbier, Henriette, Warszawski, Josiane, J Collins, Intira, Smit, Colette, Marques, Laura, Klein, Nigel, Guillén, Sara, Judd, Ali, Thorne, Claire, Goodall, Ruth, Königs, Christoph, Spoulou, Vana, Prata, Filipa, Goetghebuer, Tessa, Chiappini, Elena, Galli, Luisa, Naver, Lar, Giaquinto, Carlo, M Gibb, Diana, Marczynska, Magdalena, Okhonskaia, Liubov, Klimkait, Thoma, Lallemant, Marc, Ngo-Giang-Huong, Nicole, Kiseleva, Galyna, Malyuta, Ruslan, Volokha, Alla, Hainaut, Marc, Delforge, Marc, Le Chenadec, Jerome, Ramos, Elisa, Dialla, Olivia, Wack, Thierry, Laurent, Corine, Ait Si Selmi, Lamya, Leymarie, Isabelle, Ait Benali, Fazia, Brossard, Maud, Boufassa, Leila, Floch-Tudal, Corinne, Firtion, Ghislaine, Hau, Isabelle, Chace, Anne, Bolot, Pascal, Blanche, Stéphane, Levine, Martine, Kremlin Bicëtre, Le, Fourcade, Corinne, Heller-Roussin, Brigitte, Runel-Belliard, Camille, Tricoire, Joëlle, Chirouze, Catherine, Reliquet, Véronique, Brouard, Jacque, Kebaili, Kamila, Fialaire, Pascale, Lalande, Muriel, Schultze-Strasser, Stephan, Baumann, U, Niehues, T, Neubert, J, Kobbe, R, Berlin, Charite, Feiterna-Sperling, C, Königs, C, Buchholz, B, Notheis, G, de Martino, Maurizio, Angelo Tovo, Pier, Patrizia, Osimani, Larovere, Domenico, Ruggeri, Maurizio, Faldella, Giacomo, Baldi, Francesco, Badolato, Raffaele, Montagnani, Carlotta, Venturini, Elisabetta, Lisi, Catiuscia, Di Biagio, Antonio, Taramasso, Lucia, Giacomet, Vania, Erba, Paola, Esposito, Susanna, Lipreri, Rita, Salvini, Filippo, Tagliabue, Claudia, Cellini, Monica, Bruzzese, Eugenia, LO VECCHIO, Andrea, Paediatric Infectious Diseases / Rheumatology / Immunology, Amsterdam institute for Infection and Immunity, AII - Infectious diseases, Amsterdam Reproduction & Development (AR&D), APH - Aging & Later Life, Infectious diseases, and Global Health more...
- Subjects
0301 basic medicine ,medicine.medical_treatment ,lnfectious Diseases and Global Health Radboud Institute for Molecular Life Sciences [Radboudumc 4] ,HIV Infections ,Rate ratio ,Cohort Studies ,0302 clinical medicine ,Pregnancy ,Antiretroviral Therapy, Highly Active ,Prevalence ,030212 general & internal medicine ,Child ,poor immune response ,ddc:618 ,Immunosuppression ,Viral Load ,Hepatitis B ,Thailand ,3. Good health ,Europe ,Thailand/epidemiology ,Infectious Diseases ,Cohort ,Coinfection ,Female ,Cohort study ,Adult ,Microbiology (medical) ,viral suppression ,medicine.medical_specialty ,Adolescent ,Anti-HIV Agents ,antiretroviral therapy ,030106 microbiology ,Europe/epidemiology ,03 medical and health sciences ,children ,Acquired immunodeficiency syndrome (AIDS) ,SDG 3 - Good Health and Well-being ,Internal medicine ,medicine ,Humans ,HIV ,Aged ,Settore MED/38 - Pediatria Generale e Specialistica ,business.industry ,Immunity ,medicine.disease ,HIV Infections/drug therapy/epidemiology ,CD4 Lymphocyte Count ,lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4] ,Anti-HIV Agents/therapeutic use ,business ,[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology - Abstract
Background In human immunodeficiency virus (HIV)–positive adults, low CD4 cell counts despite fully suppressed HIV-1 RNA on antiretroviral therapy (ART) have been associated with increased risk of morbidity and mortality. We assessed the prevalence and outcomes of poor immune response (PIR) in children receiving suppressive ART. Methods Sixteen cohorts from the European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) contributed data. Children Results Of 2318 children included, median age was 6.4 years and 68% had advanced/severe immunosuppression at ART initiation. At 1 year of VS, 12% had PIR. In multivariable analysis, PIR was associated with older age and worse immunological stage at ART start, hepatitis B coinfection, and residing in Thailand (all P ≤ .03). Rates of AIDS/death (95% confidence interval) per 100 000 person-years were 1052 (547, 2022) among PIR versus 261 (166, 409) among immune responders; rate ratio of 4.04 (1.83, 8.92; P < .001). Conclusions One in eight children in our cohort experienced PIR despite sustained VS. While the overall rate of AIDS/death was low, children with PIR had a 4-fold increase in risk of event as compared with immune responders. more...
- Published
- 2020
- Full Text
- View/download PDF
40. Duration of isolation and precautions in immunocompromised patients with COVID-19
- Author
-
Taramasso, L., Sepulcri, C., Mikulska, M., Magnasco, L., Lai, A., Bruzzone, B., Dentone, C., and Bassetti, M.
- Published
- 2021
- Full Text
- View/download PDF
41. Extensive activation, tissue trafficking, turnover and functional impairment of NK cells in COVID-19 patients at disease onset associates with subsequent disease severity
- Author
-
Bozzano, F., Dentone, C., Perrone, C., Di Biagio, A., Fenoglio, D., Parodi, A., Mikulska, M., Bruzzone, B., Giacobbe, D. R., Vena, A., Taramasso, L., Nicolini, L., Patroniti, N., Pelosi, P., Gratarola, A., de Palma, R., Filaci, G., Bassetti, M., de Maria, A., Alessandrini, A., Camera, M., Delfino, E., Dodi, F., Ferrazin, A., Mazzarello, G., Toscanini, F., Balletto, E., Portunato, F., Schenone, E., Rosseti, N., Baldi, F., Berruti, M., Briano, F., Dettori, S., Labate, L., Magnasco, L., Mirabella, M., Pincino, R., Russo, C., Sarteschi, G., Sepulcri, C., Tutino, S., Pontremoli, R., Beccati, V., Casciaro, S., Casu, M., Gavaudan, F., Ghinatti, M., Gualco, E., Leoncini, G., Pitto, P., Salam, K., Bixio, M., Amelia, A., Balestra, A., Ballarino, P., Bardi, N., Boccafogli, R., Caserza, F., Calzolari, E., Castelli, M., Cenni, E., Cortese, P., Cuttone, G., Feltrin, S., Giovinazzo, S., Giuntini, P., Natale, L., Orsi, D., Pastorino, M., Perazzo, T., Pescetelli, F., Schenone, F., Serra, M. G., Sottano, M., Brunetti, I., Robba, C., Ball, L., Loconte, M., Battaglini, D., de Rito, M. R., Cerana, M., Fasce, R., Insorsi, A., Molin, A., Tallone, R., Amelotti, M., Majabo, M. J., Merlini, M., Perazzo, F., Ahamd, N., Barbera, P., Bovio, M., Cam-Podonico, P., Collida, A., Cutuli, O., Lomeo, A., Fezza, F., Genti-Lucci, N., Hussein, N., Malvezzi, E., Massobrio, L., Motta, G., Pastorino, L., Pollicardo, N., Sartini, S., Virga, P. V. V., Porto, I., Bezante, G. P., Bona, R. D., Malfa, G. L., Valbusa, A., V. G., Ad, Barisione, E., Bellotti, M., Teresita, A., Blanco, A., Grosso, M., Piroddi, M. G., Moscatelli, P., Caiti, M., Magnani, O., Sukkar, S., Cogorno, L., Gradaschi, R., Guiddo, E., Martino, E., Pisciotta, L., Cavagliere, B., Cristina, R., Francesca, F., Garibotto, G., Esposito, P., Passalacqua, G., Bagnasco, D., Braido, F., Riccio, A., Tagliabue, E., Gustavino, C., Ferraiolo, A., Giuffrida, S., Rosso, N., Morando, A., Papalia, R., Passerini, D., Tiberio, G., Orengo, G., Battaglini, A., Ruffoni, S., and Caglieris, S. more...
- Subjects
RNA viruses ,Male ,Viral Diseases ,Coronaviruses ,medicine.medical_treatment ,Cytotoxicity ,Cell ,NK cells ,Aged ,Aged, 80 and over ,COVID-19 ,Cohort Studies ,Female ,Flow Cytometry ,Humans ,Interferon-gamma ,Italy ,Killer Cells, Natural ,Lymphocyte Activation ,Middle Aged ,Severity of Illness Index ,Toxicology ,0302 clinical medicine ,Medical Conditions ,Spectrum Analysis Techniques ,Cellular types ,80 and over ,Killer Cells ,Lymphocytes ,Biology (General) ,Receptor ,Immune Response ,Pathology and laboratory medicine ,0303 health sciences ,medicine.diagnostic_test ,Immune cells ,hemic and immune systems ,Medical microbiology ,Cytokine ,medicine.anatomical_structure ,Infectious Diseases ,Spectrophotometry ,Viruses ,Natural ,White blood cells ,Cytophotometry ,medicine.symptom ,SARS CoV 2 ,Pathogens ,Research Article ,Cell biology ,Blood cells ,SARS coronavirus ,Precursor Cells ,QH301-705.5 ,Immunology ,Inflammation ,chemical and pharmacologic phenomena ,Biology ,Research and Analysis Methods ,Microbiology ,Flow cytometry ,03 medical and health sciences ,Immune system ,Signs and Symptoms ,Virology ,Genetics ,medicine ,Molecular Biology ,030304 developmental biology ,Medicine and health sciences ,Biology and life sciences ,Organisms ,Viral pathogens ,Covid 19 ,RC581-607 ,NKG2D ,Microbial pathogens ,Perforin ,Animal cells ,biology.protein ,Parasitology ,Clinical Medicine ,Immunologic diseases. Allergy ,030215 immunology - Abstract
The SARS-CoV-2 infection causes severe respiratory involvement (COVID-19) in 5–20% of patients through initial immune derangement, followed by intense cytokine production and vascular leakage. Evidence of immune involvement point to the participation of T, B, and NK cells in the lack of control of virus replication leading to COVID-19. NK cells contribute to early phases of virus control and to the regulation of adaptive responses. The precise mechanism of NK cell dysregulation is poorly understood, with little information on tissue margination or turnover. We investigated these aspects by multiparameter flow cytometry in a cohort of 28 patients hospitalized with early COVID-19. Relevant decreases in CD56brightCD16+/- NK subsets were detected, with a shift of circulating NK cells toward more mature CD56dimCD16+KIR+NKG2A+ and “memory” KIR+CD57+CD85j+ cells with increased inhibitory NKG2A and KIR molecules. Impaired cytotoxicity and IFN-γ production were associated with conserved expression of natural cytotoxicity receptors and perforin. Moreover, intense NK cell activation with increased HLA-DR and CD69 expression was associated with the circulation of CD69+CD103+ CXCR6+ tissue-resident NK cells and of CD34+DNAM-1brightCXCR4+ inflammatory precursors to mature functional NK cells. Severe disease trajectories were directly associated with the proportion of CD34+DNAM-1brightCXCR4+ precursors and inversely associated with the proportion of NKG2D+ and of CD103+ NK cells. Intense NK cell activation and trafficking to and from tissues occurs early in COVID-19, and is associated with subsequent disease progression, providing an insight into the mechanism of clinical deterioration. Strategies to positively manipulate tissue-resident NK cell responses may provide advantages to future therapeutic and vaccine approaches., Author summary This is a detailed study of activating and inhibitory receptors in NK cells of COVID-19 patients when first admitted to the hospital for respiratory insufficiency. NK cells are known to be the first line of defense against invading viruses, and regulate downstream B and T cell responses, including antibody production. We observed intense NK cell activation with decreased functional activity, as well as intense circulation of putative tissue resident CD69+CD103+CXCR6+ NK cells, with a related surge in inflammatory CD34+ precursors from the bone marrow. The findings suggest that there is unprecedented trafficking of NK cells from peripheral tissues, their increased death with recruitment of emergency precursors from the bone marrow, and a relationship with the subsequent course of the disease of the patients. This in turn suggests possible areas of treatment and prevention. more...
- Published
- 2021
42. Fattori associati con il ricovero ospedaliero per COVID-19 in 80 pazienti HIV-positivi italiani
- Author
-
Taramasso L
- Abstract
Questo studio analizza i ricoveri ospedalieri e l’outcome di 80 pazienti HIV-positivi, con diagnosi di infezione da SARS-CoV-2 effettuata tra febbraio e settembre 2020, in una rete di centri di Malattie Infettive italiani. Sesso, etnia e durata dell’infezione da HIV e dei trattamenti antiretrovirali (ART) erano simili nei soggetti ricoverati e non, mentre i 45 pazienti ricoverati erano più vecchi, avevano valori più bassi sia per quanto riguarda il nadir dei CD4 che la conta dei linfociti al momento della diagnosi. Questi due valori erano anche correlati ad un esito peggiore della COVID-19. Durante il periodo di osservazione, 10 (12.3%) pazienti sono morti. La terapia ART non sembrava associata con la severità della malattia da SARS-CoV-2. more...
- Published
- 2021
- Full Text
- View/download PDF
43. Positioning of darunavir/cobicistat-containing antiretroviral regimens in real life: results from a large multicentre observational prospective cohort (SCOLTA)
- Author
-
Taramasso L., Ricci E., Cascio A., Valsecchi L., Menzaghi B., Squillace N., Maggi P., De Socio G. V., Dentone C., Madeddu G., Pellicano G. F., Calza L., Angioni G., Bonfanti P., Di Biagio A., Sarchi E., Chichino G., Bellacosa C., Angarano G., Farinazzo M., Gussio M., Celesia B. M., Falasca K., Mastroianni A., Guadagnino G., Vichi F., Salomoni E., Martinelli C., Nicolini L., Cenderello G., Molteni C., Nunnari G., Cordier L., Parisini A., Rizzardini G., Rusconi S., Conti F., Bandera A., Gori A., Motta D., Puoti M., Migliorino G. M., Martini S., Trizzino M., Gulminetti R., Cibelli D., Parruti G., Mameli M. S., Orofino G., Guastavigna M., Lucia Taramasso, Elena Ricci, Antonio Cascio, Laura Valsecchi, Barbara Menzaghi, Nicola Squillace, Paolo Maggi, Giuseppe Vittorio De Socio, Chiara Dentone, Giordano Madeddu, Giovanni F. Pellicanò, Leonardo Calza, Goffredo Angioni, Paolo Bonfanti, Antonio Di Biagio, CISAI Study Group, Taramasso, L, Ricci, E, Cascio, A, Valsecchi, L, Menzaghi, B, Squillace, N, Maggi, P, De Socio, Gv, Dentone, C, Madeddu, G, Pellicanò, Gf, Calza, L, Angioni, G, Bonfanti, P, Di Biagio, A, Sarchi, E, Chichino, G, Bellacosa, C, Angarano, G, Farinazzo, M, Gussio, M, Celesia, B, Falasca, K, Mastroianni, A, Guadagnino, G, Vichi, F, Salomoni, E, Martinelli, C, Nicolini, L, Cenderello, G, Molteni, C, Pellicanò, G, Nunnari, G, Cordier, L, Parisini, A, Rizzardini, G, Rusconi, S, Conti, F, Bandiera, A, Gori, A, Motta, D, Puoti, M, Migliorino, G, Martini, S, Trizzino, M, Gulminetti, R, De Socio, G, Cibelli, D, Parruti, G, Mameli, M, Orofino, G, Guastavigna, M, Pellicano, G, Bandera, A, Taramasso L., Ricci E., Cascio A., Valsecchi L., Menzaghi B., Squillace N., Maggi P., De Socio G.V., Dentone C., Madeddu G., Pellicano G.F., Calza L., Angioni G., Bonfanti P., Di Biagio A., Sarchi E., Chichino G., Bellacosa C., Angarano G., Farinazzo M., Gussio M., Celesia B.M., Falasca K., Mastroianni A., Guadagnino G., Vichi F., Salomoni E., Martinelli C., Nicolini L., Cenderello G., Molteni C., Nunnari G., Cordier L., Parisini A., Rizzardini G., Rusconi S., Conti F., Bandera A., Gori A., Motta D., Puoti M., Migliorino G.M., Martini S., Trizzino M., Gulminetti R., Cibelli D., Parruti G., Mameli M.S., Orofino G., and Guastavigna M. more...
- Subjects
0301 basic medicine ,Male ,HIV Infections ,0302 clinical medicine ,Dual ,Medicine ,HIV Infection ,Pharmacology (medical) ,030212 general & internal medicine ,Prospective Studies ,Prospective cohort study ,Darunavir ,Cobicistat ,Middle Aged ,Viral Load ,Tolerability ,Anti-Retroviral Agents ,Cohort ,Molecular Medicine ,Drug Therapy, Combination ,Female ,Darunavir/cobicistat ,Human ,medicine.drug ,Adverse event ,Adult ,lcsh:Immunologic diseases. Allergy ,medicine.medical_specialty ,030106 microbiology ,Context (language use) ,Durability ,03 medical and health sciences ,Darunavir/cobicistat, Dual, Durability, Tolerability, CISAI, Adverse events ,Virology ,Internal medicine ,Humans ,business.industry ,Research ,Hypertriglyceridemia ,medicine.disease ,CISAI ,Discontinuation ,Prospective Studie ,Adverse events ,HIV-1 ,Anti-Retroviral Agent ,business ,lcsh:RC581-607 - Abstract
Background Study aim was to evaluate the safety and durability of darunavir/cobicistat (DRV/c) in a real life setting. Methods Multicentre prospective cohort study performed in the context of SCOLTA (Surveillance Cohort Long-Term Toxicity Antiretrovirals). Patients were evaluated at baseline, week 24 and 48. Changes were evaluated using the paired t test or signed rank test. The multivariable analysis was performed using a general linear model, after ranking of not normally distributed variables. Results A total of 249 patients were included, 72 (29%) were in DRV/c-based dual therapies (DT). Hypercholesterolemia, HC, (total cholesterol (TC) ≥ 200 mg/dL or low density-C (LDL-C) ≥ 130 or statin use) was present in 121 (48.6%) and hypertriglyceridemia, (triglycerides (TG) ≥ 200 mg/dl or fibrate use) in 41 (16.5%) patients. Blood lipid profile did not change significantly in either the global population or patients with HC. After a median observation of 17 months (IQR 13–20), 59 (25.3%) patients discontinued DRV/c, of which 13 were in DT. The durability DT resulted higher than that of triple therapy (log-rank test p = 0.01). Main reasons for stopping DRV/c were simplification (15 patients), adverse events (13 patients), planned discontinuation for treatment initiation with DAA (4 patients), treatment failure (2 patients); death (2 patients), other causes (10 patients). Twenty-six were lost to follow-up. Conclusions DRV/c was safe and well tolerated. Dual therapies showed a better profile of tolerability and a longer durability compared to triple therapies. more...
- Published
- 2019
44. Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort
- Author
-
Taramasso, L., Lorenzini, P., Di Biagio, A., Lichtner, M., Marchetti, G., Rossotti, R., Lapadula, G., Cozzi-Lepri, A., Vichi, F., Antinori, A., Bonora, S., D'Arminio Monforte, A., ICONA Foundation Study Group:, A d'Arminio Monforte, Antinori, A, Andreoni, M, Castagna, A, Castelli, F, Cauda, R, G Di Perri, Galli, M, Iardino, R, Ippolito, G, Lazzarin, A, C Marchetti, G, Rezza, G, F von Schloesser, Viale, P, A d'Arminio Monforte, Ceccherini-Silberstein, F, Cozzi-Lepri, A, Girardi, E, S Lo Caputo, Mussini, C, Puoti, M, F Perno, C, Bai, F, Balotta, C, Bandera, A, Bonora, S, Borderi, M, Calcagno, A, Capetti, A, R Capobianchi, M, Cicalini, S, Cingolani, A, Cinque, P, A De Luca, A Di Biagio, Gianotti, N, Gori, A, Guaraldi, G, Lapadula, G, Lichtner, M, Madeddu, G, Maggiolo, F, Marchetti, G, Monno, L, Nozza, S, Pinnetti, C, QUIROS ROLDAN, Maria Eugenia, Rossotti, R, Rusconi, S, M Santoro, M, Saracino, A, Sarmati, L, Fanti, I, Galli, L, Lorenzini, P, Rodano', A, Macchia, M, Tavelli, A, Carletti, F, Carrara, S, A Di Caro, Graziano, S, Petroni, F, Prota, G, Truffa, S, Giacometti, A, Costantini, A, Barocci, V, Angarano, G, Milano, E, Suardi, C, Donati, V, Verucchi, G, Castelnuovo, F, Minardi, C, Menzaghi, B, Abeli, C, Cacopardo, B, Celesia, B, Vecchiet, J, Falasca, K, Pan, A, Lorenzotti, S, Sighinolfi, L, Segala, D, Blanc, P, Vichi, F, Cassola, G, Viscoli, C, Alessandrini, A, Bobbio, N, Mazzarello, G, Vita, S, Bonfanti, P, Molteni, C, Chiodera, A, Milini, P, Nunnari, G, Pellicanò, G, Rizzardini, G, S Cannizzo, E, C Moioli, M, Piolini, R, Bernacchia, D, Salpietro, S, Tincati, C, Puzzolante, C, Migliorino, C, Sangiovanni, V, Borgia, G, Esposito, V, F Di Martino, Gentile, I, Rizzo, V, M Cattelan, A, Marinello, S, Cascio, A, Trizzino, M, Baldelli, F, Schiaroli, E, Parruti, G, Sozio, F, Magnani, G, A Ursitti, M, Cristaudo, A, Vullo, V, Acinapura, R, Moschese, D, Capozzi, M, Mondi, A, M Rivano Capparuccia, Iaiani, G, Latini, A, Gagliardini, R, M Plazzi, M, Savinelli, S, Vergori, A, Cecchetto, M, Viviani, F, A De Vito, Rossetti, B, Montagnani, F, Franco, A, R Fontana Del Vecchio, Francisci, D, C Di Giuli, Caramello, P, C Orofino, G, Sciandra, M, Bassetti, M, Londero, A, Pellizzer, G, Manfrin, V, Starnini, G, Ialungo, A, Taramasso, L, Lorenzini, P, Di Biagio, A, Lichtner, M, Marchetti, G, Rossotti, R, Lapadula, G, Cozzi-Lepri, A, Vichi, F, Antinori, A, Bonora, S, D'Arminio Monforte, A, d'Arminio Monforte, A, Andreoni, M, Castagna, A, Castelli, F, Cauda, R, Di Perri, G, Galli, M, Iardino, R, Ippolito, G, Lazzarin, A, Marchetti, Gc, Rezza, G, von Schloesser, F, Viale, P, Ceccherini-Silberstein, F, Girardi, E, Lo Caputo, S, Mussini, C, Puoti, M, Perno, Cf, Bai, F, Balotta, C, Bandera, A, Borderi, M, Calcagno, A, Capetti, A, Capobianchi, Mr, Cicalini, S, Cingolani, A, Cinque, P, De Luca, A, Gianotti, N, Gori, A, Guaraldi, G, Madeddu, G, Maggiolo, F, Monno, L, Nozza, S, Pinnetti, C, Quiros Roldan, E, Rusconi, S, Santoro, Mm, Saracino, A, Sarmati, L, Fanti, I, Galli, L, Rodano', A, Macchia, M, Tavelli, A, Carletti, F, Carrara, S, Di Caro, A, Graziano, S, Petroni, F, Prota, G, Truffa, S, Giacometti, A, Costantini, A, Barocci, V, Angarano, G, Milano, E, Suardi, C, Donati, V, Verucchi, G, Castelnuovo, F, Minardi, C, Menzaghi, B, Abeli, C, Cacopardo, B, Celesia, B, Vecchiet, J, Falasca, K, Pan, A, Lorenzotti, S, Sighinolfi, L, Segala, D, Blanc, P, Cassola, G, Viscoli, C, Alessandrini, A, Bobbio, N, Mazzarello, G, Vita, S, Bonfanti, P, Molteni, C, Chiodera, A, Milini, P, Nunnari, G, Pellicanò, G, Rizzardini, G, Cannizzo, E, Moioli, Mc, Piolini, R, Bernacchia, D, Salpietro, S, Tincati, C, Puzzolante, C, Migliorino, C, Sangiovanni, V, Borgia, G, Esposito, V, Di Martino, F, Gentile, I, Rizzo, V, Cattelan, Am, Marinello, S, Cascio, A, Trizzino, M, Baldelli, F, Schiaroli, E, Parruti, G, Sozio, F, Magnani, G, Ursitti, Ma, Cristaudo, A, Vullo, V, Acinapura, R, Moschese, D, Capozzi, M, Mondi, A, Capparuccia, Mr, Iaiani, G, Latini, A, Gagliardini, R, Plazzi, Mm, Savinelli, S, Vergori, A, Cecchetto, M, Viviani, F, De Vito, A, Rossetti, B, Montagnani, F, Franco, A, Fontana Del Vecchio, R, Francisci, D, Di Giuli, C, Caramello, P, Orofino, Gc, Sciandra, M, Bassetti, M, Londero, A, Pellizzer, G, Manfrin, V, Starnini, G, Ialungo, A, Taramasso L., Lorenzini P., Di Biagio A., Lichtner M., Marchetti G., Rossotti R., Lapadula G., Cozzi-Lepri A., Vichi F., Antinori A., Bonora S., Cascio A., D'Arminio Monforte A., Cascio A. in ICONA Foundation Study Group., Taramasso, L., Lorenzini, P., Di Biagio, A., Lichtner, M., Marchetti, G., Rossotti, R., Lapadula, G., Cozzi-Lepri, A., Vichi, F., Antinori, A., Bonora, S., D'Arminio Monforte, A., Castagna, A., and A d'Arminio Monforte,i, M Andreoni, A Castagna, F Castelli, R Cauda, G Di Perri, M Galli, R Iardino, G Ippolito, A Lazzarin, G Rezza, F von Schloesser, F Ceccherini-Silberstein, E Girardi, S Lo Caputo, C Mussini, M Puoti, C F Perno, F Bai, C Balotta, A Bandera, M Borderi, A Calcagno, A Capetti, M R Capobianchi, S Cicalini, A Cingolani, P Cinque, A De Luca, E Girardi, N Gianotti, A Gori, G Guaraldi, G Madeddu, F Maggiolo, L Monno, S Nozza, C Pinnetti, E Quiros Roldan, S Rusconi, M M Santoro, A Saracino, L Sarmati, I Fanti, A Rodano', M Macchia, A Tavelli, F Carletti, S Carrara, A Di Caro, S Graziano, F Petroni, G Prota, S Truffa, A Giacometti, A Costantini, V Barocci, G Angarano, L Monno, E Milano, F Maggiolo, C Suardi, P Viale, V Donati, G Verucchi, F Castelnuovo, C Minardi, B Menzaghi, C Abeli, B Cacopardo, B Celesia, J Vecchiet, K Falasca, A Pan, S Lorenzotti, L Sighinolfi, D Segala, P Blanc, G Cassola, C Viscoli, A Alessandrini, N Bobbio, G Mazzarello, S Vita, P Bonfanti, C Molteni, A Chiodera, P Milini, G Nunnari, G Pellicanò, G Rizzardini, E S Cannizzo, M C Moioli, R Piolini, D Bernacchia, S Salpietro, C Tincati, C Puzzolante, C Migliorino, V Sangiovanni, G Borgia, V Esposito, F Di Martino, I Gentile, V Rizzo, A M Cattelan, S Marinello, A Cascio, M Trizzino, F Baldelli, E Schiaroli, G Parruti, F Sozio, G Magnani, M A Ursitti, A Cristaudo, V Vullo, R Acinapura, D Moschese, M Capozzi, A Mondi, M Rivano Capparuccia, G Iaiani, A Latini, R Gagliardini, M M Plazzi, S Savinelli, A Vergori, M Cecchetto, F Viviani, G Madeddu, A De Vito, B Rossetti, F Montagnani, A Franco, R Fontana Del Vecchio, D Francisci, C Di Giuli, P Caramello, G C Orofino, M Sciandra, M Bassetti, A Londero, G Pellizzer, V Manfrin, G Starnini, A Ialungo more...
- Subjects
0301 basic medicine ,Male ,Integrase inhibitor ,Hepatitis B Surface Antigen ,HIV Infections ,0302 clinical medicine ,Risk Factors ,hivh epatitis c rna surface antigens follow-up homosexuality integrase inhibitors hepatitis b virus hepatitis b virus measurement hiv infections hepatotoxicity hepatitis c virus coinfection nucleoside reverse transcriptase inhibitors non-nucleoside reverse transcriptase inhibitors cox proportional hazards models baseline value liver enzyme raltegravir ,Pharmacology (medical) ,HIV Infection ,030212 general & internal medicine ,Prospective Studies ,Prospective cohort study ,Coinfection ,Incidence (epidemiology) ,Liver Disease ,Incidence ,Liver Diseases ,virus diseases ,Hepatitis C ,Middle Aged ,Reverse Transcriptase Inhibitor ,Infectious Diseases ,Cohort ,Population study ,Regression Analysis ,Reverse Transcriptase Inhibitors ,Female ,medicine.drug ,Human ,Microbiology (medical) ,Adult ,medicine.medical_specialty ,Anti-HIV Agents ,Regression Analysi ,NO ,03 medical and health sciences ,Internal medicine ,medicine ,Humans ,HIV Integrase Inhibitors ,HIV Protease Inhibitor ,Pharmacology ,Hepatitis B Surface Antigens ,business.industry ,Anti-HIV Agent ,HIV, ART ,HIV Protease Inhibitors ,medicine.disease ,Raltegravir ,030112 virology ,HIV Integrase Inhibitor ,Prospective Studie ,HIV-1 ,business ,Adult, Anti-HIV Agents, Coinfection, Female, Hepatitis B Surface Antigens, Hepatitis C, HIV Infections, HIV Integrase Inhibitors, HIV Protease Inhibitors, HIV-1, Humans, Incidence, Liver Diseases, Male, Middle Aged, Prospective Studies, Regression Analysis, Reverse Transcriptase Inhibitors, Risk Factors - Abstract
ObjectivesTo evaluate the incidence and risk factors for liver enzyme elevations (LEE) in patients initiating first-line ART in the ICONA prospective observational cohort, between June 2009 and December 2017.Patients and methodsIn total, 6575 ART-naive patients were selected, initiating two NRTIs with the third drug being a boosted PI (n=2436; 37.0%), an NNRTI (n=2384; 36.3%) or an integrase strand transfer inhibitor (INSTI) (n=1755; 26.7%). HBV surface antigen and HCV RNA were detected in 3.9% and 5.8% of the study population. Inverse probability weighted Cox regression analysis was used to calculate the HRs, according to first-line regimen, for LEE, defined as ALT or AST increases of ≥2.5× upper limit of normal (ULN) for patients with normal baseline values or ≥2.5× baseline for patients with higher baseline values.ResultsOne hundred and eighty-three LEE occurred over 20722 patient-years of follow-up. After adjusting for the main confounders, the risk of LEE halved with INSTIs compared with NNRTIs (HR 0.46, 95% CI 0.25–0.86), with a significant reduction in the raltegravir group (HR 0.11, 95% CI 0.02–0.84 using the NNRTI class as reference). HRs for LEE were significantly higher in subjects with HBV or HCV coinfection, in patients with poorly controlled HIV infection and in those who acquired HIV through homosexual transmission.ConclusionsIn our study, INSTI use almost halved the risk of LEE compared with other regimens. This finding could be particularly important for choosing ART in patients with risk factors for liver toxicity such as HCV and HBV coinfections. more...
- Published
- 2019
45. Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA)
- Author
-
Taramasso, L., Tatarelli, Paola, Ricci, Elena, Madeddu, G., Menzaghi, B., Squillace, Nicola, De Socio, G. V., Martinelli, C., Gulminetti, Roberto, Maggi, P., Orofino, G., Vichi, F., Di Biagio, A., Bonfanti, Paolo, Bellacosa, C., Calza, L., Abeli, C., Celesia, B. M., Grosso, C., Stagno, A., Mazzotta, F., Penco, G., Cassola, G., Nicolini, L. A., Dentone, C., Molteni, C., Palvarini, L., Scalzini, A., Carenzi, L., Rizzardini, G., Valsecchi, L., Cordier, L., Rusconi, S., Colombo, Valeria, Galli, M., Franzetti, M., Sgrelli, A., Mazzotta, E., Parruti, G., Bagella, P., Mura, M. S., Libertone, R., Antinori, A., Di Giambenedetto, S., Guastavigna, M., Caramello, P., Taramasso, L, Tatarelli, P, Ricci, E, Madeddu, G, Menzaghi, B, Squillace, N, De Socio, G, Martinelli, C, Gulminetti, R, Maggi, P, Orofino, G, Vichi, F, Di Biagio, A, Bonfanti, P, Bellacosa, C, Calza, L, Abeli, C, Celesia, B, Grosso, C, Stagno, A, Mazzotta, F, Penco, G, Cassola, G, Nicolini, L, Dentone, C, Molteni, C, Palvarini, L, Scalzini, A, Carenzi, L, Rizzardini, G, Valsecchi, L, Cordier, L, Rusconi, S, Colombo, V, Galli, M, Franzetti, M, Sgrelli, A, Mazzotta, E, Parruti, G, Bagella, P, Mura, M, Libertone, R, Antinori, A, Di Giambenedetto, S, Guastavigna, M, Caramello, P, Taramasso, L., Tatarelli, Paola, Ricci, Elena, Madeddu, G., Menzaghi, B., Squillace, Nicola, De Socio, G. V., Martinelli, C., Gulminetti, Roberto, Maggi, P., Orofino, G., Vichi, F., Di Biagio, A., Bonfanti, Paolo, Bellacosa, C., Calza, L., Abeli, C., Celesia, B. M., Grosso, C., Stagno, A., Mazzotta, F., Penco, G., Cassola, G., Nicolini, L. A., Dentone, C., Molteni, C., Palvarini, L., Scalzini, A., Carenzi, L., Rizzardini, G., Valsecchi, L., Cordier, L., Rusconi, S., Colombo, Valeria, Galli, M., Franzetti, M., Sgrelli, A., Mazzotta, E., Parruti, G., Bagella, P., Mura, M. S., Libertone, R., Antinori, A., Di Giambenedetto, S., Guastavigna, M., and Caramello, P. more...
- Subjects
0301 basic medicine ,Cyclopropanes ,Male ,Protease Inhibitor ,Integrase inhibitor ,HIV Infections ,Gastroenterology ,Piperazines ,Cohort Studies ,chemistry.chemical_compound ,0302 clinical medicine ,HIV Infection ,030212 general & internal medicine ,medicine.diagnostic_test ,Elvitegravir ,Drug Substitution ,HIV-Associated Lipodystrophy Syndrome ,Lipid ,Middle Aged ,Lipids ,Infectious Diseases ,Cholesterol ,Treatment Outcome ,Rilpivirine ,Alkynes ,Dolutegravir ,Drug Therapy, Combination ,Female ,Heterocyclic Compounds, 3-Ring ,Cholesterol, Dyslipidemia,Framingham risk score, Integrase inhibitors, Rilpivirine ,Human ,medicine.drug ,Research Article ,Benzoxazine ,Adult ,medicine.medical_specialty ,Efavirenz ,Anti-HIV Agents ,Pyridones ,030106 microbiology ,Integrase Inhibitors ,Drug Administration Schedule ,lcsh:Infectious and parasitic diseases ,03 medical and health sciences ,Internal medicine ,Oxazines ,medicine ,Humans ,lcsh:RC109-216 ,Protease Inhibitors ,Ritonavir ,business.industry ,Anti-HIV Agent ,Lipid Metabolism ,Benzoxazines ,Integrase Inhibitor ,chemistry ,Dyslipidemia ,Framingham risk score ,Cohort Studie ,Lipid profile ,business - Abstract
Background: Dyslipidemia represents a significant non-infectious comorbidity among people living with HIV. The aim of this study is to evaluate the impact on lipid profile of switches from an efavirenz (EFV) or protease inhibitor/ritonavir (PI/r)-based regimen to a rilpivirine (RPV) or a once-daily integrase inhibitor-based regimen. Methods: We analyzed data from SCOLTA prospective database. All patients with HIV-RNA < 50 copies/ml in therapy with two NRTI + EFV or PI/r were included if they switched from EFV to dolutegravir (group EFV-DTG), elvitegravir (EFV-EVG), or RPV (EFV-RPV) and from PI/r to DTG (PI/r-DTG), PI/r to EVG (PI/r-EVG), or PI/r to RPV (PI/r-RPV). Total cholesterol (TC), TC/HDL ratio, LDL-cholesterol (LDL) and triglycerides (TG) were compared at baseline, six months and one year. Comparisons among groups were performed by a general linear model. Results: Four hundred and ninety patients were enrolled, 24.9% female, mean age 47.3 years (±10.1). According to ART switch, 11.4% were classified in group EFV-DTG, 3.9% in EFV-EVG, 23.9% in EFV-RPV, 17.6% in PI/r-DTG, 17.8% in PI/r-EVG, and 25.5% in PI/r-RPV. After adjusted analysis, TC significantly decreased in all groups but EFV-EVG, TC/HDL in all but EFV-DTG and EFV-EVG, while the reduction of TG was significant only in switches to RPV (EFV-RPV and PI/r-RPV). The one year decrease of TC, TC/HDL, LDL and TG was higher in patients with higher baseline levels of the same variable (p < .0001 for all). Conclusions: In SCOLTA, all switches from PI/r regimens gave advantages on lipid profile, while stopping EFV had consistently favorable lipid effects only if replaced by RPV. more...
- Published
- 2018
46. First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison
- Author
-
Taramasso, L., Biagio, Di, Maggiolo, A., Tavelli, F., Lo Caputo, A., Bonora, S., Zaccarelli, S., Caramello, M., Costantini, P., Viscoli, A., D'Arminio, Monforte, Cozzi-Lepri, A., Andreoni, A., Angarano, M., Antinori, G., Castelli, A., Cauda, F., Perri, Di, Galli, G., Iardino, M., Ippolito, R., Lazzarin, G., Perno, A., C. F., Von, Schloesser, Viale, F., Castagna, P., Ceccherini-Silberstein, A., Girardi, F., Mussini, E., Puoti, C., Ammassari, M., Balotta, A., Bandera, C., Bonfanti, A, Borderi, P., Calcagno, M., Calza, A., Capobianchi, L., Cingolani, M. R., Cinque, A., Luca, De, Gianotti, A., Gori, N., Guaraldi, A., Lapadula, G., Lichtner, G., Madeddu, M., Marchetti, G., Marcotullio, G., Monno, S., Nozza, L., Quiros, Roldan, Rossotti, E., Rusconi, R., Santoro, S., Saracino, M. M., Fanti, A., Galli, I., Lorenzini, L, Rodano, P., Shanyinde, A., Carletti, M., Carrara, F., Caro, Di, Graziano, S., Petrone, F., Prota, G, Quartu, S., Truffa, S., Giacometti, A., Valeriani, C., Santoro, C., Suardi, C., Donati, V., Verucchi, G., Minardi, C., Quirino, T., Abeli, C., Manconi, P. E., Piano, P., Cacopardo, B., Celesia, B., Vecchiet, J., Falasca, K., Sighinolfi, L., Segala, D., Mazzotta, F., Vichi, F., Cassola, G., Alessandrini, A., Bobbio, N., Mazzarello, G., Mastroianni, C., Belvisi, V., Caramma, I., Chiodera, A., Castelli, A. P., Rizzardini, G., Ridolfo, A. L., Piolini, R., Salpietro, S., Carenzi, L., Moioli, M. C., Tincati, C., Puzzolante, C., Abrescia, N., Chirianni, A., Borgia, G., Di Martino, F., Maddaloni, L., Gentile, I., Orlando, R., Baldelli, F., Francisci, D., Parruti, G., Ursini, T., Magnani, G., Ursitti, M. A., Vullo, V., Cristaudo, A., Baldin, G., Cicalini, S., Gallo, L., Nicastri, E., Acinapura, R., Capozzi, M., Libertone, R., Savinelli, S., Latini, A., Cecchetto, M., Viviani, F., Mura, M. S., Rossetti, B., Orofino, G. C., Sciandra, M., Bassetti, M., Londero, A., Pellizzer, G., Manfrin, V., Taramasso, L, Di Biagio, A, Maggiolo, F, Tavelli, A, Lo Caputo, S, Bonora, S., Zaccarelli, M, Caramello, P, Costantini, A, Viscoli, C., d'Arminio Monforte, A, Cozzi-Lepri, A, on behalf of the Italian Cohort NaiveAntiretrovirals (ICONA) Foundation Study, Group, Castagna, A, Taramasso, L., Di Biagio, A., Maggiolo, F., Tavelli, A., Lo Caputo, S., Zaccarelli, M., Caramello, P., Costantini, A., d'Arminio Monforte, A., Cozzi-Lepri, A., Andreoni, M., Angarano, G., Antinori, A., Castelli, F., Cauda, R., Di Perri, G., Galli, M., Iardino, R., Ippolito, G., Lazzarin, A., Perno, C.F., von Schloesser, F., Viale, P., Castagna, A., Ceccherini-Silberstein, F., Girardi, E., Mussini, C., Puoti, M., Ammassari, A., Balotta, C., Bandera, A., Bonfanti, P., Borderi, M., Calcagno, A., Calza, L., Capobianchi, M.R., Cingolani, A., Cinque, P., De Luca, A., Gianotti, N., Gori, A., Guaraldi, G., Lapadula, G., Lichtner, M., Madeddu, G., Marchetti, G., Marcotullio, S., Monno, L., Nozza, S., Quiros Roldan, E., Rossotti, R., Rusconi, S., Santoro, M.M., Saracino, A., Fanti, I., Galli, L., Lorenzini, P., Rodano, A., Shanyinde, M., Carletti, F., Carrara, S., Di Caro, A., Graziano, S., Petrone, F., Prota, G., Quartu, S., Truffa, S., Giacometti, A., Valeriani, C., Santoro, C., Suardi, C., Donati, V., Verucchi, G., Minardi, C., Quirino, T., Abeli, C., Manconi, P.E., Piano, P., Cacopardo, B., Celesia, B., Vecchiet, J., Falasca, K., Sighinolfi, L., Segala, D., Mazzotta, F., Vichi, F., Cassola, G., Alessandrini, A., Bobbio, N., Mazzarello, G., Mastroianni, C., Belvisi, V., Caramma, I., Chiodera, A., Castelli, A.P., Rizzardini, G., Ridolfo, A.L., Piolini, R., Salpietro, S., Carenzi, L., Moioli, M.C., Tincati, C., Puzzolante, C., Abrescia, N., Chirianni, A., Borgia, G., Di Martino, F., Maddaloni, L., Gentile, I., Orlando, R., Baldelli, F., Francisci, D., Parruti, G., Ursini, T., Magnani, G., Ursitti, M.A., Vullo, V., Cristaudo, A., Baldin, G., Cicalini, S., Gallo, L., Nicastri, E., Acinapura, R., Capozzi, M., Libertone, R., Savinelli, S., Latini, A., Cecchetto, M., Viviani, F., Mura, M.S., Rossetti, B., Orofino, G.C., Sciandra, M., Bassetti, M., Londero, A., Pellizzer, G., Manfrin, V., Bonora, S, Viscoli, C, Andreoni, M, Angarano, G, Antinori, A, Castelli, F, Cauda, R, Di Perri, G, Galli, M, Iardino, R, Ippolito, G, Lazzarin, A, Perno, C, von Schloesser, F, Viale, P, Ceccherini-Silberstein, F, Girardi, E, Mussini, C, Puoti, M, Ammassari, A, Balotta, C, Bandera, A, Bonfanti, P, Borderi, M, Calcagno, A, Calza, L, Capobianchi, M, Cingolani, A, Cinque, P, De Luca, A, Gianotti, N, Gori, A, Guaraldi, G, Lapadula, G, Lichtner, M, Madeddu, G, Marchetti, G, Marcotullio, S, Monno, L, Nozza, S, Quiros Roldan, E, Rossotti, R, Rusconi, S, Santoro, M, Saracino, A, Fanti, I, Galli, L, Lorenzini, P, Rodano, A, Shanyinde, M, Carletti, F, Carrara, S, Di Caro, A, Graziano, S, Petrone, F, Prota, G, Quartu, S, Truffa, S, Giacometti, A, Valeriani, C, Santoro, C, Suardi, C, Donati, V, Verucchi, G, Minardi, C, Quirino, T, Abeli, C, Manconi, P, Piano, P, Cacopardo, B, Celesia, B, Vecchiet, J, Falasca, K, Sighinolfi, L, Segala, D, Mazzotta, F, Vichi, F, Cassola, G, Alessandrini, A, Bobbio, N, Mazzarello, G, Mastroianni, C, Belvisi, V, Caramma, I, Chiodera, A, Castelli, A, Rizzardini, G, Ridolfo, A, Piolini, R, Salpietro, S, Carenzi, L, Moioli, M, Tincati, C, Puzzolante, C, Abrescia, N, Chirianni, A, Borgia, G, Di Martino, F, Maddaloni, L, Gentile, I, Orlando, R, Baldelli, F, Francisci, D, Parruti, G, Ursini, T, Magnani, G, Ursitti, M, Vullo, V, Cristaudo, A, Baldin, G, Cicalini, S, Gallo, L, Nicastri, E, Acinapura, R, Capozzi, M, Libertone, R, Savinelli, S, Latini, A, Cecchetto, M, Viviani, F, Mura, M, Rossetti, B, Orofino, G, Sciandra, M, Bassetti, M, Londero, A, Pellizzer, G, Manfrin, V, Perno, C. F., Capobianchi, M. R., Santoro, M. M., Manconi, P. E., Castelli, A. P., Ridolfo, A. L., Moioli, M. C., Ursitti, M. A., Mura, M. S., and Orofino, G. C. more...
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Efavirenz ,combination antiretroviral therapy ,durability ,efavirenz ,naïve ,rilpivirine ,Health Policy ,Infectious Diseases ,Pharmacology (medical) ,Infectious Disease ,Emtricitabine ,Gastroenterology ,NO ,03 medical and health sciences ,chemistry.chemical_compound ,Interquartile range ,Internal medicine ,medicine ,business.industry ,030112 virology ,Confidence interval ,Discontinuation ,naive ,Regimen ,chemistry ,combination antiretroviral therapy, durability, efavirenz, naïve, rilpivirine ,Rilpivirine ,business ,Viral load ,medicine.drug - Abstract
Objectives: The aim of this study was to compare the durabilities of efavirenz (EFV) and rilpivirine (RPV) in combination with tenofovir/emtricitabine (TDF/FTC) in first-line regimens. Methods: A multicentre prospective and observational study was carried out. We included all patients participating in the Italian Cohort Naive Antiretrovirals (ICONA) Foundation Study who started first-line combination antiretroviral therapy (cART) with TDF/FTC in combination with RPV or EFV, with a baseline viral load < 100 000 HIV-1 RNA copies/mL. Survival analyses using Kaplan–Meier (KM) curves and Cox regression with time-fixed covariates at baseline were employed. Results: Overall, 1490 ART-naïve patients were included in the study, of whom 704 were initiating their first cART with EFV and 786 with RPV. Patients treated with EFV, compared with those on RPV, were older [median 36 (interquartile range (IQR) 30–43) years vs. 33 (IQR 27–39) years, respectively; P < 0.001], were more frequently at Centers for Disease Control and Prevention (CDC) stage C (3.1% vs. 1.4%, respectively; P = 0.024), and had a lower median baseline CD4 count [340 (IQR 257–421) cells/μL vs. 447 (IQR 347–580) cells/μL, respectively; P < 0.001] and a higher median viral load [4.38 (IQR 3.92–4.74) log10 copies/mL vs. 4.23 (IQR 3.81–4.59) log10 copies/mL, respectively], (P = 0.004). A total of 343 patients discontinued at least one drug of those included in the first cART regimen, more often EFV (26%) than RPV (13%), by 2 years (P < 0.0001). After adjustment, patients treated with EFV were more likely to discontinue at least one drug for any cause [relative hazard (RH) 4.09; 95% confidence interval (CI) 2.89–5.80], for toxicity (RH 2.23; 95% CI 1.05–4.73) for intolerance (RH 5.17; 95% CI 2.66–10.07) and for proactive switch (RH 10.96; 95% CI 3.17–37.87) than those starting RPV. Conclusions: In our nonrandomized comparison, RPV was better tolerated, less toxic and showed longer durability than EFV, without a significant difference in rates of discontinuation because of failures. more...
- Published
- 2018
47. Factors associated with hospital admission for COVID-19 in HIV patients
- Author
-
Di Biagio, A., Ricci, E., Calza, L., Squillace, N., Menzaghi, B., Rusconi, S., Orofino, G., Bargiacchi, O., Molteni, C., Valsecchi, L., Cenderello, G., Ferrara, S., Saracino, A., Maggi, P., Falasca, K., Taramasso, L., Bonfanti, P., for the CISAI Study Group, Nunnari, G., F. Pellicanò., G, Di Biagio, A, Ricci, E, Calza, L, Squillace, N, Menzaghi, B, Rusconi, S, Orofino, G, Bargiacchi, O, Molteni, C, Valsecchi, L, Cenderello, G, Ferrara, S, Saracino, A, Maggi, P, Falasca, K, Taramasso, L, Bonfanti, P, and Bonfanti, P. more...
- Subjects
0301 basic medicine ,Male ,medicine.medical_specialty ,2019-20 coronavirus outbreak ,Coronavirus disease 2019 (COVID-19) ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Immunology ,Pneumonia, Viral ,SARS-CoV-2 ,COVID-19 ,HIV ,hospital admission ,Human immunodeficiency virus (HIV) ,HIV Infections ,medicine.disease_cause ,Antiviral Agents ,03 medical and health sciences ,Betacoronavirus ,0302 clinical medicine ,Disease severity ,Risk Factors ,Internal medicine ,medicine ,Immunology and Allergy ,Humans ,030212 general & internal medicine ,Pandemics ,business.industry ,Middle Aged ,medicine.disease ,CD4 Lymphocyte Count ,Hospitalization ,Pneumonia ,030104 developmental biology ,Infectious Diseases ,Italy ,Hospital admission ,Hiv patients ,Female ,business ,Coronavirus Infections ,Hydroxychloroquine - Abstract
This study reports on hospital admission and outcomes of 69 HIV-infected individuals who were diagnosed with SARS-CoV-2 infection between February and May 2020, in a network of Italian centres. Patients' characteristics and median days between symptoms and diagnosis were similar by hospital admission, whereas admitted patients had lower nadir CD4 cells and current lymphocytes count. These values were also correlated to worse COVID-19 outcome. Antiretroviral drugs did not seem to be associated with disease severity. more...
- Published
- 2020
48. Smoking habits in HIV-infected people compared with the general population in Italy: a cross-sectional study
- Author
-
De Socio GV, Pasqualini M, Ricci E, Maggi P, Orofino G, Squillace N, Menzaghi B, Madeddu G, Taramasso L, Francisci D, Bonfanti P, Vichi F, dell'Omo M, Pieroni L, De Socio, Gv, Pasqualini, M, Ricci, E, Maggi, P, Orofino, G, Squillace, N, Menzaghi, B, Madeddu, G, Taramasso, L, Francisci, D, Bonfanti, P, Vichi, F, Dell'Omo, M, and Pieroni, L more...
- Published
- 2020
49. Positioning of darunavir/cobicistat-containing antiretroviral regimens in real life: Results from a large multicentre observational prospective cohort (SCOLTA)
- Author
-
Taramasso, L, Ricci, E, Cascio, A, Valsecchi, L, Menzaghi, B, Squillace, N, Maggi, P, De Socio, G, Dentone, C, Madeddu, G, Pellicano, G, Calza, L, Angioni, G, Bonfanti, P, Di Biagio, A, Sarchi, E, Chichino, G, Bellacosa, C, Angarano, G, Farinazzo, M, Gussio, M, Celesia, B, Falasca, K, Mastroianni, A, Guadagnino, G, Vichi, F, Salomoni, E, Martinelli, C, Nicolini, L, Cenderello, G, Molteni, C, Nunnari, G, Cordier, L, Parisini, A, Rizzardini, G, Rusconi, S, Conti, F, Bandera, A, Gori, A, Motta, D, Puoti, M, Migliorino, G, Martini, S, Trizzino, M, Gulminetti, R, Cibelli, D, Parruti, G, Mameli, M, Orofino, G, Guastavigna, M, Taramasso L., Ricci E., Cascio A., Valsecchi L., Menzaghi B., Squillace N., Maggi P., De Socio G. V., Dentone C., Madeddu G., Pellicano G. F., Calza L., Angioni G., Bonfanti P., Di Biagio A., Sarchi E., Chichino G., Bellacosa C., Angarano G., Farinazzo M., Gussio M., Celesia B. M., Falasca K., Mastroianni A., Guadagnino G., Vichi F., Salomoni E., Martinelli C., Nicolini L., Cenderello G., Molteni C., Nunnari G., Cordier L., Parisini A., Rizzardini G., Rusconi S., Conti F., Bandera A., Gori A., Motta D., Puoti M., Migliorino G. M., Martini S., Trizzino M., Gulminetti R., Cibelli D., Parruti G., Mameli M. S., Orofino G., Guastavigna M., Taramasso, L, Ricci, E, Cascio, A, Valsecchi, L, Menzaghi, B, Squillace, N, Maggi, P, De Socio, G, Dentone, C, Madeddu, G, Pellicano, G, Calza, L, Angioni, G, Bonfanti, P, Di Biagio, A, Sarchi, E, Chichino, G, Bellacosa, C, Angarano, G, Farinazzo, M, Gussio, M, Celesia, B, Falasca, K, Mastroianni, A, Guadagnino, G, Vichi, F, Salomoni, E, Martinelli, C, Nicolini, L, Cenderello, G, Molteni, C, Nunnari, G, Cordier, L, Parisini, A, Rizzardini, G, Rusconi, S, Conti, F, Bandera, A, Gori, A, Motta, D, Puoti, M, Migliorino, G, Martini, S, Trizzino, M, Gulminetti, R, Cibelli, D, Parruti, G, Mameli, M, Orofino, G, Guastavigna, M, Taramasso L., Ricci E., Cascio A., Valsecchi L., Menzaghi B., Squillace N., Maggi P., De Socio G. V., Dentone C., Madeddu G., Pellicano G. F., Calza L., Angioni G., Bonfanti P., Di Biagio A., Sarchi E., Chichino G., Bellacosa C., Angarano G., Farinazzo M., Gussio M., Celesia B. M., Falasca K., Mastroianni A., Guadagnino G., Vichi F., Salomoni E., Martinelli C., Nicolini L., Cenderello G., Molteni C., Nunnari G., Cordier L., Parisini A., Rizzardini G., Rusconi S., Conti F., Bandera A., Gori A., Motta D., Puoti M., Migliorino G. M., Martini S., Trizzino M., Gulminetti R., Cibelli D., Parruti G., Mameli M. S., Orofino G., and Guastavigna M. more...
- Abstract
Background: Study aim was to evaluate the safety and durability of darunavir/cobicistat (DRV/c) in a real life setting. Methods: Multicentre prospective cohort study performed in the context of SCOLTA (Surveillance Cohort Long-Term Toxicity Antiretrovirals). Patients were evaluated at baseline, week 24 and 48. Changes were evaluated using the paired t test or signed rank test. The multivariable analysis was performed using a general linear model, after ranking of not normally distributed variables. Results: A total of 249 patients were included, 72 (29%) were in DRV/c-based dual therapies (DT). Hypercholesterolemia, HC, (total cholesterol (TC) ≥ 200 mg/dL or low density-C (LDL-C) ≥ 130 or statin use) was present in 121 (48.6%) and hypertriglyceridemia, (triglycerides (TG) ≥ 200 mg/dl or fibrate use) in 41 (16.5%) patients. Blood lipid profile did not change significantly in either the global population or patients with HC. After a median observation of 17 months (IQR 13-20), 59 (25.3%) patients discontinued DRV/c, of which 13 were in DT. The durability DT resulted higher than that of triple therapy (log-rank test p = 0.01). Main reasons for stopping DRV/c were simplification (15 patients), adverse events (13 patients), planned discontinuation for treatment initiation with DAA (4 patients), treatment failure (2 patients); death (2 patients), other causes (10 patients). Twenty-six were lost to follow-up. Conclusions: DRV/c was safe and well tolerated. Dual therapies showed a better profile of tolerability and a longer durability compared to triple therapies. more...
- Published
- 2019
50. Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort
- Author
-
Taramasso, L, Lorenzini, P, Di Biagio, A, Lichtner, M, Marchetti, G, Rossotti, R, Lapadula, G, Cozzi-Lepri, A, Vichi, F, Antinori, A, Bonora, S, D'Arminio Monforte, A, Taramasso L., Lorenzini P., Di Biagio A., Lichtner M., Marchetti G., Rossotti R., Lapadula G., Cozzi-Lepri A., Vichi F., Antinori A., Bonora S., D'Arminio Monforte A., Taramasso, L, Lorenzini, P, Di Biagio, A, Lichtner, M, Marchetti, G, Rossotti, R, Lapadula, G, Cozzi-Lepri, A, Vichi, F, Antinori, A, Bonora, S, D'Arminio Monforte, A, Taramasso L., Lorenzini P., Di Biagio A., Lichtner M., Marchetti G., Rossotti R., Lapadula G., Cozzi-Lepri A., Vichi F., Antinori A., Bonora S., and D'Arminio Monforte A. more...
- Abstract
Objectives: To evaluate the incidence and risk factors for liver enzyme elevations (LEE) in patients initiating first-line ART in the ICONA prospective observational cohort, between June 2009 and December 2017. Patients and methods: In total, 6575 ART-naive patients were selected, initiating two NRTIs with the third drug being a boosted PI (n=2436; 37.0%), an NNRTI (n=2384; 36.3%) or an integrase strand transfer inhibitor (INSTI) (n=1755; 26.7%). HBV surface antigen and HCV RNA were detected in 3.9% and 5.8% of the study population. Inverse probability weighted Cox regression analysis was used to calculate the HRs, according to first-line regimen, for LEE, defined as ALT or AST increases of ≥2.5× upper limit of normal (ULN) for patients with normal baseline values or ≥2.5× baseline for patients with higher baseline values. Results: One hundred and eighty-three LEE occurred over 20722 patient-years of follow-up. After adjusting for the main confounders, the risk of LEE halved with INSTIs compared with NNRTIs (HR 0.46, 95% CI 0.25-0.86), with a significant reduction in the raltegravir group (HR 0.11, 95% CI 0.02-0.84 using the NNRTI class as reference). HRs for LEE were significantly higher in subjects with HBV or HCV coinfection, in patients with poorly controlled HIV infection and in those who acquired HIV through homosexual transmission. Conclusions: In our study, INSTI use almost halved the risk of LEE compared with other regimens. This finding could be particularly important for choosing ART in patients with risk factors for liver toxicity such as HCV and HBV coinfections. more...
- Published
- 2019
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.